Exhibit
10.1
EMPLOYMENT
AGREEMENT
Employment
Agreement dated as of November
6, 2006, between OXIS INTERNATIONAL INC., a Delaware corporation (with its
successors and assigns, referred to as the “Corporation”) and MARVIN S. HAUSMAN,
M.D. (hereinafter referred to as “HAUSMAN”).
PRELIMINARY
STATEMENT
The
Corporation desires to employ HAUSMAN as President and Chief Executive Officer
of the Corporation, and HAUSMAN wishes to be employed by the Corporation,
upon
the terms and subject to the conditions set forth in this Agreement. The
Corporation and HAUSMAN also wish to enter into the other agreements set
forth
in this Agreement, all of which are related to HAUSMAN’s employment under this
Agreement.
AGREEMENT
HAUSMAN
and the Corporation therefore agree as follows:
1.
Term
of Employment.
The
Corporation hereby employs HAUSMAN and HAUSMAN hereby accepts employment
with
the Corporation for the period (the “Initial Term”) commencing as of October 15,
2006 (the “Commencement Date”), and ending on the third anniversary of the
Commencement Date hereof or
upon
the earlier termination of the Initial Term pursuant to Section 6. The Initial
Term will be extended automatically for additional one-year periods (each,
an
“Additional Term,” together with the Initial Term, the “Term”), subject to the
rights of the parties generally to terminate this Agreement in accordance
with
the provisions of Section 6(a). The termination of the Term for any reason
shall
end HAUSMAN’s employment under this Agreement, but, except as otherwise set
forth herein, shall not terminate HAUSMAN’s or the Corporation’s other
agreements in this Agreement.
2.
Position
and Duties.
Upon the
commencement of the Initial Term, HAUSMAN shall serve as President and Chief
Executive Officer of the Corporation. HAUSMAN shall also serve as the Chairman
of the Board of Directors and shall also hold such additional positions and
titles as the Board of Directors (“Board”) may determine from time to time.
HAUSMAN shall report to the Board. During the Term, HAUSMAN shall devote
substantial time and attention to performing his duties as an employee of
the
Corporation. The Corporation acknowledges that the foregoing sentence shall
not
restrict HAUSMAN from devoting time and attention to other business ventures,
including without limitation those activities identified on Schedule A annexed
hereto, which the Corporation acknowledges are not business opportunities
of the
Corporation. Additionally, HAUSMAN may continue serving on the Board of
Directors of TorreyPines Therapeutics, Inc. and as a member of its Board
committees and may serve in similar capacities with other companies or
organizations subject to his obtaining prior approval from Board.
3.
Compensation.
(a)
Base
Salary.
The
Corporation shall pay HAUSMAN a base salary, beginning on the first day of
the
Initial Term and ending on the last day of the Initial Term, of $250,000
per
annum. The base salary initially will be payable quarterly in advance in
the
form of the Corporation’s common stock (“Common Stock”), at a price equal to 85%
of the “Market Price” for the Corporation’s common stock, which shall equal the
average of the closing price for the five trading days prior to the date
that
the issuance is authorized by the Board of Directors. In lieu of receiving
Common Stock for such payments, HAUSMAN may elect to receive that number
of ten
year Warrants (with cashless exercise provisions) equal to 1.5 times the
number
of shares of Common Stock that would otherwise be received, at an exercise
price
equal to the Market Price. The first installment, representing $67,500 of
HAUSMAN’s base salary, and payable at HAUSMAN’s election either in the shares of
Common Stock or form of warrants described in the foregoing sentence, will
be
paid promptly after the initial determination of the Market Price, and
thereafter, will be paid on the dates that are three months, six months and
nine
months from the date hereof, and quarterly thereafter for the duration of
the
Term. Notwithstanding the foregoing, once the Corporation has raised at least
$2.5 million in one or more financings (equity, debt or convertible debt,
in
addition to the financing closed on October 27, 2006) or in a strategic
transaction (a “Qualifying Financing”), HAUSMAN may elect, at any time, in lieu
of receiving a quarterly issuance of stock (or warrants in lieu thereof),
to
receive his base salary in cash, payable monthly on the Corporation’s regular
pay cycle for professional employees. All shares of Common Stock issuable
to
HAUSMAN under Sections 3 and 4 hereof (if not otherwise registered pursuant
to
an existing stock option plan covered by a registration statement on Form
S-8),
or upon the exercise of the warrants to be issued in lieu thereof ,shall
have
the benefit of piggyback registration rights, pursuant to a Registration
Rights
Agreement to be executed by the Corporation and HAUSMAN (the “Registration
Rights Agreement”); provided, however, that the failure to execute such a
Registration Rights Agreement shall not limit HAUSMAN’s piggyback registration
rights hereunder. Furthermore, the Corporation will obtain advice of counsel
that the issuance of shares of Common Stock by the Corporation to HAUSMAN
under
Sections 3 and 4 hereof do not violate the provisions of Section 203 of the
Delaware General Corporation Law. Following the Initial Term, the Board shall,
in accordance with its customary review of executive management compensation,
review HAUSMAN’s base salary and make adjustments the Board (or its Compensation
Committee) feels are appropriate, but in any event HAUSMAN’s base salary shall
not be lower than $250,000.
(b) Other
and Additional Compensation.
(i) Annual
Bonus.
During
the Term, HAUSMAN shall receive an annual bonus based upon the attainment
of
agreed upon goals and milestones as determined by the Board and its Compensation
Committee. During the remainder of calendar year 2006, HAUSMAN’s bonus shall be
pro rated on an annual bonus rate in the range of 25% to 50% of his base
salary,
and his bonus for subsequent years of the Term shall be in a similar target
range. Additional bonus calculations and payments determined by the Board
and
the Compensation Committee shall be made based upon (i) each $1 million in
combined annual sales of the Corporation and its subsidiary BioCheck exceeding
$6,500,000, (ii) successful financings an/or strategic transactions completed,
taking into account the aggregate amount of funds raised for the Corporation
and
(iii) performance of the trading price of the Common Stock.
The
bonuses payable hereunder shall be paid in cash, although at HAUSMAN’s sole
option, they may be paid in stock (or in the form of ten year warrants with
cashless exercise provisions, with 1.5 times the number of warrants to be
issued
in lieu of the number of shares of Common Stock), based upon the average
of the
closing bid and asked prices for the 5 trading days immediately prior to
the
awarding to HAUSMAN of the bonus for a particular year (which shall also
be the
exercise price of the warrants, if the Advisor elects to receive warrants).
HAUSMAN shall make his election no more than ten (10) days following
notification by the Corporation of his bonus award, and the failure to make
timely election shall mean that HAUSMAN shall receive the bonus in the form
of
cash.
(ii) Stock
Options.
As soon
as practicable following execution of this Agreement, HAUSMAN shall be granted
options for the purchase of up to 495,000 shares (the “Initial Option Grant”) of
Common Stock under the Corporation’s existing stock option plan (the “Plan”).
The terms of the grant, including the vesting schedule and exercise price
of the
Initial Option Grant, shall be as set forth in a separate option agreement
executed by and between the parties and will provide, among other things,
(i)
for cashless exercise provisions and (ii) for the vesting of 247,500 options
in
four equal quarterly installments commencing on the date that is three months
from the Commencement Date and every three months thereafter, (iii) for the
vesting of the remaining 247,500 options in eight quarterly installments
over
the subsequent two years and (iv) for an exercise price equal to the average
of
the closing bid and asked prices for the Common Stock on the trading day
immediately prior to the date hereof. Subsequent stock option grants, including
an annual grant in 2007, will be determined annually by the Board and the
Compensation Committee, taking into account the previous year’s performance of
the Corporation’s Common Stock, sales, revenue and income performance, as well
as the frequency and success of financings and/or strategic transactions.
(iii) Additional
Compensation.
The
foregoing establishes the minimum compensation during the Term and shall
not
preclude the Board from awarding HAUSMAN a higher salary or any additional
bonuses or stock options in the event of a successful financing or strategic
transaction or otherwise, and in any event, in the discretion of the
Board.
(iv) Sign-on
Bonus.
As a
sign-on bonus and as soon as practicable following execution of this Agreement,
, the Corporation shall issue to HAUSMAN 500,000 shares of Common Stock and
ten
year warrants (the “Warrants”) to purchase 1,505,000 shares of Common Stock, at
an exercise price equal to the Market Price. The Warrants shall have a cashless
exercise provision and otherwise shall be in form mutually satisfactory to
the
parties. All of the shares of Common Stock issued under this Section 3(b)(iv)
will be subject to repurchase by the Corporation at a price of par value
per
share, and the amount of shares subject to repurchase will be reduced in
six
equal monthly increments commencing on the 30 days after the Commencement
Date
and every 30th
day
thereafter until 180 days after the Commencement Date, when none of such
shares
shall be subject to repurchase. The Warrants issued under this Section 3(b)(iv)
will vest monthly in six equal installments, commencing on the date that
is 30
days after the Commencement Date, through the 180th
day
after the Commencement Date.
4.
Employee
Benefits.
(a) General.
During
the Term, HAUSMAN shall be entitled to the employee benefits generally made
available to the Corporation’s executive officers, including four-weeks paid
vacation (no more than 2 weeks per month) and all U.S. national holidays,
participation in the Corporation’s 401(k) plan or other plans that may be made
available from time to time to the Corporation’s executive officers.
Additionally, HAUSMAN shall receive family health and dental insurance benefits.
As soon as reasonably practicable following the date hereof, the Corporation
shall arrange for and maintain short-term and long-term disability policies
for
benefit of HAUSMAN in such amounts generally customary for similarly situated
executive employees in the industry.
(b) Other
Benefits. During
the Term, the Corporation shall provide HAUSMAN with an annual office expense
allowance of $50,000, for the costs of maintaining an office in the Stevenson,
Washington area. The office expense allowance shall be payable quarterly
in
advance in the form of Common Stock, at a price equal to 85% of the Market
Price. The first installment, representing $12,500 of the office expense
allowance, will be paid promptly after the determination of the Market Price,
and thereafter, will be paid on the dates that are three months, six months
and
nine months from the date hereof, and quarterly thereafter for the duration
of
the Term. Notwithstanding the foregoing, once the Corporation has completed
a
Qualifying Financing, the office expense allowance will be paid in cash in
advance, commencing for the quarter next following the quarter in which the
Qualifying Financing occurred.
(c) Indemnification.
The
Corporation will indemnify HAUSMAN for his actions in the capacity as an
officer
and director of the Corporation and any of its subsidiaries to the full extent
permitted by law and as provided in the Corporation’s Certificate of
Incorporation and by-laws.
5.
Expenses.
During
the Term, the Corporation shall reimburse HAUSMAN in cash for actual
out-of-pocket travel, entertainment and other business expenses incurred
by him
in the performance of his services for the Corporation upon the receipt of
appropriate documentation of such expenses.
6.
Termination;
Non-Renewal.
(a)
General.
The Term
shall end immediately upon HAUSMAN’s death, or upon termination for Cause,
Disability or Good Reason, each as defined in Section 7. Upon termination
of the
Term due to HAUSMAN’s death, all compensation due HAUSMAN under this Agreement
will cease. In all other cases, (i) the Corporation may terminate this Agreement
either upon sixty (60) days prior written notice, if such termination shall
be
effective in the calendar year 2006, or otherwise upon ninety (90) days written
notice and (ii) HAUSMAN may terminate this Agreement upon sixty (60) days
written notice. The parties agree that the mere act to providing notice to
the
other party of termination shall not in any event be deemed to provide such
other party the right to immediately terminate this Agreement.
The
Corporation may elect not to renew this Agreement by giving no less than
90 days
written notice prior to the expiration of any Term. HAUSMAN may elect not
to
renew this Agreement by giving not less than 60 days written notice prior
to the
expiration of any Term. Upon the receipt of any notice of non-renewal as
provided in this Section 6(a), HAUSMAN shall continue to be compensated in
the
manner set forth in this Agreement until the expiration of the applicable
Term.
(b)
Notice
of Termination - Generally.
Any
termination by the Corporation of HAUSMAN’s employment hereunder shall be in
writing and delivered to HAUSMAN at the address set forth herein or at such
address kept in the records of the Corporation and shall specify the reasons
for
such termination.
(c) Termination
by the Corporation for Cause. Any
written notice of termination by the Corporation of HAUSMAN for Cause shall,
to
the extent determined by the Board that the Cause is curable, allow HAUSMAN
the
opportunity to cure, but in any event no more than ten (10) days (except
in the
event of a termination pursuant to Section 7(a)(vi), in which case the cure
period shall be 30 days). Such notice of termination shall also state in
reasonable detail the Board’s understanding of the facts leading to the
determination of Cause. Upon the Corporation’s final termination of the Term for
Cause, all compensation due to HAUSMAN under this Agreement will cease, other
than that described in Section 9 below. Moreover, any unexercised portions
of
the Initial Option Grant or other stock option grants to HAUSMAN by the
Corporation shall expire upon such termination.
(d) Termination
by the Corporation upon a Change of Control. In
the
event that the Corporation terminates its relationship with HAUSMAN within
one
(1) year of a “Change of Control”, as defined in Section 7(c), other than for
Cause, HAUSMAN shall receive the following:
(i) an
amount
equal to twelve (12) months of base salary for the then current Term (which
is
in addition to the base salary paid to HAUSMAN after the Corporation’s delivery
of notice of termination pursuant to Section 6 and the actual date of
termination) plus an amount equal to the prior year’s bonus (and if occurring
before the bonus for 2007 has been determined, an amount equal to 50% of
the
then current base salary); and
(ii) the
full
vesting of the Initial Option Grant and any other stock option grants to
HAUSMAN
by the Corporation, and extended exercisability thereof until their respective
expiration dates; and
(iii) Other
Compensation (as defined in Section 9); and
(iv) If
the
foregoing payments and benefits provided to HAUSMAN in Sections 6(d)(i) through
(iii) above (the “Change of Control Payments”) are or become subject to the tax
(“Excise Tax”) imposed by Section 4999 of the Internal Revenue Code of 1986, as
amended, the Corporation shall pay to HAUSMAN such amount (the “Gross-up
Payment”) as may be necessary to place HAUSMAN in the same after-tax position as
if no portion of the Change of Control Payments and any amounts paid to him
pursuant to this paragraph 6(d) had been subject to the Excise Tax.
For
the
avoidance of doubt, HAUSMAN shall be entitled to the foregoing benefits once
notice of termination is given by the Corporation pursuant to this Section
6(d),
regardless of his subsequent Death or Disability.
(e)
Termination
by the Corporation other than upon Change of Control, Death, Disability or
Cause. In
the
event that the Corporation terminates its relationship with HAUSMAN, including
a
non-renewal of this Agreement by the Corporation but other than upon a Change
of
Control, Death, Disability or Cause, HAUSMAN shall receive the
following:
(i) if
employment was terminated during the calendar year 2006, an amount equal
to six
(6) months of the then current base salary; if employment was terminated
commencing in the calendar year 2007 or if the Corporation elects not to
renew
this Agreement following the Initial Term or any Additional Term, an amount
equal to twelve (12) months of base salary for the then current Term plus
an
amount equal to the prior year’s bonus (and if occurring before the bonus for
2007 has been determined, an amount equal to 50% of the then current base
salary) ;
(ii) if
employment was terminated during the calendar year 2006, 50% of the previously
unvested portion of the Initial Option Grant shall vest and such vested options
shall be exercisable until their respective expiration dates; if employment
was
terminated commencing in the calendar year 2007 and thereafter or if the
Corporation elects not to renew this Agreement following the Initial Term
or any
Additional Term, all stock options granted to HAUSMAN (including without
limitation the Initial Option Grant) shall immediately vest and shall remain
exercisable until their respective expiration dates; and
(iii) Other
Compensation.
(f)
Termination
by HAUSMAN upon Good Reason; Other Terminations. In
the
event HAUSMAN terminates his relationship with the Corporation for “Good Reason”
as defined in Section 7, within one (1) year of the occurrence of the event
which established the “Good Reason,” or for “Good Reason” within one (1) year of
a Change of Control, HAUSMAN shall receive the following:
(i) if
the
termination occurred during the calendar year 2006 for Good Reason, an amount
equal to six (6) months of base salary; if the termination occurred during
the
calendar year 2006 due to a Change of Control, an amount equal to twelve
(12)
months of base salary; if termination for Good Reason occurred during the
calendar year 2007 or thereafter, an amount equal to twelve (12) months of
the
then current base salary plus an amount equal to the prior year’s bonus (and if
occurring before the bonus for 2007 has been determined, an amount equal
to 50%
of the then current base salary);
(ii) if
termination occurred during the calendar year 2006, 50% of the previously
unvested portion of the Initial Option Grant shall vest and such vested options
shall be exercisable until their respective expiration dates, except that
if
termination is by HAUSMAN for Good Reason subsequent to a Change of Control,
then 100% of any option grants to HAUSMAN (including, without limitation,
the
Initial Option Grant) shall vest and shall remain exercisable until its
respective expiration dates; if employment was terminated commencing in the
calendar year 2007 and thereafter, all stock options granted to HAUSMAN
(including, without limitation, the Initial Option Grant) shall immediately
vest
and shall remain exercisable until their respective expiration dates; and
(iii) Other
Compensation.
HAUSMAN
shall provide prior written notice to the Corporation of his termination
pursuant to this Section 6(f), and such notice shall describe the particular
“Good Reason(s)” at issue.
If
HAUSMAN otherwise terminates his employment without Good Reason, all options
vested at the time of such termination shall expire on their respective
expiration dates.
7.
Definitions.
(a)
"Cause"
Defined.“Cause”
means (i)
willful
malfeasance or willful misconduct by HAUSMAN in connection with his employment;
(ii)
HAUSMAN’s gross negligence in performing any of his duties under this Agreement;
(iii)
HAUSMAN’s conviction of, or entry of a plea of guilty to, or entry of a plea of
nolo contendere with respect to, any felony; (iv) HAUSMAN’s habitual drunkenness
or use or possession of illegal drugs while performing his duties under this
Agreement or excessive absenteeism not related to illness; (v) HAUSMAN’s
material breach of any written policy applicable to all employees adopted
by the
Corporation; or (vi) material breach by HAUSMAN of any of his agreements
in this
Agreement having a material detrimental impact on the Corporation.
(b)
“Disability”
Defined.“Disability”
shall mean HAUSMAN’s incapacity due to physical or mental illness that results
in his being unable to substantially perform his duties hereunder for six
consecutive months (or for six months out of any nine-month period). During
a
period of Disability, HAUSMAN shall continue to receive his base salary
hereunder, provided that if the Corporation provides HAUSMAN with disability
insurance coverage, payments of HAUSMAN’s base salary shall be reduced by the
amount of any disability insurance payments received by HAUSMAN due to such
coverage. Upon termination, after the end of the period of Disability, all
compensation due HAUSMAN under this Agreement shall cease.
(c)
“Change
of Control” Defined. “Change
of Control” shall mean the occurrence of any one or more of the following
events:
(i) An
acquisition (whether directly from the Corporation or otherwise) of any voting
securities of the Corporation (the “Voting Securities”) by any “Person” (as the
term person is used for purposes of Section 13(d) or 14(d) of the Securities
and
Exchange Act of 1934, as amended (the “1934 Act”)), immediately after which such
Person has “Beneficial Ownership” (within the meaning of Rule 13d-3 promulgated
under the 1934 Act) of fifty percent (50 %) or more of the combined voting
power
of the Corporation’s then outstanding Voting Securities.
(ii) The
individuals who, as of the Commencement Date, are members of the Board (the
“Incumbent Board”), cease for any reason to constitute at least fifty-one
percent (51%) of the Board; or
(iii) Approval
by the Board and, if required, stockholders of the Corporation of, or execution
by the Corporation of any agreement with respect to, or the consummation
of (it
being understood that the mere execution of a term sheet, memorandum of
understanding or other non-binding document shall not constitute a Change
of
Control):
(A) A
merger,
consolidation or reorganization involving the Corporation, where either or
both
of the events described in Section 7(c)(i) or 7(c)(ii) would be the
result;
(B) A
liquidation or dissolution of or appointment of a receiver, rehabilitator,
conservator or similar person for, the Corporation; or
(C) An
agreement for the sale or other disposition of all or substantially all of
the
assets of the Corporation to any Person (other than a transfer to a subsidiary
of the Corporation).
Notwithstanding
anything contained in this Agreement to the contrary, if HAUSMAN’s employment is
terminated prior to a Change in Control and HAUSMAN reasonably demonstrates
that
such termination (i) was at the request of a third party who has indicated
an
intention or taken steps reasonably calculated to effect a Change in Control
and
who effectuates a Change in Control (a “Third Party”) or (ii) otherwise occurred
in connection with, or in anticipation of, a Change in Control which actually
occurs, then for all purposes of this Agreement, the date of a Change in
Control
with respect to HAUSMAN shall mean the date immediately prior to the date
of
such termination of HAUSMAN’s employment.
(d)
“Good
Reason” Defined. “Good
Reason” shall mean the occurrence, whether or not after a Change in Control, of
any of the events or conditions described below:
(i) a
change
in HAUSMAN’s status, title, position or responsibilities (including reporting
responsibilities) which represents a material adverse change from his status,
title, position or responsibilities as in effect immediately prior to such
change; the assignment to HAUSMAN of any duties or responsibilities which
are
inconsistent with his status, title, position or responsibilities as in effect
immediately prior to such change; or any removal of HAUSMAN from any of such
offices or positions (except in those cases where a change is either at the
request of HAUSMAN, in connection with a general corporate restructuring
of
officer responsibilities, or a result of the promotion of HAUSMAN);
(ii) the
Corporation’s requiring HAUSMAN to spend substantially all of his time
performing his duties hereunder at a location other than his current home
office
facility, including requiring him to relocate to Foster City or the San
Francisco area, except for required travel relating to the Corporation’s
business;
(iii) the
failure by the Corporation to provide HAUSMAN with benefits, in the aggregate,
at least equal (in terms of benefit levels) to those provided for under each
employee benefit plan, program and practice in which HAUSMAN was participating
at any time prior to such failure; or
(iv) any
material breach by the Corporation of any provision of this Agreement which
is
not cured within ten (10) days after the receipt of written notice by the
Corporation of a description of the breach.
8. Payment
Terms.
Payment
of any amounts to which HAUSMAN shall be entitled pursuant to the provisions
of
Sections 6 and 7 shall be made no later than sixty (60) days following receipt
of notice of termination or the event giving rise to such termination. Any
amounts payable pursuant to Sections 6 and 7 which are not made within the
period specified in this Section 8 shall bear interest at a rate equal to
the
lesser of (i) the maximum interest rate allowable pursuant to applicable
law or
(ii) five points above the “prime rate” of interest as published from
time-to-time in the Eastern Edition of the Wall Street Journal.
9. Post-Termination
Benefits.
The
benefits hereunder shall be deemed the “Other Compensation” referenced in
Section 6(d), 6(e) and 6(f) hereof. Except if HAUSMAN resigns without Good
Reason (other than retirement on or after the age of 62), in the event HAUSMAN’s
employment with the Corporation is terminated for any reason prior to the
end of
the Term, HAUSMAN and his dependents, if any, will continue to participate
in
any group health plan sponsored by the Corporation in which HAUSMAN was
participating on the date of such termination, at
a cost
to HAUSMAN and his dependents equal to the amount charged by the Corporation
to
similarly situated employees while employed by the Corporation, for the
remainder of the Initial Term or, if termination occurs within an Additional
Term, for the remainder of such Additional Term. Thereafter, HAUSMAN and
his
dependents, if any, shall be entitled to elect to continue such health coverage,
at a cost to HAUSMAN and his dependents equal to the amount paid by the
Corporation for similarly situated employees while employed by the Corporation,
for the longest period of time permitted by the agents of the Corporation
who
arrange for such health coverage, with such period to last at least twelve
(12)
months from the date of termination. Upon termination for any reason, in
addition to any payments to which HAUSMAN may be entitled upon termination
of
his Employment pursuant to any provision of this Agreement, HAUSMAN shall
be
entitled to any benefits under any pension, supplemental pension, savings,
or
other employee benefit plan (other than life insurance) in which HAUSMAN
was
participating on the date of any such termination.
10.
Confidentiality.
(a)
"Corporation
Information" Defined.“Corporation
Information” means all information, knowledge or data of or pertaining to (i)
the Corporation, its employees and all work undertaken on behalf of the
Corporation, and (ii) any other person, firm, corporation or business
organization with which the Corporation may do business during the Term,
that is
not in the public domain (and whether relating to methods, processes,
techniques, discoveries, pricing, marketing or any other matters).
(b) Confidentiality.
HAUSMAN
hereby recognizes that the value of all trade secrets and other proprietary
data
and all other information of the Corporation not in the public domain disclosed
by the Corporation in the course of his employment with the Corporation is
attributable substantially to the fact that such confidential information
is
maintained by the Corporation in strict confidentiality and secrecy and would
be
unavailable to others without the expenditure of substantial time, effort
or
money. HAUSMAN therefore, except as provided in the next two sentences,
covenants and agrees that all Corporation Information shall be kept secret
and
confidential at all times during and after the end of the Term and shall
not be
used or divulged by him outside the scope of his employment as contemplated
by
this Agreement, except as the Corporation may otherwise expressly authorize
by
action of the Board. In the event that HAUSMAN is requested in a judicial,
administrative or governmental proceeding to disclose any of the Corporation
Information, HAUSMAN will promptly so notify the Corporation so that the
Corporation may seek a protective order or other appropriate remedy and/or
waive
compliance with this Agreement. If disclosure of any of the Corporation
Information is required, HAUSMAN may furnish the material so required to
be
furnished, but HAUSMAN will furnish only that portion of the Corporation
Information that legally is required.
11. Non-Competition,
Non-disparagement and Non-Solicitation Covenants; Intellectual Property.
(a) Non-Competition.
The
Corporation and HAUSMAN acknowledge that: (i) the Corporation has a special
interest in and derives significant benefit from the unique skills and
experience of HAUSMAN; (ii) HAUSMAN will use and have access to proprietary
and
valuable Corporation Information (as defined in Section 10 hereof) during
the
course of his employment; and (iii) the agreements and covenants contained
herein are essential to protect the business and goodwill of the Corporation
or
any of its subsidiaries, affiliates or licensees. Accordingly, except as
hereinafter noted, HAUSMAN covenants and agrees that during the Term, and
for a
period of one year following the termination of HAUSMAN’s employment, HAUSMAN
shall not provide any labor, work, services or assistance (whether as an
officer, director, employee, partner, agent, owner, independent contractor,
stockholder or otherwise) to a “Competing Business.” For purposes hereof,
“Competing Business” shall mean any business engaged in (i) the research,
diagnosis, treatment and prevention of diseases of oxidative stress associated
with damage from free radical and reactive oxygen species or (ii) the provision
of high quality enzyme immunoassay research services and products including
immunoassay kits for cardiac and tumor markers, infectious diseases, thyroid
function, steroids, and fertility hormones or
any
other business engaged in by the Company during the Term. Notwithstanding
the
foregoing, a “Competing Business” shall not include any of the business
activities identified on Schedule A annexed hereto, activities which the
Corporation hereby acknowledges do not constitute corporate opportunities
of the
Corporation and in which HAUSMAN has previously engaged and may continue
to
engage. In consideration of all of the compensation provisions in this
Agreement, HAUSMAN agrees to the provisions of this Section 11 and also agrees
that the non-competition obligations imposed herein, are fair and reasonable
under all the circumstances.
(b) Non-Solicitation
of Employees.
HAUSMAN
covenants and agrees that during the Term, and for a period of one year
following termination of employment hereunder for any reason whatsoever,
HAUSMAN
shall not directly or indirectly solicit any other employee of or consultant
to
the Corporation, or any of its subsidiaries or affiliates to terminate such
employee’s employment or consultant’s relationship with the Corporation, or any
of its subsidiaries or affiliates, as the case may be, or to become employed
by
or a consultant to a Competing Business.
(c) Ownership
of Intellectual Property.
Any
material or other work which may be subject to copyright or patent, and which
is
conceived, derived, made or written by HAUSMAN in connection with the
Corporation Information shall be deemed a “work for hire,” (and is herein
referred to as a “Development”). As between HAUSMAN and the Corporation, HAUSMAN
acknowledges that all Developments will be the sole and exclusive property
of
the Corporation and shall also be deemed Corporation Information under this
Agreement. HAUSMAN further acknowledges the Corporation may in turn negotiate
with any third party regarding their respective ownership rights to such
Developments. HAUSMAN shall execute such documents as may be necessary to
vest
in the Corporation or any third party, if applicable, all right, title and
interest in and to the Developments. The Corporation (or a third party, if
applicable) will pay all costs and expenses associated with any applications
and
the transfer of title to Developments, including paying HAUSMAN’s reasonable
attorneys’ fees for reviewing such documents and instruments presented for
execution.
(d) HAUSMAN’s
Intellectual Property Rights. Notwithstanding
the foregoing, the assignment by HAUSMAN to the Corporation (or a third party,
if applicable) of Developments, as well as the right to apply for and obtain
patents and/or registered copyrights on the same, shall be expressly limited
to
those specifically involving the Corporation Information relating to such
projects as mutually agreed upon by the parties hereto, and shall specifically
not include (i) any right, license or interest of the Corporation to general
concepts, formats, methods, testing techniques, study designs, computer software
or other procedures utilized or designed by HAUSMAN in performing his duties
hereunder, or any general inventions, discoveries, improvements, or
copyrightable materials relating thereto, nor (ii) any patentable or
copyrightable materials which can be shown by competent proof not to concern
the
subject matter of the Corporation Information, or, which predate this Agreement
or HAUSMAN’s receipt of the Corporation Information, or (iii) any intellectual
property relating to HAUSMAN’s current activities identified on Schedule
A.
(e) Remedies.
HAUSMAN
acknowledges that any such breach of the provisions of this Section 11 is
likely
to result in immediate and irreparable harm to the Corporation for which
money
damages are likely to be inadequate. Accordingly, HAUSMAN consents to injunctive
and other appropriate equitable relief upon the institution of proceedings
therefor by the Corporation in order to protect its rights hereunder. Such
relief may include, without limitation, an injunction to prevent: (i) the
breach
or continuation of HAUSMAN’s breach; (ii) HAUSMAN from disclosing any trade
secrets or Corporation Information; (iii) any Competing Business from receiving
from HAUSMAN or using any such trade secrets or Corporation Information;
and/or
(iv) any such Competing Business from retaining or seeking to retain any
employees of the Corporation. The provisions of this Section 11(e) shall
survive
the termination of this Agreement and HAUSMAN’s Term of employment.
12. Successors
and Assigns; Expenses.
(a) The
Employee.
This
Agreement is a personal contract, and the rights and interests that the
Agreement accords to HAUSMAN may not be sold, transferred, assigned, pledged,
encumbered, or hypothecated by him. All rights and benefits of HAUSMAN shall
be
for the sole personal benefit of HAUSMAN, and no other person shall acquire
any
right, title or interest under this Agreement by reason of any sale, assignment,
transfer, claim or judgment or bankruptcy proceedings against HAUSMAN. Except
as
so provided, this Agreement shall inure to the benefit of and be binding
upon
HAUSMAN and his personal representatives, distributees and
legatees.
(b) The
Corporation. This
Agreement shall be binding upon the Corporation and inure to the benefit
of the
Corporation and its successors and assigns.
(c) Expenses.
The
costs
of HAUSMAN’s counsel, Adam Eilenberg, related to the negotiation, preparation
and review of this Agreement, in the amount of $5,000, shall be paid by the
Corporation, in the form of shares of Common Stock, based on a price equal
to
85% of the Market Price, and shall be issued to Adam Eilenberg. Any shares
issued pursuant to the foregoing sentence shall have the same registration
rights as those being provided to HAUSMAN hereunder and pursuant to the
Registration Rights Agreement. Furthermore, in the event of any dispute between
HAUSMAN and the Corporation relating to this Agreement which follows a Change of
Control, the Corporation will pay all reasonable legal expenses incurred
by
HAUSMAN in connection with such dispute unless a court of competent jurisdiction
determines that the facts surrounding such dispute originates from events
that
occurred prior to the Change of Control.
13. Entire
Agreement.
This
Agreement, together with the Initial Option Grant and the Registration Rights
Agreement, represents the entire agreement between the parties concerning
HAUSMAN’s employment with the Corporation and supersedes all prior negotiations,
discussions, understandings and agreements, whether written or oral, between
HAUSMAN and the Corporation relating to the subject matter of this Agreement,
including any existing consulting agreements.
14. Amendment
or Modification; Waiver.
No
provision of this Agreement may be amended or waived unless such amendment
or
waiver is agreed to in writing signed by HAUSMAN and by a duly authorized
officer of the Corporation. No waiver by any party to this Agreement of any
breach by another party of any condition or provision of this Agreement to
be
performed by such other party shall be deemed a waiver of a similar or
dissimilar condition or provision at the same time, any prior time or any
subsequent time.
15. Notices.
Any
notice to be given under this Agreement shall be in writing and delivered
personally or sent by overnight courier or registered or certified mail,
postage
prepaid, return receipt requested, addressed to the party concerned at the
address indicated below, or to such other address of which such party
subsequently may give notice in writing:
If
to
HAUSMAN: MARVIN
S.
HAUSMAN, M.D
90
NW
Second Street, P.O. Box 910,
Stevenson,
Washington 98648
with
a
copy to: Eilenberg
& Krause LLP
11
East
44th
Street
New
York,
NY 10017
Attention:
Adam Eilenberg, Esq.
If
to the
Corporation: OXIS
International, Inc.
323
Vintage Park Drive, Suite B,
Foster
City, California 94404
Attention:
Chairman of the Board
with
a
copy to: __________________________
__________________________
__________________________
Attention:
__________________
Any
notice delivered personally or by overnight courier shall be deemed given
on the
date delivered and any notice sent by registered or certified mail, postage
prepaid, return receipt requested, shall be deemed given on the date
mailed.
16. Severability.
If any
provision of this Agreement or the application of any such provision to any
party or circumstances shall be determined by any court of competent
jurisdiction to be invalid and unenforceable to any extent, the remainder
of
this Agreement or the application of such provision to such person or
circumstances other than those to which it is so determined to be invalid
and
unenforceable shall not be affected, and each provision of this Agreement
shall
be validated and shall be enforced to the fullest extent permitted by law.
If
for any reason any provision of this Agreement containing restrictions is
held
to cover an area or to be for a length of time that is unreasonable or in
any
other way is construed to be too broad or to any extent invalid, such provision
shall not be determined to be entirely null, void and of no effect; instead,
it
is the intention and desire of both the Corporation and HAUSMAN that, to
the
extent that the provision is or would be valid or enforceable under applicable
law, any court of competent jurisdiction shall construe and interpret or
reform
this Agreement to provide for a restriction having the maximum enforceable
area,
time period and such other constraints or conditions (although not greater
than
those contained currently contained in this Agreement) as shall be valid
and
enforceable under the applicable law.
17. Survivorship.
The
respective rights and obligations of the parties hereunder shall survive
any
termination of this Agreement to the extent necessary to the intended
preservation of such rights and obligations.
18. Headings.
All
descriptive headings of sections and paragraphs in this Agreement are intended
solely for convenience of reference, and no provision of this Agreement is
to be
construed by reference to the heading of any section or paragraph.
19. Withholding
Taxes.
All
salary, benefits, reimbursements and any other payments to HAUSMAN under
this
Agreement shall be subject to all applicable payroll and withholding taxes
and
deductions required by any law, rule or regulation of and federal, state
or
local authority.
20.
Counterparts.
This
Agreement may be executed in one or more counterparts, each of which shall
be
deemed to be an original but all of which together constitute one and same
instrument.
21. Applicable
Law; Jurisdiction.
The laws
of the State of California shall govern the interpretation, validity and
performance of the terms of this Agreement, without reference to rules relating
to conflicts of law. Any suit, action or proceeding against HAUSMAN with
respect
to this Agreement, or any judgment entered by any court in respect thereof,
may
be brought in any court of competent jurisdiction in the State of California,
as
the Corporation may elect in its sole discretion, and HAUSMAN hereby submits
to
the exclusive jurisdiction of such courts for the purpose of any such suit,
action, proceeding or judgment.
[THE
BALANCE OF THIS PAGE HAS BEEN LEFT BLANK INTENTIONALLY]
IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
date
first written above.
___s/
Marvin
S. Hausman, M.D._______
MARVIN
S. HAUSMAN,
M.D.
OXIS
INTERNATIONAL,
INC.
|
By:
|
____/s/
Michael D. Centron_____________
|
Name:
Michael D.
Centron
Title:
Vice President &
CFO
SCHEDULE
A
PERMITTED
OUTSIDE BUSINESS ACTIVITIES OF HAUSMAN
|
1.
|
HAUSMAN’s
previously disclosed current activities in the field of mushrooms
and
associated oxidative stress and bioactive substances, as well as
to the
avian flu virus, previously acknowledged by the Board not to constitute
business opportunities of the Corporation.
|
|
2.
|
Patent
activity, research and development and commercial development of
patent
applications and related intellectual property entitled “Identification of
Selenoergothioneine as a Natural Organic Form of Selenium from
Cultivated
Mushrooms” for which HAUSMAN is a
co-inventor.
|
|
3.
|
Patent
activity, research and development and commercial development of
patent
applications and related intellectual property entitled “Identification of
ergothioneine transporter and therapeutic uses thereof” to which HAUSMAN
and related entities have acquired rights.
|
14
Exhibit
10.2
ADVISORY
AGREEMENT dated
as
of November 6, 2006, between Oxis International, Inc., a Delaware corporation
(the “Company”), and Ambient Advisors LLC (the “Advisor”).
The
Company desires to retain the Advisor to provide management and advisory
services to the Company, and the Advisor desires to perform such management
and
advisory services for the Company, in each case, upon the terms and conditions
hereinafter set forth.
NOW,
THEREFORE,
in
consideration of the mutual covenants and obligations hereinafter set forth,
the
parties agree as follows:
1.
Retention
of Advisor.
The
Company hereby retains the Advisor, and the Advisor hereby accepts such
retention by the Company, upon the terms and conditions hereinafter set
forth.
The Advisor shall perform all such services as an independent contractor
to the
Company and not as an employee, agent or representative of the
Company.
2.
Term.
The
retention of the Advisor hereunder shall be for a period (the “Initial Term”)
that commenced on October 15, 2006 (the “Commencement Date”) and shall end on
October 15, 2009 or such earlier date provided in this Section 2. The Initial
Term will be extended automatically for additional one-year periods (each
an
“Additional Term,” together with the Initial Term, the “Term”). This Agreement
shall automatically terminate prior to October 15, 2009 or the expiration
of any
Additional Term upon the first to occur of (i) the death or disability
of Mr.
Gary M. Post, Managing Director of the Advisor, (ii) the resignation by
the
Advisor following the delivery by it to the Company of ten days’ advance written
notice of such resignation or (iii) termination by the Company following
the
delivery to the Advisor of 60 days’ advance written notice from the Company’s
Board of Directors of its intention to terminate the Agreement.
3.
Duties.
During
the Term, the Advisor shall advise the Company and provide management services
in the areas of (a) strategic planning, (b) financial planning and budgeting,
(c) investor relations, (d) corporate finance (including advising on new
capital
formation and mergers and acquisitions), (e) day to day operational management
and (f) such additional roles and responsibilities as the Advisor and the
Company shall mutually agree. The parties acknowledge that Mr. Gary M.
Post
shall perform substantially all of the services of the Advisor under this
Agreement, and that although he will not formally be named an officer of
the
Company, he will be empowered to sign checks and enter into contracts on
the
Company’s behalf in the capacity of “Acting Chief Operating Officer.” The
Advisor shall report directly to, and shall reasonably update, the CEO
or his
designee on the status of each project, and shall reasonably coordinate
its
efforts with members of management, the Board of Directors and other advisors
and consultants to the Company.
4.
Time
to be Devoted to Services.
During
the Term, the Advisor agrees to spend approximately one-third (1/3) of
the
Advisor’s working time to the provisions of services hereunder.
5.
Compensation.
(a) Advisory
Fee.
The
Company shall pay to the Advisor an advisory fee of $83,333 per annum.
The
advisory fee initially will be payable quarterly in advance in the form
of
either the Company’s common stock (“Common Stock”), at a price equal to 85% of
the “Market Price” for the Company’s common stock, which shall equal the average
of the closing price for the five trading days prior to the date that the
issuance is authorized by the Board of Directors. In lieu of receiving
Common
Stock for such payments, the Advisor may elect to receive that number of
ten
year Warrants (with cashless exercise provisions) equal to 1.5 times the
number
of shares of Common Stock that would otherwise be received, at an exercise
price
equal to the Market Price. The first installment, representing $20,833
of the
annual advisory fee, and payable at the Advisor’s election in the form of
warrants described in the foregoing sentence, will be made as soon as
practicable after the execution of this Agreement, and thereafter, will
be paid
on the dates that are three months, six months and nine months from the
date
hereof, and quarterly thereafter for the duration of the Term. Notwithstanding
the foregoing, once the Company has raised at least $2.5 million in one
or more
financings (equity, debt or convertible debt, in addition to the financing
closed on October 27, 2006) or in a strategic transaction (a “Qualifying
Financing”), the Advisor may elect, at any time, in lieu of receiving a
quarterly issuance of stock (or warrants in lieu thereof), to receive the
advisory fee in cash, payable monthly on the Corporation’s regular pay cycle for
professional employees. All shares of Common Stock issuable to the Advisor
under
this Agreement (if not otherwise registered pursuant to an existing stock
option
plan covered by a registration statement on Form S-8), or upon the exercise
of
the warrants to be issued in lieu thereof, shall have the benefit of piggyback
registration rights, pursuant to a Registration Rights Agreement to be
executed
by the Company and the Advisor (the “Registration Rights Agreement”); provided,
however, that the failure to execute such a Registration Rights Agreement
shall
not limit the Advisor’s piggyback registration rights hereunder. Following the
Initial Term, the Board shall in accordance with its customary review of
executive management and consultants’ compensation, review Advisor’s annual
advisory fee and make adjustments the Board (or its Compensation Committee)
feels are appropriate, but in any event Advisor’s base compensation shall not be
lower than $250,000 (on a full-time annual basis).
(b)
Other and Additional Compensation.
(i) Annual
Bonus.
During
the Term, the Advisor shall receive an annual bonus based upon the attainment
of
agreed upon goals and milestones as determined by the Board and its Compensation
Committee. During the remainder of calendar year 2006, the Advisor’s bonus shall
be pro rated on an annual bonus rate in the range of 25% to 50% of the
advisory
fee, and the bonus for subsequent years of the Term shall be in a similar
target
range. Additional bonus calculations and payments determined by the Board
and
the Compensation Committee shall be made based upon (i) increases in the
Company’s sales and reductions in its expenses, improvements in operations, and
completion of a merger with Biochek and integration of its operations with
those
of the Company, (ii) successful financings an/or strategic transactions
completed, taking into account the aggregate amount of funds raised for
the
Company and (iii) performance of the trading price of the Company’s Common
Stock.
The
bonuses payable hereunder shall be paid in cash, although at the Advisor’s sole
option, they may be paid in stock (or in the form of ten year warrants
with
cashless exercise provisions, with 1.5 times the number of warrants to
be issued
in lieu of the number of shares of Common Stock), based upon the average
of the
closing bid and asked prices for the 5 trading days immediately prior to
the
awarding to the Advisor of the bonus for a particular year (which shall
also be
the exercise price of the warrants, if the Advisor elects to receive warrants).
The Advisor shall make its election no more than ten (10) days following
notification by the Company of the bonus award, and the failure to make
timely
election shall mean that the Advisor shall receive the bonus in the form
of
cash.
(ii) Warrants.
As soon
as practicable following execution of this Agreement, the Company shall
issue to
the Advisor ten year warrants to purchase 550,000 shares of Common Stock
(the
“Warrants”), at an exercise price equal to the Market Price. The Warrants shall
have a cashless exercise provision and otherwise shall be in form mutually
satisfactory to the parties. The Warrants will vest as follows: 275,000
Warrants
in four equal quarterly installments commencing on the date that is three
months
from the Commencement Date and every three months thereafter, (iii) and
the
remaining 275,000 Warrants in eight quarterly installments over the subsequent
two years and (iv) for an exercise price equal to the average of the closing
bid
and asked prices for the Common Stock on the trading day immediately prior
to
the date of the execution of this Agreement.
(iii) Additional
Compensation.
The
foregoing establishes the minimum compensation during the Term and shall
not
preclude the Board from awarding the Advisor a higher salary or any additional
bonuses or stock options in the event of a successful financing or strategic
transaction or otherwise, and in any event, in the discretion of the Board.
(iv) Sign-on
Bonus.
As a
sign-on bonus and as soon as practicable following execution of this Agreement,
the Advisor shall be granted non-qualified options for the purchase of
up to
333,333 shares (the “Initial Option Grant”) of Common Stock under the Company’s
existing stock option plan (the “Plan”). The terms of the grant, including the
vesting schedule and exercise price of the Initial Option Grant, shall
be as set
forth in a separate option agreement executed by and between the parties
and
will provide, among other things, (i) for cashless exercise provisions
and (ii)
for the vesting in six equal installments, commencing on the date that
is 30
days after the Commencement Date, through the 180th
day
after the Commencement Date. The options issued under this Section 5(b)(iv)
will
vest monthly in six equal installments, commencing on the date that is
30 days
after the Commencement Date, through the 180th
day
after the Commencement Date. Subsequent stock option grants, including
an annual
grant in 2007, will be determined annually by the Board and the Compensation
Committee, taking into account the previous year’s performance of the Company’s
Common Stock, sales, revenue and income performance, as well as the frequency
and success of financings and/or strategic transactions.
6.
Business
Expenses: Benefits.
The
Company shall reimburse the Advisor in cash, in accordance with its practice
from time to time, for all reasonable and necessary travel, entertainment
and
other expenses and other disbursements incurred by the Advisor for or on
behalf
of the Company in the performance of the Advisor’s duties hereunder. The Advisor
shall provide such appropriate documentation of expenses and disbursements
as
may from time to time be required by the Company. Any travel expenses in
excess
of $1,000 for any one trip must be pre-approved by the CEO.
The
Company shall have no obligation to provide any benefits to Advisor or
to Gary
M. Post, including without limitation, any health, life or disability
benefits.
7.
Indemnification;
Insurance.
The
Company will indemnify the Advisor for its actions in the capacity as a
Advisor
hereunder (other than resulting from the Advisor’s gross negligence or willful
misconduct) and Gary M. Post for his actions as a director of the Company
and
any of its subsidiaries to the full extent permitted by law and as provided
in
the Company’s Certificate of Incorporation and by-laws. The Company also will
include the Advisor and Gary M. Post on its existing Directors and Officers
liability insurance policy, which the Company represents is for a customary
amount for similar public companies in the life sciences
industry.
8.
Termination
Payments.
If
the
Company terminates this Agreement pursuant to Section 2(iii) without Cause
after
the six month anniversary of the date of this Advisory Agreement, Advisor
shall
receive an amount equal to twelve (12) months of the advisory fee for the
then
current Term in a lump sum payment and all outstanding stock options shall
become fully vested and the warrants vested as of the date of termination
and
the stock options shall remain exercisable through their respective expiration
dates. If the Company terminates this Agreement pursuant to Section 2(iii)
without Cause prior the six month anniversary of the date of this Advisory
Agreement, Advisor shall be paid any expenses due to him and all vested
stock
options and warrants shall remain exercisable through their respective
expiration dates. “Cause” shall mean means (i) willful malfeasance or willful
misconduct by the Advisor in connection with the performance of its duties
hereunder; (ii) the Advisor’s gross negligence in performing any of its duties
under this Agreement; (iii) the Advisor’s or Gary M. Post’s conviction of, or
entry of a plea of guilty to, or entry of a plea of nolo contendere with
respect
to, any felony; (iv) the habitual drunkenness or use or possession of illegal
drugs by Gary M. Post while performing the Advisor’s duties under this Agreement
or excessive absenteeism not related to illness; (v) the Advisor’s material
breach of any written policy applicable to all employees and Advisors adopted
by
the Corporation; or (vi) material breach by the Advisor of any of its agreements
in this Agreement having a material detrimental impact on the Company after
written notice and a reasonable opportunity to cure of not less than 30
days.
If
the
Company terminates this Agreement pursuant to Section 2(iii) for Cause,
the
Company will only be required to give ten (10) days’ prior notice (other than
pursuant to Section 8(a)(vi), for which the notice requirement is 30 days),
stating in reasonable detail the Board’s understanding of the facts leading to
the determination of Cause, and in such event the Advisor shall not be
entitled
to any further payments of its advisory fee hereunder, and any unexercised
stock
options shall expire.
If
the
Advisor resigns pursuant to Section 2(ii), for whatever reason, or if Gary
M.
Post dies or becomes disabled, the Advisor (or its successors or assigns)
shall
not be entitled to any further payments of the advisory fee hereunder,
all
unvested stock options and warrants shall expire, and all vested stock
options
and warrants shall remain exercisable until their respective expiration
dates.
“Disability” shall mean the incapacity of Gary Post due to physical or mental
illness that results in the Advisor’s being unable to substantially perform its
duties hereunder for six consecutive months (or for six months out of any
nine-month period). During a period of Disability, the Advisor shall continue
to
receive the advisory fee hereunder.
9.
Corporate
Opportunities; Intellectual Property.
(a) The
Advisor acknowledges that by virtue of its efforts as a Advisor hereunder
to the
Company and of Gary M. Post’s serving as a director, the Advisor may become
aware of confidential information identified as such in writing by the
Company
relating to the Company’s business opportunities and potential acquisitions of
companies and or technologies/compounds (“Confidential Information”), and that
the Advisor will not, during the Term and for a period of 6 months thereafter
(the “Restricted Period”), directly or indirectly use any such Confidential
Information for its own benefit or for the benefit of any third person
other
than the Company or its affiliates or enter into or negotiate a transaction
with
any person that was the subject of the Company’s business opportunity or
potential acquisition without the prior written approval of the Company
or
following an express decision by the CEO or the Board not to pursue the
specific
business opportunity or potential acquisition. The foregoing limitation
shall
not apply to the Advisor after the end of the Restricted Period. The
restrictions set forth in this Section 9 are in addition to any of the
fiduciary
obligations of Gary M. Post to the Company by virtue of his being a director
of
the Company.
(b)
Notwithstanding the foregoing, the Company acknowledges that the Advisor
may
pursue its own independent business interests and activities during the
Restricted Period, including those relating to life sciences and medical
technologies, which the Company acknowledges are not business opportunities
of
the Company and, therefore, which may be pursued by the Advisor on its
own or in
association with others independently of the Company during the Restricted
Period. The Advisor is under no obligation hereunder to identify specific
potential business opportunities or acquisitions for the Company. However,
once
the Advisor informs the Company of a potential opportunity during the Term,
it
may not independently pursue that opportunity during the Restricted Period
without the prior written approval of the Company or following an express
decision by the CEO or the Board not to pursue the specific business opportunity
or potential acquisition.
(c)
Any
material or other work which may be subject to copyright or patent, and
which is
conceived, derived, made or written by the Advisor in connection with the
Confidential Information shall be deemed a “work for hire,” (and is herein
referred to as a “Development”). As between the Advisor and the Company, Advisor
acknowledges that all Developments will be the sole and exclusive property
of
the Company and shall also be deemed Confidential Information under this
Agreement. The Advisor further acknowledges the Company may in turn negotiate
with any third party regarding their respective ownership rights to such
Developments. The Advisor shall execute such documents as may be necessary
to
vest in the Company or any third party, if applicable, all right, title
and
interest in and to the Developments. The Company (or a third party, if
applicable) will pay all costs and expenses associated with any applications
and
the transfer of title to Developments, including paying the Advisor’s reasonable
attorneys’ fees for reviewing such documents and instruments presented for
execution.
(d)
Notwithstanding the foregoing, the assignment by the Advisor to the Company
(or
a third party, if applicable) of Developments, as well as the right to
apply for
and obtain patents and/or registered copyrights on the same, shall be expressly
limited to those specifically involving the Confidential Information relating
to
such projects as mutually agreed upon by the parties hereto, and shall
specifically not include (i) any right, license or interest of the Company
to
general concepts, formats, methods, testing techniques, study designs,
computer
software or other procedures utilized or designed by the Advisor in performing
its duties hereunder, or any general inventions, discoveries, improvements,
or
copyrightable materials relating thereto, nor (ii) any patentable or
copyrightable materials which can be shown by competent proof not to concern
the
subject matter of the Confidential Information, or, which predate this
Agreement
or the Advisor’s receipt of the Confidential Information, or (iii) any
intellectual property relating to the Advisor’s current activities.
(e)
The
Advisor agrees that this Section 9 may be enforced by the Company by injunction,
or other equitable relief, without prejudice to any other rights and remedies
that the Company may have under this Agreement and without the posting
of any
bond.
10. Legal
Expenses.
The
costs of the Advisor’s counsel, Adam Eilenberg related to the negotiation,
preparation and review of this Agreement, in the amount of $2,500, shall
be paid
by the Corporation, in the form of shares of Common Stock, based on a price
equal to 85% of the Market Price, and shall be issued to Adam Eilenberg.
Any
shares issued pursuant to the foregoing sentence shall have the same
registration rights as those being provided to Advisor hereunder and pursuant
to
the Registration Rights Agreement.
11.
Notices.
All
notices, claims, certificates, requests, demands and other communications
hereunder shall be in writing and shall be deemed to have been duly given
and
delivered if personally delivered or if sent by nationally-recognized overnight
courier, by telecopy, or by registered or certified mail, return receipt
requested and postage prepaid, addressed as follows:
If
to the
Company, to:
OXIS
International, Inc.
323
Vintage Park Drive, Suite B
Foster
City, California 94404
Attention:
Chairman of the Board
if
to the
Advisor, to:
Ambient
Advisors LLC
Box
24976
Los
Angeles, CA 90024
Attention:
Gary M. Post
or
to
such other address as the party to whom notice is to be given may have
furnished
to the other party or parties in writing in accordance herewith. Any such
notice
or communication shall be deemed to have been received in the case of personal
delivery, on the date of such delivery, in the case of nationally-recognized
overnight courier, on the next business day after the date when sent, in
the
case of telecopy transmission, when received, and in the case of mailing,
on the
third business day following that on which the piece of mail containing
such
communication is posted.
12.
Binding
Agreement; Benefit.
Subject
to Section 16, the provisions of this Agreement will be binding upon, and
will
inure to the benefit of, the respective heirs, legal representatives, successors
and assigns of the parties.
13.
Governing
Law.
This
Agreement will be governed by, and construed and enforced in accordance
with,
the laws of the State of California (without giving effect to principles
of
conflicts of laws).
14.
Waiver
of Breach.
The
waiver by either party of a breach of any provision of this Agreement must
be in
writing and shall not operate or be construed as a waiver of any other
breach.
15.
Entire
Agreement; Amendments.
This
Agreement contains the entire agreement between the parties with respect
to the
subject matter hereof and supersedes all prior agreements or understandings
between the parties with respect thereto. This Agreement may be amended
only by
and agreement in writing signed by the parties.
16.
Headings.
The
section headings contained in this Agreement are for reference purposes
only and
shall not affect in any way the meaning or interpretation of this
Agreement.
17.
Assignment.
This
Agreement is personal in its nature and the parties shall not, without
the
consent of the other, assign or transfer this Agreement or any rights or
obligations hereunder; provided,
however,
that
the Company may assign this Agreement to any of its subsidiaries.
18.
Counterparts.
This
Agreement may be executed in counterparts, and each such counterpart shall
be
deemed to be an original instrument, but both such counterparts together
shall
constitute but one agreement.
[remainder
of page left intentionally blank]
IN
WITNESS WHEREOF,
the
parties hereto have executed and delivered this Advisory Agreement as of
the
date first written above.
OXIS
INTERNATIONAL,
INC.
By:
/s/
Marvin S.
Hausman, M.D.
Name:
Title:
AMBIENT
ADVISORS
LLC
By:/s/
Gary M.
Post
Gary
M.
Post
7
CONSULTING
AGREEMENT dated
as
of November 6, 2006, between Oxis International, Inc., a Delaware corporation
(the “Company”), and John E. Repine, M.D. (the “Consultant”).
The
Company desires to retain the Consultant to perform consulting services
in the
field of antioxidant and inflammation research for the Company, and the
Consultant desires to perform such consulting services for the Company,
in each
case, upon the terms and conditions hereinafter set forth.
NOW,
THEREFORE,
in
consideration of the mutual covenants and obligations hereinafter set
forth, the
parties agree as follows:
1.
Retention
of Consultant.
The
Company hereby retains the Consultant as a consultant, and the Consultant
hereby
accepts such retention by the Company, upon the terms and conditions
hereinafter
set forth. The Consultant shall perform all such services as an independent
contractor to the Company and not as an employee, agent or representative
of the
Company.
2.
Term.
The
retention of the Consultant hereunder shall be for a period commencing
as of
October 15, 2006 (the “Commencement Date”) and ending on October 15, 2009 or
such earlier date provided in this Section 2. This Agreement shall automatically
terminate prior to such date upon the first to occur of (i) the death
or
disability of the Consultant, (ii) the resignation by the Consultant
following
the delivery by him to the Company of ten days’ advance written notice of such
resignation or (iii) termination by the Company following the delivery
to the
Consultant of 60 days’ advance written notice from the Company’s Board of
Directors of its intention to terminate the Agreement. The period commencing
on
the Commencement Date and ending on the date of termination of the Consultant’s
retention hereunder shall be called the “Term”.
3.
Duties.
During
the Term, the Consultant shall advise the Company concerning matters
of
antioxidant and inflammation research and potential acquisitions (including
products/compounds/intellectual property as well as companies), and product
research and development. The Consultant shall also advise the Company
regarding
the development and establishment of reference labs for oxidative stress
and
inflammatory reactions. For each such matter, the Consultant will initiate
his
advisory services only after being requested to do so by the Chief Executive
Officer of the Company (the “CEO”). At the outset of each project, the CEO will
define its scope and timing. The Consultant shall report directly to,
and shall
reasonably update, the CEO or his designee on the status of each project,
and
shall reasonably coordinate his efforts with members of management and
other
consultants to the Company.
4.
Time
to be Devoted to Services.
During
the Term, the Consultant shall not be required to devote any specified
amount of
time to the provisions of services hereunder and shall only be required
to
devote such reasonable amount of time to the business of the Company
as the
Consultant shall reasonably determine to be necessary to fulfill his
duties
hereunder.
5.
Compensation.
The
Company shall pay to the Consultant a consulting fee of $36,000 per annum.
The
consulting fee initially will be payable quarterly in advance in the
form of the
Company’s common stock (“Common Stock”), at a price equal to 85% of the “Market
Price” for the Company’s common stock, which shall equal the average of the
closing prices for the five trading days prior to the date that the issuance
is
authorized by the Board of Directors. In lieu of receiving Common Stock
for such
payments, the Consultant may elect to receive that number of ten year
Warrants
(with cashless exercise provisions) equal to 1.5 times the number of
shares of
Common Stock that would otherwise be received, at an exercise price equal
to the
Market Price. The first installment, representing $9,000 of the annual
consulting fee, and payable at the Consultant’s election either in the shares of
Common Stock of form of warrants described in the foregoing sentence,
will be
paid promptly after the determination of the Market Price, and thereafter,
will
be paid on the dates that are three months, six months and nine months
from the
date hereof, and quarterly thereafter for the duration of the Term.
Notwithstanding the foregoing, once the Company has raised at least $2.5
million
in one or more financings (equity, debt or convertible debt, in addition
to the
financing closed on October 27, 2006) or in a strategic transaction (a
“Qualifying Financing”), the consultant may elect, at any time, in lieu of
receiving a quarterly issuance of stock (or warrants in lieu thereof),
to
receive his consulting fee in cash, payable quarterly. All shares of
Common
Stock issuable to the Consultant under this Agreement (if not otherwise
registered pursuant to an existing stock option plan covered by a registration
statement on Form S-8), or upon the exercise of the warrants to be issued
in
lieu thereof, shall have the benefit of piggyback registration rights,
pursuant
to a Registration Rights Agreement to be executed by the Company and
the
Consultant (the “Registration Rights Agreement”); provided, however, that the
failure to execute such a Registration Rights Agreement shall not limit
the
Consultant’s piggyback registration rights hereunder.
6.
Bonus
Awards.
During
the Term, the Consultant shall be eligible to annual and special bonuses
based
upon the attainment of agreed upon goals and milestones as determined
by the
CEO, relating to special contributions made by the Consultant to the
Company’s
business, product development and intellectual property. Each bonus payable
hereunder shall be paid in cash, although at the Consultant’s sole option, such
bonus may be paid in stock (or in the form of ten year warrants with
cashless
exercise provisions, with 1.5 times the number of warrants to be issued
in lieu
of the number of shares of Common Stock), based upon the average of the
closing
bid and asked prices for the 5 trading days immediately prior to the
awarding to
the Consultant of the particular bonus (which shall also be the exercise
price
of the warrants, if the Consultant elects to receive warrants). The Consultant
shall make his election no more than ten (10) days following notification
by the
Company of a bonus award, and the failure to make timely election shall
mean
that the Consultant shall receive the bonus in the form of cash.
7.
Stock
Options.
As
soon
as practicable following execution of this Agreement, the Consultant
shall be
granted ten-year options for the purchase of up to 200,000 shares (the
“Initial
Option Grant”) of Common Stock under the Company’s existing stock option plan
(the “Plan”). The terms of the grant, including the vesting schedule and
exercise price of the Initial Option Grant, shall be as set forth in
a separate
option agreement executed by and between the parties and will provide,
among
other things, (i) for cashless exercise provisions and (ii) for the vesting
of
100,000 options in four equal quarterly installments commencing on the
date that
is three months from the Commencement Date and every three months thereafter,
(iii) for the vesting of the remaining 100,000 options in eight quarterly
installments over the subsequent two years and (iv) for an exercise price
equal
to the average of the closing bid and asked prices for the Common Stock
on the
trading day immediately prior to the date hereof. Subsequent stock option
grants
will be determined annually by the Company’s Board of Directors (the “Board”)
and its Compensation Committee. During the Term, the Consultant will
be deemed
to be an employee of the Company for the purpose of his existing stock
options,
including those granted pursuant to Sections 7 and 8 hereof.
8.
Sign
On Bonus.
As
a
sign-on bonus and as soon as practicable following execution of this
Agreement,
the Company shall issue to the Consultant an additional ten-year option
under
the Plan for the purchase of up to 200,000 shares (the “Sign On Option Grant”).
The terms of the grant, including the vesting schedule and exercise price
of the
Sign On Option Grant, shall be as set forth in a separate option agreement
executed by and between the parties and will provide, among other things,
(i)
for cashless exercise provisions, and (ii) for an exercise price equal
to the
average of the closing bid and asked prices for the Common Stock on the
trading
day immediately prior to the Commencement Date. The options issued under
this
Section 8 will vest monthly in six equal installments, commencing on
the date
that is 30 days after the Commencement Date, through the 180th
day
after the Commencement Date.
9.
Business
Expenses: Benefits.
The
Company shall reimburse the Consultant in cash, in accordance with its
practice
from time to time, for all reasonable and necessary travel, entertainment
and
other expenses and other disbursements incurred by the Consultant for
or on
behalf of the Company in the performance of the Consultant’s duties hereunder.
The Consultant shall provide such appropriate documentation of expenses
and
disbursements as may from time to time be required by the Company.
The
Company shall have no obligation to provide any benefits to Consultant,
including without limitation, any health, life or disability
benefits.
10.
Indemnification;
Insurance.
The
Company will indemnify the Consultant for his actions in the capacity
as a
consultant hereunder (other than resulting from his gross negligence
or willful
misconduct) and as a director of the Company and any of its subsidiaries
to the
full extent permitted by law and as provided in the Company’s Certificate of
Incorporation and by-laws. The Company also will include the Consultant
on its
existing Directors and Officers liability insurance policy, which the
Company
represents is for a customary amount for similar public companies in
the life
sciences industry.
11.
Additional
Payments and Stock Issuances.
The
Company agrees whenever it makes any payment of cash to the Consultant
hereunder
(other than for the reimbursement of expenses), it will simultaneously
pay to
University Physicians Inc., 13611 East Colfax Avenue, Aurora, CO 80011
(“UPI”) a
cash payment equal to 13.5% of the cash paid to the Consultant, and that
whenever the Company grants a stock option to the Consultant, it will
simultaneously grant to UPI an award for 10% of the number of options
awarded to
the Consultant, at the same exercise price and subject to the same rights,
terms
and conditions as the option grant awarded to Consultant (including,
without
limitation, exercise price, vesting provisions, cashless exercise rights
and
piggyback registration rights). UPI shall be a third party beneficiary
of this
Section 11.
12.
Termination
Payments.
If
the
Company terminates this Agreement pursuant to Section 2(iii) without
Cause after
the six month anniversary of the date of this Consulting Agreement, Consultant
shall receive an amount equal to twelve (12) months of the consulting
fee for
the then current Term in a lump sum payment, and all outstanding stock
options
shall become fully vested and the warrants vested as of the date of termination
and the stock options shall remain exercisable through their respective
expiration dates. If the Company terminates this Agreement pursuant to
Section
2(iii) without Cause prior the six month anniversary of the date of this
Consulting Agreement, Consultant shall be paid any expenses due to him
and all
vested stock options and warrants shall remain exercisable through their
respective expiration dates. “Cause” shall mean means (i) willful malfeasance or
willful misconduct by the Consultant in connection with the performance
of his
duties hereunder; (ii) the Consultant’s gross negligence in performing any of
his duties under this Agreement; (iii) the Consultant’s conviction of, or entry
of a plea of guilty to, or entry of a plea of nolo contendere with respect
to,
any felony; (iv) the Consultant’s habitual drunkenness or use or possession of
illegal drugs while performing his duties under this Agreement or excessive
absenteeism not related to illness; (v) the Consultant’s material breach of any
written policy applicable to all employees and consultants adopted by
the
Corporation; or (vi) material breach by the Consultant of any of his
agreements
in this Agreement having a material detrimental impact on the Corporation
after
written notice and a reasonable opportunity to cure of not less than
30
days.
If
the
Company terminates this Agreement pursuant to Section 2(iii) for Cause
(other
than pursuant to Section 8(a)(vi), for which the notice requirement is
30 days),
the Company will only be required to give ten (10) days’ prior notice, and in
such event the Consultant shall not be entitled to any further payments
of his
consulting fee hereunder, and any unexercised stock options shall
expire.
If
the
Consultant resigns pursuant to Section 2(ii), for whatever reason, or
dies or
becomes disabled, the Consultant (or his estate) shall not be entitled
to any
further payments of his consulting fee hereunder, all unvested stock
options and
warrants shall expire, and all vested stock options and warrants shall
remain
exercisable until their respective expiration dates. “Disability” shall mean the
Consultant’s incapacity due to physical or mental illness that results in his
being unable to substantially perform his duties hereunder for six consecutive
months (or for six months out of any nine-month period). During a period
of
Disability, the Consultant shall continue to receive his consulting fee
hereunder.
13.
Corporate
Opportunities; Intellectual Property.
(a) The
Consultant acknowledges that by virtue of his efforts as a consultant
hereunder
to the Company and as a director, he may become aware of confidential
information identified as such in writing by the Company relating to
the
Company’s business opportunities and potential acquisitions of companies and
or
technologies/compounds (“Confidential Information”), and that he will not,
during the Term and for a period of 6 months thereafter (the “Restricted
Period”), directly or indirectly use any such Confidential Information for his
own benefit or for the benefit of any third person other than the Company
or its
affiliates or enter into or negotiate a transaction with any person that
was the
subject of the Company’s business opportunity or potential acquisition without
the prior written approval of the Company or following an express decision
by
the CEO or the Board not to pursue the specific business opportunity
or
potential acquisition. The foregoing limitation shall not apply to the
Consultant after the end of the Restricted Period. The restrictions set
forth in
this Section 12 are in addition to any of Consultant’s fiduciary obligations to
the Company by virtue of his being a director of the Company.
(b)
Notwithstanding the foregoing, the Company acknowledges that the Consultant
may
pursue his own independent business interests and activities during the
Restricted Period, including those relating to life sciences and medical
technologies. Such business interests and activities include, without
limitation, those identified on Schedule A annexed hereto, which the
Company
acknowledges are not business opportunities of the Company and, therefore,
which
may be pursued by the Consultant on his own or in association with others
independently of the Company during the Restricted Period. The Consultant
is
under no obligation hereunder to identify specific potential business
opportunities or acquisitions for the Company. However, once the Consultant
informs the Company of a potential opportunity during the Term (other
than those
set forth on Schedule A), he may not independently pursue that opportunity
during the Restricted Period without the prior written approval of the
Company
or following an express decision by the CEO or the Board not to pursue
the
specific business opportunity or potential acquisition.
(c)
Any
material or other work which may be subject to copyright or patent, and
which is
conceived, derived, made or written by the Consultant in connection with
the
Confidential Information shall be deemed a “work for hire,” (and is herein
referred to as a “Development”). As between the Consultant and the Company,
Consultant acknowledges that all Developments will be the sole and exclusive
property of the Company and shall also be deemed Confidential Information
under
this Agreement. The Consultant further acknowledges the Company may in
turn
negotiate with any third party regarding their respective ownership rights
to
such Developments. The Consultant shall execute such documents as may
be
necessary to vest in the Company or any third party, if applicable, all
right,
title and interest in and to the Developments. The Company (or a third
party, if
applicable) will pay all costs and expenses associated with any applications
and
the transfer of title to Developments, including paying the Consultant’s
reasonable attorneys’ fees for reviewing such documents and instruments
presented for execution.
(d)
Notwithstanding the foregoing, the assignment by the Consultant to the
Company
(or a third party, if applicable) of Developments, as well as the right
to apply
for and obtain patents and/or registered copyrights on the same, shall
be
expressly limited to those specifically involving the Confidential Information
relating to such projects as mutually agreed upon by the parties hereto,
and
shall specifically not include (i) any right, license or interest of
the Company
to general concepts, formats, methods, testing techniques, study designs,
computer software or other procedures utilized or designed by the Consultant
in
performing his duties hereunder, or any general inventions, discoveries,
improvements, or copyrightable materials relating thereto, nor (ii) any
patentable or copyrightable materials which can be shown by competent
proof not
to concern the subject matter of the Confidential Information, or, which
predate
this Agreement or the Consultant’s receipt of the Confidential Information, or
(iii) any intellectual property relating to the Consultant’s current activities
identified on Schedule A.
(e)
The
Consultant agrees that this Section 12 may be enforced by the Company
by
injunction, or other equitable relief, without prejudice to any other
rights and
remedies that the Company may have under this Agreement and without the
posting
of any bond.
14. Legal
Expenses.
The
costs of the Consultant’s counsel, Adam Eilenberg, related to the negotiation,
preparation and review of this Agreement, up to $2,500, shall be paid
by the
Corporation, in the form of shares of Common Stock, based on a price
equal to
85% of the Market Price and shall be issued to Adam Eilenberg. Any shares
issued
pursuant to the foregoing sentence shall have the same registration rights
as
those being provided to Consultant hereunder and pursuant to the Registration
Rights Agreement.
15.
Notices.
All
notices, claims, certificates, requests, demands and other communications
hereunder shall be in writing and shall be deemed to have been duly given
and
delivered if personally delivered or if sent by nationally-recognized
overnight
courier, by telecopy, or by registered or certified mail, return receipt
requested and postage prepaid, addressed as follows:
If
to the
Company, to:
OXIS
International, Inc.
323
Vintage Park Drive, Suite B
Foster
City, California 94404
Attention:
Chairman of the Board
if
to the
Consultant, to:
John
E.
Repine, M.D.
c/o
Webb-Waring Institute
Box
c322
4200
E.
Ninth Avenue, Denver, CO 80262
with
a
copy to:
John
E.
Repine, M.D.
70
Cherry
Hills Farm Drive
Englewood,
CO 80113
or
to
such other address as the party to whom notice is to be given may have
furnished
to the other party or parties in writing in accordance herewith. Any
such notice
or communication shall be deemed to have been received in the case of
personal
delivery, on the date of such delivery, in the case of nationally-recognized
overnight courier, on the next business day after the date when sent,
in the
case of telecopy transmission, when received, and in the case of mailing,
on the
third business day following that on which the piece of mail containing
such
communication is posted.
16.
Binding
Agreement; Benefit.
Subject
to Section 20, the provisions of this Agreement will be binding upon,
and will
inure to the benefit of, the respective heirs, legal representatives,
successors
and assigns of the parties.
17.
Governing
Law.
This
Agreement will be governed by, and construed and enforced in accordance
with,
the laws of the State of California (without giving effect to principles
of
conflicts of laws).
18.
Waiver
of Breach.
The
waiver by either party of a breach of any provision of this Agreement must be in
writing and shall not operate or be construed as a waiver of any other
breach.
19.
Entire
Agreement; Amendments.
This
Agreement contains the entire agreement between the parties with respect
to the
subject matter hereof and supersedes all prior agreements or understandings
between the parties with respect thereto. This Agreement may be amended
only by
and agreement in writing signed by the parties.
20.
Headings.
The
section headings contained in this Agreement are for reference purposes
only and
shall not affect in any way the meaning or interpretation of this
Agreement.
21.
Assignment.
This
Agreement is personal in its nature and the parties shall not, without
the
consent of the other, assign or transfer this Agreement or any rights
or
obligations hereunder; provided,
however,
that
the Company may assign this Agreement to any of its subsidiaries.
22.
Counterparts.
This
Agreement may be executed in counterparts, and each such counterpart
shall be
deemed to be an original instrument, but both such counterparts together
shall
constitute but one agreement.
[remainder
of page left intentionally blank]
IN
WITNESS WHEREOF,
the
parties hereto have executed and delivered this Consulting Agreement
as of the
date first written above.
OXIS
INTERNATIONAL,
INC.
By:
/s/
Marvin S.
Hausman, M.D.
Name:
Marvin S. Hausman, M.D.
Title:
President
& Chief Executive Officer
/s/
John E. Repine, M.D.
John
E. Repine, M.D.
SCHEDULE
A
EXISTING
BUSINESS INTERESTS AND ACTIVITIES OF THE CONSULTANT
1.
Use of
Near-Infrared Spectrometry technique to non-invasively measure factors
that
predict and reflect changes in Diabetes, ARDS and other disorders.
2.
Development of intellectual property of ways to treat age-related macular
degeneration.
3.
Development of CD40 T Cell diagnostics and therapeutics
4.
Development of biomarker microarrays to predict the acute respiratory
distress
syndrome (ARDS) and of proprietary elastase inhibitors to prevent
ARDS.
5.
Development of novel glucose molecules for nutritional and therapeutic
purposes.
9
U.
S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
10-QSB
T Quarterly
report pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
For
the
quarterly period ended September 30, 2006
Transition
report pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
For
the
transition period from
to
.
Commission
File Number 0-8092
(Exact
name of small business issuer as specified in its charter)
Delaware
(State
or other jurisdiction of
incorporation
or organization)
|
94-1620407
(I.R.S.
employer
identification
number)
|
323
Vintage Park Drive, Suite B, Foster City, CA 94404
(Address
of principal executive offices and zip code)
(650)
212-2568
(Registrant’s
telephone number, including area
code)
|
Check
mark whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for
such
shorter period that the registrant was required to file such reports), and
(2)
has been subject to such filing requirements for the past 90 days. YES
T NO
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). YES
NO
T
At
November 10, 2006, the issuer had outstanding the indicated number of shares
of
common stock: 43,505,254.
Transitional
Small Business Disclosure Format YES
NO
T
OXIS
International, Inc.
Form
10-QSB
For
the Quarter Ended September 30, 2006
Table
of Contents
PART
I - FINANCIAL INFORMATION
|
Page
|
Item
1.
|
Financial
Statements
|
|
|
Consolidated
Balance Sheets as of September 30, 2006 (Unaudited) and December
31,
2005
|
1
|
|
Consolidated
Statements of Operations for the periods ended September 30, 2006
and 2005
(Unaudited)
|
2
|
|
Consolidated
Statements of Cash Flows for the periods ended September 30, 2006
and 2005
(Unaudited)
|
3
|
|
Condensed
Notes to Consolidated Financial Statements
|
4
|
Item
2.
|
Management’s
Discussion and Analysis or Plan of Operation
|
19
|
Item
3.
|
Controls
and Procedures
|
49
|
PART
II - OTHER INFORMATION
|
Item
1.
|
Legal
Proceedings
|
50
|
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
50
|
Item
3.
|
Defaults
Upon Senior Securities
|
50
|
Item
4.
|
Submission
of Matters to a Vote of Security Holders
|
50
|
Item
5.
|
Other
Information
|
51
|
Item
6.
|
Exhibits
|
51
|
SIGNATURE
|
52
|
PART
I. FINANCIAL INFORMATION
Item
1. Financial
Statements.
OXIS
INTERNATIONAL, INC.
CONSOLIDATED
BALANCE SHEETS
|
|
September
30, 2006
(Unaudited)
|
|
December
31, 2005
|
|
ASSETS
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
677,000
|
|
$
|
614,000
|
|
Accounts
receivable, net
|
|
|
894,000
|
|
|
865,000
|
|
Inventories,
net
|
|
|
554,000
|
|
|
650,000
|
|
Prepaid
expenses and other current assets
|
|
|
83,000
|
|
|
238,000
|
|
Deferred
tax assets
|
|
|
13,000
|
|
|
14,000
|
|
Restricted
cash
|
|
|
3,060,000
|
|
|
3,060,000
|
|
Total
current assets
|
|
|
5,281,000
|
|
|
5,441,000
|
|
Property,
plant and equipment, net
|
|
|
252,000
|
|
|
243,000
|
|
Patents,
net
|
|
|
796,000
|
|
|
831,000
|
|
Goodwill
and other assets
|
|
|
1,299,000
|
|
|
1,291,000
|
|
|
|
$
|
7,628,000
|
|
$
|
7,806,000
|
|
LIABILITIES
AND SHAREHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
819,000
|
|
$
|
505,000
|
|
Accrued
expenses
|
|
|
682,000
|
|
|
468,000
|
|
Accounts
payable to related party
|
|
|
129,000
|
|
|
194,000
|
|
Notes
payable to related party
|
|
|
200,000
|
|
|
—
|
|
Taxes
payable
|
|
|
115,000
|
|
|
—
|
|
Notes
payable
|
|
|
3,345,000
|
|
|
3,060,000
|
|
Total
current liabilities
|
|
|
5,290,000
|
|
|
4,227,000
|
|
Long-term
deferred taxes
|
|
|
41,000
|
|
|
41,000
|
|
Total
liabilities
|
|
|
5,331,000
|
|
|
4,268,000
|
|
Minority
interest in subsidiary
|
|
|
778,000
|
|
|
604,000
|
|
Shareholders’
equity:
|
|
|
|
|
|
|
|
Convertible
preferred stock - $0.01 par value; 15,000,000 shares authorized;
Series C
- 96,230 shares issued and outstanding
|
|
|
1,000
|
|
|
1,000
|
|
Common
stock- $0.001 par value; 150,000,000 shares authorized; 43,124,485
and
42,538,397 shares issued and outstanding at September 30, 2006
and
December 31, 2005, respectively
|
|
|
43,000
|
|
|
43,000
|
|
Additional
paid-in capital
|
|
|
69,193,000
|
|
|
68,686,000
|
|
Accumulated
deficit
|
|
|
(67,301,000
|
)
|
|
(65,379,000
|
)
|
Accumulated
other comprehensive loss
|
|
|
(417,000
|
)
|
|
(417,000
|
)
|
Total
shareholders’ equity
|
|
|
1,519,000
|
|
|
2,934,000
|
|
|
|
$
|
7,628,000
|
|
$
|
7,806,000
|
|
See
accompanying condensed notes to consolidated financial
statements.
OXIS
INTERNATIONAL, INC.
CONSOLIDATED
STATEMENTS OF OPERATIONS
(UNAUDITED)
|
|
Three
Months Ended September 30,
|
|
Nine
Months Ended September 30,
|
|
|
|
2006
|
|
2005
|
|
2006
|
|
2005
|
|
Product
revenues
|
|
$
|
1,462,000
|
|
$
|
532,000
|
|
$
|
4,331,000
|
|
$
|
1,718,000
|
|
License
revenues
|
|
|
50,000
|
|
|
—
|
|
|
50,000
|
|
|
—
|
|
Total
revenues
|
|
|
1,512,000
|
|
|
532,000
|
|
|
4,381,000
|
|
|
1,718,000
|
|
Cost
of product revenues
|
|
|
725,000
|
|
|
333,000
|
|
|
2,374,000
|
|
|
906,000
|
|
Gross
profit
|
|
|
787,000
|
|
|
199,000
|
|
|
2,007,000
|
|
|
812,000
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
|
207,000
|
|
|
69,000
|
|
|
598,000
|
|
|
191,000
|
|
Selling,
general and administrative
|
|
|
953,000
|
|
|
470,000
|
|
|
2,854,000
|
|
|
1,551,000
|
|
Total
operating expenses
|
|
|
1,160,000
|
|
|
539,000
|
|
|
3,452,000
|
|
|
1,742,000
|
|
Loss
from operations
|
|
|
(373,000
|
)
|
|
(340,000
|
)
|
|
(1,445,000
|
)
|
|
(930,000
|
)
|
Other
income (expenses):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income
|
|
|
14,000
|
|
|
22,000
|
|
|
45,000
|
|
|
74,000
|
|
Other
income
|
|
|
—
|
|
|
—
|
|
|
2,000
|
|
|
—
|
|
Interest
expense
|
|
|
(91,000
|
)
|
|
—
|
|
|
(146,000
|
)
|
|
(11,000
|
)
|
Total
other income (expenses)
|
|
|
(77,000
|
)
|
|
22,000
|
|
|
(99,000
|
)
|
|
63,000
|
|
Allocation
to minority interest in subsidiary
|
|
|
(88,000
|
)
|
|
—
|
|
|
(174,000
|
)
|
|
—
|
|
Loss
before provision for income taxes
|
|
|
(538,000
|
)
|
|
(318,000
|
)
|
|
(1,718,000
|
)
|
|
(867,000
|
)
|
Provision
for income taxes
|
|
|
115,000
|
|
|
—
|
|
|
204,000
|
|
|
—
|
|
Net
loss
|
|
$
|
(653,000
|
)
|
$
|
(318,000
|
)
|
$
|
(1,922,000
|
)
|
$
|
(867,000
|
)
|
Net
loss per share - basic and diluted
|
|
|
($0.02
|
)
|
|
($0.01
|
)
|
|
($0.04
|
)
|
|
($0.02
|
)
|
Weighted
average shares outstanding - basic
and
diluted
|
|
|
43,090,280
|
|
|
42,438,261
|
|
|
42,752,223
|
|
|
42,104,110
|
|
See
accompanying condensed notes to consolidated financial
statements.
OXIS
INTERNATIONAL, INC.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(UNAUDITED)
|
|
Nine
Months Ended September 30,
|
|
|
|
2006
|
|
2005
|
|
Cash
flows from operating activities:
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(1,922,000
|
)
|
$
|
(867,000
|
)
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
Depreciation
of property, plant and equipment
|
|
|
55,000
|
|
|
21,000
|
|
Amortization
of intangible assets
|
|
|
101,000
|
|
|
37,000
|
|
Accretion
of interest on discounted note payable
|
|
|
45,000
|
|
|
—
|
|
Common
stock issued to vendor for accounts payable
|
|
|
23,000
|
|
|
—
|
|
Share-based
compensation expense
|
|
|
249,000
|
|
|
8,000
|
|
Minority
interest in subsidiary
|
|
|
174,000
|
|
|
—
|
|
Changes
in assets and liabilities:
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(29,000
|
)
|
|
(68,000
|
)
|
Inventories
|
|
|
96,000
|
|
|
(43,000
|
)
|
Prepaid
expenses and other current assets
|
|
|
155,000
|
|
|
9,000
|
|
Deferred
tax asset
|
|
|
1,000
|
|
|
—
|
|
Other
assets
|
|
|
(8,000
|
)
|
|
—
|
|
Accounts
payable
|
|
|
290,000
|
|
|
(157,000
|
)
|
Accrued
expenses
|
|
|
214,000
|
|
|
(532,000
|
)
|
Taxes
payable
|
|
|
115,000
|
|
|
—
|
|
Accounts
payable to related party
|
|
|
(65,000
|
)
|
|
—
|
|
Net
cash used in operating activities
|
|
|
(506,000
|
)
|
|
(1,592,000
|
)
|
Cash
flows from investing activities:
|
|
|
|
|
|
|
|
Acquisition
of common shares of subsidiary
|
|
|
—
|
|
|
(88,000
|
)
|
Investment
in restricted certificate of deposit
|
|
|
(3,060,000
|
)
|
|
—
|
|
Purchases
of property, plant and equipment
|
|
|
(64,000
|
)
|
|
(22,000
|
)
|
Increase
in patents
|
|
|
(42,000
|
)
|
|
(171,000
|
)
|
Proceeds
from restricted certificate of deposit
|
|
|
3,060,000
|
|
|
—
|
|
Net
cash used in investing activities
|
|
|
(106,000
|
)
|
|
(281,000
|
)
|
Cash
flows from financing activities:
|
|
|
|
|
|
|
|
Collection
of private placement proceeds receivable, net of registration statement
costs
|
|
|
—
|
|
|
1,948,000
|
|
Issuance
of common stock
|
|
|
—
|
|
|
239,000
|
|
Proceeds
from exercise of stock options
|
|
|
69,000
|
|
|
44,000
|
|
Proceeds
from short-term borrowing
|
|
|
3,666,000
|
|
|
—
|
|
Repayment
of short-term borrowings
|
|
|
(3,060,000
|
)
|
|
(1,200,000
|
)
|
Net
cash provided by financing activities
|
|
|
675,000
|
|
|
1,031,000
|
|
Net
increase (decrease) in cash and cash equivalents
|
|
|
63,000
|
|
|
(842,000
|
)
|
Cash
and cash equivalents - beginning of period
|
|
|
614,000
|
|
|
4,687,000
|
|
Cash
and cash equivalents - end of period
|
|
$
|
677,000
|
|
$
|
3,845,000
|
|
See
accompanying condensed notes to consolidated financial
statements.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2006
1. The
Company and Summary of Significant Accounting Policies
OXIS
International, Inc. with its subsidiaries (collectively, “OXIS” or the
"Company") is a clinical diagnostics company engaged in the development of
clinical and research assays, diagnostics, nutraceutical and therapeutic
products, which include new technologies applicable to conditions and diseases
associated with oxidative stress. OXIS derives its revenues primarily from
sales
of research diagnostic assays to research laboratories. The Company’s diagnostic
products include five cardiac marker assays and 25 research assays to measure
markers of oxidative and nitrosative stress.
In
1965,
the corporate predecessor of OXIS, Diagnostic Data, Inc., was incorporated
in
the State of California. Diagnostic Data changed its incorporation to the
State
of Delaware in 1972 and changed its name to DDI Pharmaceuticals, Inc. in
1985.
In 1994, DDI Pharmaceuticals merged with International BioClinical, Inc.
and
Bioxytech S.A. and changed its name to OXIS International, Inc. The Company’s
principal executive offices were relocated to Foster City, California from
Portland, Oregon on February 15, 2006.
On
September 19, 2005, the Company entered into a stock purchase agreement with
BioCheck, Inc. (“BioCheck”) and certain shareholders of BioCheck to purchase all
of the common stock of BioCheck for $6.0 million in cash. On
December 6, 2005, the Company purchased 51% of the common stock of BioCheck
from each of the shareholders of BioCheck on a pro rata basis, for $3,060,000
in
cash. BioCheck’s products include over 40 clinical diagnostic assays. The
consolidated statements of operations for the three and nine months ended
September 30, 2006 include the results of operations of BioCheck and the
consolidated balance sheets at December 31, 2005 and September 30,
2006 include the assets and liabilities of BioCheck.
The
Company incurred net losses of $1.9 million in the nine months ended
September 30, 2006 and $3.1 million in 2005. The Company began expensing
stock options effective January 1, 2006 in accordance with the Statement
of
Financial Accounting Standards No. 123 (revised 2004), “Share-Based Payments”
(“SFAS 123R”). The Company extended the terms of existing debt during the third
quarter of 2006 and obtained additional debt financings subsequent to September
30, 2006 that included the issuance of warrants. Non-cash financing charges
resulting from such financings and the additional non-cash charges related
to
stock options may delay profitability. The Company’s plan is to increase
revenues to generate sufficient gross profit in excess of selling, general
and
administrative, and research and development expenses in order to achieve
profitability. However, the Company cannot provide assurances that it will
accomplish this task and there are many factors that may prevent the Company
from reaching its goal of profitability.
On
a
consolidated basis, the Company had cash and cash equivalents of $677,000
at
September 30, 2006, of which $656,000 was held by BioCheck. Since BioCheck
has
been and is expected to continue to be cash flow positive, management believes
that its cash will be sufficient to sustain its operating
activities.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
The
OXIS
parent company had cash and cash equivalents of $21,000 at September 30,
2006.
OXIS cannot access the cash held by its majority-held subsidiary, BioCheck,
to
pay for the corporate purposes of the OXIS parent company. The Company incurred
negative operating cash flows of $0.5 million during the nine months ended
September 30, 2006 and $2.1 million during 2005. The OXIS parent company
incurred negative operating cash flows of $0.9 million during the nine months
ended September 30, 2006. The current rate of cash usage raises substantial
doubt about the OXIS parent Company’s ability to continue as a going concern,
absent any new sources of significant cash flows. In an effort to mitigate
this
near-term concern, the Company obtained debt financing in which it received
proceeds of $1,350,000 subsequent to September 30, 2006 and is seeking equity
financings to obtain sufficient funds to sustain operations and purchase
the
remaining 49% of BioCheck for approximately $3.0 million. From the
aforementioned debt financing, $635,000 was used to repay existing debt,
accrued
interest and related legal fees. The Company plans to increase revenues by
introducing new products. However, the Company cannot provide assurances
that it
will successfully obtain equity financing, if any, sufficient to finance
its
goals or that the Company will increase product related revenues. The financial
statements do not include any adjustments relating to the recoverability
and
classification of recorded assets, or the amounts and classification of
liabilities that might be necessary in the event the Company cannot continue
in
existence.
Basis
of Presentation
The
consolidated financial statements have been prepared by the Company in
accordance with the rules and regulations of the Securities and Exchange
Commission regarding interim financial information. Accordingly, these financial
statements and notes thereto do not include certain disclosures normally
associated with financial statements prepared in accordance with accounting
principles generally accepted in the United States of America. This interim
financial information should be read in conjunction with the Company’s audited
consolidated financial statements and notes thereto for the year ended December
31, 2005 included in the Company’s Annual Report on Form 10-KSB.
The
consolidated financial statements include the accounts of OXIS International,
Inc. and its subsidiaries. All intercompany balances and transactions have
been
eliminated. On December 6, 2005, the Company purchased 51% of the common
stock of BioCheck. The consolidated statements of operations for the three
and
nine months ended September 30, 2006 include the results of operations of
BioCheck and the consolidated balance sheets include the assets and liabilities
of BioCheck at September 30, 2006 and December 31, 2005.
BioCheck’s revenues and expenses are not included in the consolidated statements
of operations for the three and nine months ended September 30, 2005
because those results of operations were incurred before the
December 6, 2005 date of acquisition. In the opinion of the Company’s
management, the consolidated financial statements include all adjustments
(consisting of only normal recurring adjustments) and disclosures considered
necessary for a fair presentation of the results of the interim periods
presented. This interim financial information is not necessarily indicative
of
the results of any future interim periods or for the Company’s full year ending
December 31, 2006.
Segment
Reporting
The
Company operates in one reportable segment.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
Restricted
Cash
The
Company invested $3,060,000 of cash into a 30-day certificate of deposit
at
KeyBank, N.A. (“KeyBank”) and entered into a $3,060,000 non-revolving one-year
loan agreement with KeyBank on December 2, 2005 for the purpose of
completing the initial closing of the BioCheck acquisition. The Company granted
a security interest in its $3,060,000 certificate of deposit to KeyBank under
the loan agreement. The $3,060,000 loan with KeyBank was repaid during February
2006 and a new one-year loan agreement for $3,060,000 was entered into at
Bridge
Bank, N.A. (“Bridge Bank”). As part of the loan arrangement with Bridge Bank,
the Company granted a security interest in a $3,060,000 certificate of deposit
transferred from KeyBank to Bridge Bank. The certificate of deposit bears
interest at 1.0%. Consequently, these certificates of deposit were classified
as
restricted cash on the consolidated balance sheets at September 30, 2006
and
December 31, 2005 as the cash is restricted as to use.
Share-Based
Compensation
The
Company has historically accounted for stock options granted to employees
and
directors and other share-based employee compensation plans using the intrinsic
value method of accounting in accordance with Accounting Principles Board
Opinion No. 25, "Accounting for Stock Issued to Employees" (“APB 25”) and
related interpretations. As such, the Company recognized compensation expense
for stock options only if the quoted market value of the Company’s common stock
exceeded the exercise price of the option on the grant date. Any compensation
expense realized using this intrinsic value method is being amortized over
the
vesting period of the option.
In
December 2004, the Financial Accounting Standards Board (“FASB”) issued SFAS
123R, which requires a public entity to measure the cost of employee services
received in exchange for an award of equity instruments based on the fair
value
of the award on the grant date (with limited exceptions). That cost will
be
recognized in the entity’s financial statements over the period during which the
employee is required to provide services in exchange for the award.
Management
implemented SFAS 123R effective January 1, 2006, using the modified prospective
application method. Under the modified prospective application method, SFAS
123R
applies to new awards and to awards modified, repurchased or cancelled after
January 1, 2006. Additionally, compensation costs for the portion of awards
for
which the requisite service has not been rendered that are outstanding as
of
January 1, 2006 are recognized as the requisite service is rendered on or
after
January 1, 2006. The compensation cost for that portion of awards is based
on
the grant-date fair value of those awards as calculated for proforma disclosures
under Statement of Financial Accounting Standards No. 123, “Accounting for
Stock-Based Compensation” (“SFAS 123”). The compensation cost for awards issued
prior to January 1, 2006 attributed to services performed in years after
January
1, 2006 uses the attribution method applied prior to January 1, 2006 according
to SFAS 123, except that the method of recognizing forfeitures only as they
occur was not continued.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
The
recognition of share-based employee compensation costs during 2006 had no
related tax effect since the Company provides a valuation allowance equal
to its
net deferred tax assets. The adoption of SFAS 123R had no effect on cash
flow
from operations, cash flow from financing activities and basic and diluted
earnings per share. The effect of adoption of SFAS 123R on the results of
operations for the nine months ended September 30, 2006 was:
|
|
Loss
from Operations
|
|
Loss
Before Provision
for Income
Taxes
|
|
Net
Loss
|
|
Results
as reported
|
|
$
|
(1,445,000
|
)
|
$
|
(1,718,000
|
)
|
$
|
(1,922,000
|
)
|
Additional
compensation expense - effect of adoption of SFAS 123R
|
|
|
191,000
|
|
|
191,000
|
|
|
191,000
|
|
Proforma
results applying the original provisions of SFAS 123
using the intrinsic value method of APB 25
|
|
$
|
(1,254,000
|
)
|
$
|
(1,527,000
|
)
|
$
|
(1,731,000
|
)
|
The
following table presents the effect on net loss and net loss per share if
the
Company had applied the fair value recognition provisions of SFAS 123 to
share-based awards to employees prior to January 1, 2006:
|
|
Three
Months Ended
September 30,
|
|
Nine
Months Ended
September 30,
|
|
|
|
2006
|
|
2005
|
|
2006
|
|
2005
|
|
Net
loss as reported
|
|
$
|
(653,000
|
)
|
$
|
(318,000
|
)
|
$
|
(1,922,000
|
)
|
$
|
(867,000
|
)
|
Share-based employee
compensation expense included in reported net loss
|
|
|
60,000
|
|
|
—
|
|
|
191,000
|
|
|
—
|
|
Share-based employee
compensation expense that would have been included in net income
if the
fair value method had been applied to all awards
|
|
|
(60,000
|
)
|
|
(34,000
|
)
|
|
(191,000
|
)
|
|
(124,000
|
)
|
Pro
forma net loss
|
|
$
|
(653,000
|
)
|
$
|
(352,000
|
)
|
$
|
(1,922,000
|
)
|
$
|
(991,000
|
)
|
Net
loss per share:
Basic
and diluted - as reported
Basic
and diluted - pro forma
|
|
$
$
|
(0.02
(0.02
|
)
)
|
$
$
|
(0.01
(0.01
|
)
)
|
$
$
|
(0.04
(0.04
|
)
)
|
$
$
|
(0.02
(0.02
|
)
)
|
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
The
Company undertook a comprehensive study of options issued from 1994 through
2001
to determine historical patterns of options being exercised and forfeited.
The
results of this study were used as a source to estimate expected life and
forfeiture rates. The new estimated life of 4.45 years was applied only to
determine the fair value of awards issued after January 1, 2006. The estimated
forfeiture rate of 40% was applied to all awards that vested after January
1,
2006, including awards issued prior to that date, to determine awards expected
to be exercised.
The
Company issued options to purchase 120,000 shares of the Company’s common stock
to employees and directors during the three months ended September 30, 2006.
The
Company issued no options to employees and directors during the three months
ended September 30, 2005. The Company issued options to purchase 400,000
and
615,000 shares of the Company’s common stock to employees and directors during
the nine months ended September 30, 2006 and 2005, respectively. The fair
values
of employee stock options are estimated for the calculation of employee
compensation expense in 2006 and the pro forma adjustments in 2005 in the
above
table at the date of grant using the Black-Scholes option-pricing model with
the
following weighted-average assumptions during 2006 and 2005: expected volatility
of 90% and 170%, respectively; average risk-free interest rate of 4.59% and
4.00%, respectively; initial expected life of 4.45 years and 6 years,
respectively; no expected dividend yield; and amortization over the vesting
period of typically one to four years.
Stock
options issued to non-employees as consideration for services provided to
the
Company have been accounted for under the fair value method in accordance
with
SFAS 123 and Emerging Issues Task Force No. 96-18, “Accounting for Equity
Instruments That Are Issued to Other Than Employees for Acquiring, or in
Conjunction with Selling, Goods or Services,” which requires that compensation
expense be recognized for all such options. The Company issued options to
purchase 50,000 shares of the Company’s common stock to non-employees and a
warrant to purchase 108,000 shares of the Company’s common stock to a director
under a consulting agreement during the nine months ended September 30, 2006.
The Company issued no options to non-employees during the nine months ended
September 30, 2005.
Net
Loss Per Share
Basic
net
loss per share is computed by dividing the net loss for the period by the
weighted average number of common shares outstanding during the period. Diluted
net loss per share is computed by dividing the net loss for the period by
the
weighted average number of common shares outstanding during the period, plus
the
potential dilutive effect of common shares issuable upon exercise or conversion
of outstanding stock options and warrants during the period. The weighted
average number of potentially dilutive common shares were 318,940 and 769,558
for the three months ended September 30, 2006 and 2005, respectively, and
611,497 and 869,352 for the nine months ended September 30, 2006 and 2005,
respectively. These shares were excluded from net diluted loss per share
because
of their anti-dilutive effect.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
Recent
Accounting Pronouncements
In
February 2006, the FASB issued Statement of Financial Accounting Standards
No.
155, “Accounting for Certain Hybrid Financial Instruments, an Amendment of FASB
Standards No. 133 and 140” (“SFAS No. 155”). SFAS No. 155 established the
accounting for certain derivatives embedded in other instruments. It simplifies
accounting for certain hybrid financial instruments by permitting fair value
remeasurement for any hybrid instrument that contains an embedded derivative
that otherwise would require bifurcation under Statement of Financial Accounting
Standards No. 133 “Accounting for Derivative Instruments and Hedging Activities”
as well as eliminating a restriction on the passive derivative instruments
that
a qualifying special-purpose entity (“SPE”) may hold under Statement of
Financial Accounting Standards No. 140 “Accounting for Transfers and Servicing
of Financial Assets and Extinguishments of Liabilities” (“SFAS No. 140”). SFAS
No. 155 allows a public entity to irrevocably elect to initially and
subsequently measure a hybrid instrument that would be required to be separated
into a host contract and derivative in its entirety at fair value (with changes
in fair value recognized in earnings) so long as that instrument is not
designated as a hedging instrument pursuant to the statement. SFAS No. 140
previously prohibited
a qualifying special-purpose entity from holding a derivative financial
instrument that pertains to a beneficial interest other than another derivative
financial instrument. SFAS
No.
155 is effective for fiscal years beginning after September 15, 2006, with
early
adoption permitted as of the beginning of an entity’s fiscal year. Management
believes the adoption of SFAS No. 155 will have no impact on the Company’s
financial condition or results of operations.
In
March
2006, the FASB issued Statement of Financial Accounting Standards No. 156,
“Accounting for Servicing of Financial Assets—an amendment of FASB Statement No.
140” (“SFAS No. 156”). SFAS No. 156 requires an entity to recognize a servicing
asset or servicing liability each time it undertakes an obligation to service
a
financial asset by entering into a servicing contract in any of the following
situations: a transfer of the servicer’s financial assets that meets the
requirements for sale accounting; a transfer of the servicer’s financial assets
to a qualifying special-purpose entity in a guaranteed mortgage securitization
in which the transferor retains all of the resulting securities and classifies
them as either available-for-sale securities or trading securities; or an
acquisition or assumption of an obligation to service a financial asset that
does not relate to financial assets of the servicer or its consolidated
affiliates. SFAS No. 156 also requires all separately recognized servicing
assets and servicing liabilities to be initially measured at fair value,
if
practicable and permits an entity to choose either the amortization or fair
value method for subsequent measurement of each class of servicing assets
and
liabilities. SFAS No. 156 further permits, at its initial adoption, a one-time
reclassification of available for sale securities to trading securities by
entities with recognized servicing rights, without calling into question
the
treatment of other available for sale securities under Statement of Financial
Accounting Standards No. 115, “Accounting for Certain Investments in Debt and
Equity Securities”, provided that the available for sale securities are
identified in some manner as offsetting the entity’s exposure to changes in fair
value of servicing assets or servicing liabilities that a servicer elects
to
subsequently measure at fair value and requires separate presentation of
servicing assets and servicing liabilities subsequently measured at fair
value
in the statement of financial position and additional disclosures for all
separately recognized servicing assets and servicing liabilities. SFAS No.
156
is effective for fiscal years beginning after September 15, 2006, with early
adoption permitted as of the beginning of an entity’s fiscal year. Management
believes the adoption of SFAS No. 156 will have no impact on the Company’s
financial condition or results of operations.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
In
June
2006, the FASB issued Interpretation No. 48, “Accounting for Uncertainty in
Income Taxes - an interpretation of FASB Statement No. 109” (“FIN 48”), which
prescribes a recognition threshold and measurement attribute for the financial
statement recognition and measurement of a tax position taken or expected
to be
taken in a tax return. FIN 48 also provides guidance on de-recognition,
classification, interest and penalties, accounting in interim periods,
disclosure and transition. FIN 48 is effective for fiscal years beginning
after
December 15, 2006. The Company does not expect the adoption of FIN 48 to
have a
material impact on its financial reporting, and the Company is currently
evaluating the impact, if any, the adoption of FIN 48 will have on its
disclosure requirements.
In
September 2006, the Financial Accounting Standards Board issued Statement
of
Financial Accounting Standards No. 157, “Fair Value Measurements” (“SFAS No.
157”) which defines fair value, establishes a framework for measuring fair value
in generally accepted accounting principles (“GAAP”), and expands disclosures
about fair value measurements. Where applicable, SFAS No. 157 simplifies
and codifies related guidance within GAAP and does not require any new fair
value measurements. SFAS No. 157 is effective for financial statements
issued for fiscal years beginning after November 15, 2007, and interim
periods within those fiscal years. Earlier adoption is encouraged. The
Company does not expect the adoption of SFAS No. 157 to have a significant
effect on its financial position or results of operation.
2. Acquisition
of BioCheck
On
September 19, 2005, the Company entered into a stock purchase agreement with
BioCheck and certain shareholders of BioCheck to purchase all of the common
stock of BioCheck for $6.0 million in cash. BioCheck is a privately held
California corporation engaged in the development of immunoassays, with a
number
of clinical diagnostic tests that have been approved by the United States
Food
and Drug Administration. On December 6, 2005, the Company purchased 51% of
the common stock of BioCheck from each of the shareholders of BioCheck on
a pro
rata basis, for $3,060,000 in cash. This acquisition was accounted for by
the
purchase method of accounting according to Statement of Financial Accounting
Standards No. 141, “Business Combinations,” (“SFAS No. 141”).
Pursuant
to the stock purchase agreement, OXIS will use its reasonable best efforts
to
consummate a follow-on financing transaction to raise additional capital
with
which to purchase the remaining outstanding shares of BioCheck in one or
more
additional closings. The purchase price for any BioCheck shares purchased
after
the initial closing will be increased by an additional 8% per annum from
December 6, 2005. If OXIS has not purchased all of the outstanding shares
of BioCheck within twelve months of December 6, 2005, the earnings before
interest, taxes, depreciation and amortization expenses, if any, of BioCheck,
will be used to repurchase the remaining outstanding BioCheck shares at one
or
more additional closings. The purchase of the remaining outstanding shares
of
BioCheck will be accounted for the same as the initial purchase of 51% of
BioCheck using the purchase method of accounting according to SFAS No. 141.
The
additional purchase price will be allocated over the purchased assets of
BioCheck and the consolidated statements of operations will continue to include
the results of operations of BioCheck reduced by the minority interest, if
any,
in BioCheck. The Company may obtain additional independent valuations of
BioCheck’s assets related to the acquisition of the remaining 49% of BioCheck
and additional acquisition costs may be incurred. Such information and costs
may
affect the disclosures as presented herein.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
On
June
23, 2006, OXIS entered into a mutual services agreement with BioCheck. Both
OXIS
and BioCheck will provide certain services to the other corporation to be
charged monthly at an hourly rate with an overhead surcharge. The services
that
BioCheck will provide include manufacturing the bulk of OXIS’ research assay
test kits, assisting in packaging and shipping such research assay test kits
to
OXIS customers, and undertaking research and development of certain new OXIS
research assay test kits on a case-by-case basis to be agreed upon between
the
parties. OXIS will provide services to BioCheck, including marketing and
sales,
website management and materials requirement and control systems.
The
agreement terminates on December 6, 2009, or earlier upon mutual consent
of the
parties, upon 90 day prior written notice by either party, by either party
if a
monthly billing is unpaid after 60 days if a 15 day notice and opportunity
to
cure has been provided, or upon a material breach of the agreement after
30
days’ notice and opportunity to cure the breach. As of September 30, 2006, OXIS
owed BioCheck approximately $103,000 for services rendered under the agreement.
OXIS has not made that payment. If OXIS receives written notice of breach
of the
agreement due to this non-payment, it will have 15 days to cure that breach.
If
OXIS fails to cure the breach during the cure period, BioCheck would have
the
right to terminate the agreement.
3. Notes
Payable
|
|
September
30, 2006
|
|
December
31, 2005
|
|
|
|
Maturity
Value
|
|
Discounted
Value
|
|
|
|
Note
payable to KeyBank, N.A.
|
|
$
|
—
|
|
$
|
—
|
|
$
|
3,060,000
|
|
Note
payable to Bridge Bank, N.A.
|
|
|
3,060,000
|
|
|
3,060,000
|
|
|
—
|
|
Note
payable to the Company’s former President & CEO
|
|
|
200,000
|
|
|
200,000
|
|
|
—
|
|
Note
payable to Fagan Capital, Inc.
|
|
|
406,000
|
|
|
285,000
|
|
|
—
|
|
Total
notes payable
|
|
$
|
3,666,000
|
|
$
|
3,545,000
|
|
$
|
3,060,000
|
|
On
December 2, 2005, the Company entered into non-revolving one-year loan
agreement with KeyBank in the amount of $3,060,000, for the purpose of
completing the initial closing of the BioCheck acquisition. The Company granted
a security interest in its $3,060,000 certificate of deposit at KeyBank under
the loan agreement. The loan bore interest at an annual rate that was 2.0%
greater than the interest rate on the certificate of deposit. The Company’s
$3,060,000 loan with KeyBank was repaid during February 2006 and a new one-year
loan agreement was entered into with Bridge Bank. The Company has granted
a
security interest in its $3,060,000 certificate of deposit transferred from
KeyBank to Bridge Bank. The loan bears interest at 3.0% and the certificate
of
deposit bears interest at 1.0%.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
On
March
10, 2006, the Company received $200,000 in exchange for an unsecured promissory
note with Steven T. Guillen, the Company’s president and chief executive officer
at that time. The related party note bears interest at 7.0%. Interest and
principal were due on September 10, 2006. Mr. Guillen’s employment with the
Company was terminated on September 15, 2006. The Company was in default
on this
note at September 30, 2006. Subsequent to September 30, 2006, Mr. Guillen
sued
the Company for payment of interest and principal due under the note. On
November 2, 2006, the Company repaid Mr. Guillen the principal and accrued
interest due on the promissory note in the amount of $209,000. The purpose
of
this loan was to provide the Company with short term financing as it sought
longer term financing.
On
March
31, 2006, the Company issued a $400,000 unsecured promissory note to Fagan
Capital, Inc. (“Fagan Capital”). Interest accrued at an annual rate of 8.0% and
interest and principal were initially due on June 2, 2006. The purpose of
this
loan was to provide the Company with short term financing as it sought longer
term financing. On July 26, 2006, Fagan Capital extended the maturity date
of
the promissory note by entering into a renewal and modification promissory
note
(“Renewal Note”). The Renewal Note had a principal amount of $406,000, comprised
of the principal amount of the original promissory note plus accrued interest
of
$6,000. The effective date of the Renewal Note was June 2, 2006. On October
25,
2006, the Company paid to Fagan Capital amounts
owing under the Renewal Note
as
described in Note 7.
In
conjunction with the issuance of the Renewal Note, on July 26, 2006 the Company
issued to Fagan Capital a common stock purchase warrant to purchase 1,158,857
shares of common stock at an initial exercise price of $0.35 per share. The
exercise price is adjustable pursuant to certain anti-dilution provisions
and
upon the occurrence of a stock split. The common stock purchase warrant expires
on June 1, 2014. On October 23, 2006, the parties signed a registration rights
agreement covering the shares underlying the common stock purchase warrant.
This
warrant was valued using the Black-Scholes option-pricing model and the proceeds
of $406,000 were allocated to the warrant and note based on their relative
fair
values. This resulted in the note being recorded as a liability at a discounted
value of $240,000 and the warrant being record as equity under additional
paid-in capital at a value of $166,000. The discounted note will accrete
to its
maturity value over the life of the loan. This resulted in a non-cash interest
expense of $45,000 during the quarter ended September 30, 2006. With the
payment
of this note from the proceeds of the Company’s October 25, 2006 financing, the
remaining discount of $121,000 will be accelerated and recorded as interest
expense during October 2006.
4. Supplemental
Cash Flow Disclosures
The
Company recognized non-cash compensation expense of $58,000 and $8,000 related
to the issuance and vesting of stock options issued to consultants in the
nine
months ended September 30, 2006 and 2005, respectively. The Company recognized
non-cash compensation expense of $191,000 related to the issuance and vesting
of
stock options issued to employees in the nine months ended September 30,
2006.
No employee non-cash compensation expense was recognized in the nine months
ended September 30, 2005 prior to the implementation of SFAS 123R. Cash interest
paid was $88,000 and $11,000 in the nine months ended September 30, 2006
and
2005, respectively. Interest expense attributed to the accretion of interest
on
discounted note payable was $45,000 in the three and nine months ended September
30, 2006.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
5. Relocation
of Operations
On
December 6, 2005, the Company committed itself to a plan to cease
operations in Portland, Oregon and relocate operations to Foster City,
California (the “Relocation”). The Company decided to effect the Relocation
after reviewing and evaluating all aspects of the Company’s operations to
determine the profitability and viability of continuing in the Portland,
Oregon
location. During the first quarter of 2006, operations were relocated to
California and on February 15, 2006 the Portland, Oregon facility was closed
with the termination of employment of all Portland based employees who did
not
relocate to California. The Company’s subsidiary, BioCheck, has commenced
shipping of the Company’s products and is manufacturing all of its research
assay kit products not manufactured by third party suppliers.
In
connection with the Relocation, the Company accrued $119,000 during 2005
for
employee severances offered to all regular full-time employees who were not
relocated to Foster City, California. Of this amount, $103,000 has been paid
during the first nine months of 2006, resulting in $16,000 of accrued expenses
at September 30, 2006. The Company expects $8,000 of this amount to be paid
during the remainder of 2006 and $8,000 is to be paid during 2007. The Company
accrues for these benefits in the period when benefits are communicated to
the
terminated employees. Typically, terminated employees are not required to
provide continued service to receive termination benefits. In general, the
Company uses a formula based on the number of years of service to calculate
the
termination benefits to be provided to affected employees.
In
connection with the Relocation, the Company signed a lease agreement to occupy
4,136 square feet of space adjacent to space occupied by its BioCheck subsidiary
in Foster City, California. The lease commenced on April 1, 2006 at an annual
base rent of $62,000 per year that increases incrementally to $66,000 by
the end
of the lease term on March 31, 2009. In addition to the base rent, the Company
will be responsible for its proportionate share of the building's operating
expenses and real estate taxes. The Company has a renewal option to extend
the
lease for one three-year period at the prevailing market rental value for
rentable property in the same area.
6.
Related Party Transactions
BioCheck
and EverNew Biotech, Inc., a California corporation (“EverNew”), entered into a
services agreement dated December 6, 2005 (the “Services Agreement”). The
holders of the shares of capital stock of EverNew are substantially the same
set
of individuals and entities who held BioCheck’s common stock immediately prior
to the initial closing of OXIS’ acquisition of BioCheck, including Dr. John
Chen, President of BioCheck, as a significant shareholder. EverNew is an
emerging point-of-care diagnostics company, with a number of products in
development. EverNew renders certain services to BioCheck, including assay
research and development work, and BioCheck renders certain administrative
services to EverNew. In consideration of services provided by EverNew, BioCheck
agreed to pay to EverNew $12,000 per month, provided, however, if the sum
of
EverNew’s gross revenues for a consecutive three month period during the term of
the Services Agreement equals or exceeds $100,000, then BioCheck shall no
longer
be obligated to pay EverNew any amounts for the remainder of the term of
the
Services Agreement. Further, in such event, EverNew shall pay BioCheck an
amount
equal to the EverNew Service Cost per month for the remainder of the term
of the
Services Agreement, and the EverNew Service Cost for such month shall be
reduced
by the amount of the BioCheck compensation paid to BioCheck for such month
under
the Services Agreement. As
used
in the Services Agreement, EverNew Service Cost means the cost of all BioCheck
services provided by BioCheck each month under the Services Agreement, as
incurred and determined in good faith by BioCheck. Amounts
due to EverNew from BioCheck are $129,000 and $194,000 at September 30, 2006
and
December 31, 2005, respectively.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
7. Subsequent
Events
On
September 15, 2006, Marvin S. Hausman, M.D. was appointed by the board of
directors as President and Chief Executive Officer of the Company. Dr. Hausman
remains Chairman of the board of directors. On November 6, 2006, OXIS entered
into an employment agreement with Dr. Hausman. The commencement date of the
agreement was set retroactively at October 15, 2006 (the “Commencement
Date”).
Pursuant
to the employment agreement, Dr. Hausman will serve as the President and
Chief
Executive Officer of OXIS for a three year period from the Commencement Date,
thereafter on a one year basis. Dr. Hausman will receive annual compensation
in
the amount of $250,000, payable quarterly in advance in cash, common stock
based
on a price equal to 85% of average of the five closing prices for the five
trading days prior to the date that the issuance is authorized by the Board
of
Directors, or in ten year warrants equal to that number of warrants equal
to 1.5
times the number of shares that would otherwise be received. For the initial
quarterly payment, Dr. Hausman was issued 347,222 restricted shares of common
stock. During the three year term of the agreement, Dr. Hausman shall receive
an
annual bonus based upon the attainment of agreed upon goals and milestones
as
determined by the Board of Directors and its Compensation Committee. During
the
remainder of calendar year 2006, Dr. Hausman’s bonus shall be pro rated on an
annual bonus rate in the range of 25% to 50% of his base salary, and the
bonus
for subsequent years of the term of the agreement shall be in a similar target
range. The bonuses payable hereunder shall be paid in cash, although at Dr.
Hausman’s sole option, they may be paid in stock (or in the form of ten year
warrants with cashless exercise provisions, with 1.5 times the number of
warrant
shares to be issued in lieu of the number of shares of common stock), based
upon
the average of the closing bid and asked prices for the 5 trading days
immediately prior to the awarding to Dr. Hausman of the bonus for a particular
year. Once OXIS has raised at least $2.5 million in one or more financings
(equity, debt or convertible debt, in addition to the financing closed on
October 25, 2006) or in a strategic transaction (in each case, a Qualifying
Financing), Dr. Hausman may elect, at any time, in lieu of receiving a quarterly
issuance of stock (or warrants in lieu thereof), to receive his base salary
in
cash, payable monthly on OXIS’s regular pay cycle for professional employees. As
part of the compensation under the employment agreement, OXIS granted Dr.
Hausman a ten year a non-qualified option to purchase 495,000 shares of OXIS
common stock at an exercise price of $0.20 per share, vesting as follows:
(i)
247,500 option shares vesting in four equal quarterly installments commencing
on
January 15, 2007 and every three months thereafter and (ii) and the remaining
247,500 option shares vesting in eight quarterly installments over two years
(the “Initial Option Grant”). Additionally, OXIS granted Dr. Hausman, as a sign
on bonus, 500,000 restricted shares of common stock and a ten year common
stock
purchase warrant to purchase 1,505,000 shares at an exercise price of $0.20
per
share, with vesting in six equal installments, commencing on November 14,
2006,
through the 180th
day
after the Commencement Date. OXIS shall provide Dr. Hausman with an annual
office expense allowance of $50,000, for the costs of maintaining an office
in
the Stevenson, Washington area. The office expense allowance shall be payable
quarterly in advance in the form of common stock, at a price equal to 85%
of the
Market Price. For the first installment, representing $12,500 of the office
expense allowance, Dr. Hausman was issued 69,444 restricted shares of common
stock. Hereafter, the office allowance expense will be paid promptly after
the
determination of the Market Price on the dates that are three months, six
months
and nine months from the date hereof, and quarterly thereafter for the duration
of the term of the agreement. Notwithstanding the foregoing, once OXIS has
completed a Qualifying Financing, the office expense allowance will be paid
in
cash in advance, commencing for the quarter next following the quarter in
which
the Qualifying Financing occurred. Additionally, Dr. Hausman shall receive
family health and dental insurance benefits and short-term and long-term
disability policies.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
On
November 6, 2006, OXIS entered into an advisory agreement with Ambient Advisors
LLC (“Ambient Advisors”). Gary M. Post, a member of the board of directors, is
the manager of Ambient Advisors. The commencement date of the agreement was
set
retroactively at October 15, 2006 (the “Commencement Date”).
Pursuant
to the advisory agreement, Ambient Advisors will provide certain services
pertaining to strategic planning, financial planning and budgeting, investor
relations, corporate finance and such additional roles and responsibilities
as
requested for a three year period from the Commencement Date, thereafter
on a
one year basis. Ambient Advisors will receive annual compensation in the
amount
of $83,333, payable quarterly in advance in cash, common stock based on a
price
equal to 85% of average of the five closing prices for the five trading days
prior to the date that the issuance is authorized by the Board of Directors,
or
in ten year warrants equal to that number of warrants equal to 1.5 times
the
number of shares that would otherwise be received. For the initial quarterly
payment, Ambient Advisors received a ten year warrant to purchase 173,608
shares
of common stock with an exercise price of $0.20 per share, vesting immediately.
As part of the compensation under the advisory agreement, OXIS granted Ambient
Advisors a ten year common stock purchase warrant to purchase 550,000 shares
of
OXIS common stock at an exercise price of $0.20 per share, vesting as follows:
(i) 275,000 warrant shares vesting in four equal quarterly installments
commencing on January 15, 2007 and every three months thereafter and (ii)
and
the remaining 275,000 warrant shares vesting in eight quarterly installments
over two years. Additionally, OXIS granted Ambient Advisors, as a sign on
bonus,
a non-qualified option to purchase 333,333 shares at exercise price of $0.20
per
share, with vesting in six equal installments, commencing on November 14,
2006,
through the 180th
day
after the Commencement Date. During the three year term of the agreement,
Ambient Advisors shall receive an annual bonus based upon the attainment
of
agreed upon goals and milestones as determined by the Board of Directors
and its
Compensation Committee. During the remainder of calendar year 2006, Ambient
Advisors’ bonus shall be pro rated on an annual bonus rate in the range of 25%
to 50% of the advisory fee, and the bonus for subsequent years of the term
of
the agreement shall be in a similar target range. The bonuses payable hereunder
shall be paid in cash, although at Ambient Advisors’ sole option, they may be
paid in stock (or in the form of ten year warrants with cashless exercise
provisions, with 1.5 times the number of warrant shares to be issued in lieu
of
the number of shares of common stock), based upon the average of the closing
bid
and asked prices for the 5 trading days immediately prior to the awarding
to
Ambient Advisors of the bonus for a particular year.
On
November 6, 2006, OXIS entered into a consulting agreement with John E. Repine,
M.D. The commencement date of the agreement was set retroactively at October
15,
2006 (the “Commencement Date”).
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
Pursuant
to the consulting agreement, Dr. Repine shall advise OXIS concerning matters
of
antioxidant and inflammation research and potential acquisitions (including
products/compounds/intellectual property, companies), product research and
development, and the development and establishment of reference labs for
oxidative stress and inflammatory reactions for a three year period from
the
Commencement Date, thereafter on a one year basis. Dr. Repine will receive
annual compensation in the amount of $36,000, payable quarterly in advance
in
cash, common stock based on a price equal to 85% of average of the five closing
prices for the five trading days prior to the date that the issuance is
authorized by the Board of Directors, or in ten year warrants equal to that
number of warrants equal to 1.5 times the number of shares that would otherwise
be received. For the initial quarterly payment, Dr. Repine received 50,000
restricted shares of common stock. As part of the compensation under the
consulting agreement, OXIS granted Dr. Repine a ten year stock option to
purchase 200,000 shares of OXIS common stock at an exercise price of $0.20
per
share, vesting as follows: (i) 100,000 option shares vesting in four equal
quarterly installments commencing on January 15, 2007 and every three months
thereafter and (ii) and the remaining 100,000 option shares vesting in eight
quarterly installments over two years. Additionally, OXIS granted Dr. Repine,
as
a sign on bonus, a non-qualified option to purchase 200,000 shares at exercise
price of $0.20 per share, with vesting in six equal installments, commencing
on
November 14, 2006, through the 180th
day
after the Commencement Date. During the term of the consulting agreement,
Dr.
Repine shall be eligible to receive annual and special bonuses based upon
the
attainment of agreed upon goals and milestones as determined by the OXIS
Chief
Executive Officer. Each bonus payable shall be paid in cash, although at
Dr.
Repine’s sole option, such bonus may be paid in stock (or in the form of ten
year warrants with cashless exercise provisions, with 1.5 times the number
of
warrant shares to be issued in lieu of the number of shares of common stock),
based upon the average of the closing bid and asked prices for the 5 trading
days immediately prior to the awarding to Dr. Repine of the particular bonus.
On
October 25, 2006, OXIS entered into a securities purchase agreement (“Purchase
Agreement”) with four accredited investors (the “Purchasers”). In conjunction
with the signing of the Purchase Agreement, OXIS issued secured convertible
debentures (“Debentures”) and Series A, B, C, D, and E common stock warrants
(“Warrants”) to the Purchasers, and the parties also entered into a registration
rights agreement and a security agreement (collectively, the “Transaction
Documents”).
Pursuant
to the terms of the Purchase Agreement, OXIS issued the Debentures in an
aggregate principal amount of $1,694,250 to the Purchasers. The Debentures
are
subject to an original issue discount of 20.318% resulting in proceeds to
OXIS
of $1,350,000 from the transaction. The Debentures mature on October 25,
2008,
but may be prepaid by OXIS at any time provided that the common stock issuable
upon conversion and exercise of the Warrants is covered by an effective
registration statement. The Debentures are convertible, at the option of
the
Purchasers, at any time, into shares of common stock at $0.35 per share,
as
adjusted pursuant to a full ratchet anti-dilution provision (the “Conversion
Price”). Beginning on the first of the month following the earlier of the
effective date of the registration statement to be filed pursuant to the
registration rights agreement and February 1, 2007, OXIS shall amortize the
Debentures in equal installments on a monthly basis resulting in a complete
repayment by the maturity date (the “Monthly Redemption Amounts”). The Monthly
Redemption Amounts can be paid in cash or in shares, subject to certain
restrictions. If OXIS chooses to make any Monthly Redemption Amount payment
in
shares of common stock, the price per share is the lesser of the Conversion
Price then in effect and 85% of the weighted average price for the 10 trading
days prior to the due date of the Monthly Redemption Amount.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
Pursuant
to the Debentures, OXIS covenants that it will not incur additional indebtedness
for borrowed money, other than its current Bridge Bank promissory note. OXIS
also covenants that it will not pledge, grant or convey any new liens on
its
assets. The obligation to pay all unpaid principal will be accelerated upon
an
event of default, including upon failure to perform its obligations under
the
Debenture covenants, failure to make required payments, default on any of
the
Transaction Documents or any other material agreement, lease, document or
instrument to which OXIS is obligated, the bankruptcy of OXIS or related
events.
The Purchasers have a right of first refusal to participate in up to 100%
of any
future financing undertaken by OXIS until the later of the date that the
Debentures are no longer outstanding and the one year anniversary of the
effective date of the registration statement. OXIS is restricted from issuing
shares of common stock or instruments convertible into common stock for 90
days
after the effective date of the registration statement with certain exceptions.
OXIS is also prohibited from effecting any subsequent financing involving
a
variable rate transaction until such time as no Purchaser holds any of the
Debentures. In addition, until such time as any Purchaser holds any of the
securities issued in the Debenture transaction, if OXIS issues or sells any
common stock or instruments convertible into common stock which a Purchaser
reasonably believes is on terms more favorable to such investors than the
terms
pursuant to the Transaction Documents, OXIS is obligated to amend the terms
of
the Transaction Documents to such Purchaser the benefit of such better terms.
OXIS may prepay the entire outstanding principal amount of the Debentures,
plus
accrued interest and other amounts payable, at its option at any time without
penalty, provided that a registration statement is available for the resale
of
shares underlying the Debentures and Warrants, as more fully described in
the
Debentures. The purpose of this Debenture transaction is to provide the
corporation with intermediate term financing as it seeks longer term financing.
On
October 25, 2006, in conjunction with the signing of the Purchase Agreement,
OXIS issued to the Purchasers five year Series A Warrants to purchase an
aggregate of 2,420,357 shares of common stock at an initial exercise price
of
$0.35 per share, one year Series B Warrants to purchase 2,420,357 shares
of
common stock at an initial exercise price of $0.385 per share, and two year
Series C Warrants to purchase an aggregate of 4,840,714 shares of common
stock
at an initial exercise price of $0.35 per share. In addition, OXIS issued
to the
Purchasers Series D and E Warrants which become exercisable on a pro-rata
basis
only upon the exercise of the Series C Warrants. The six year Series D Warrants
to purchase 2,420,357 shares of common stock have an initial exercise price
of
$0.35 per share. The six year Series E Warrants to purchase 2,420,357
shares of common stock have an initial exercise price of $0.385 per share.
The
initial exercise prices for each warrant are adjustable pursuant to a full
ratchet anti-dilution provision and upon the occurrence of a stock split
or a
related event.
Pursuant
to the registration rights agreement, OXIS must file a registration statement
covering the public resale of the shares underlying the Series A, B, C, D
and E
Warrants and the Debentures within 45 days of the closing of the transaction
and
cause the registration to be declared effective within 120 days of the closing
date. Cash liquidated damages equal to 2% of the face value of the Debentures
per month are payable to the purchasers for any failure to timely file or
obtain
an effective registration statement.
Pursuant
to the Security Agreement, OXIS agreed to grant the purchasers, pari passu,
a
security interest in substantially all of the Company's assets. OXIS also
agreed
to pledge its respective ownership interests in its wholly-owned subsidiaries,
OXIS Therapeutics, OXIS Isle of Man, and its partial subsidiary, BioCheck,
Inc.
OXIS Therapeutics and OXIS Isle of Man also provided a subsidiary guarantee
to
the Purchasers in connection with the transaction.
OXIS
INTERNATIONAL, INC.
CONDENSED
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
September
30, 2006
On
September 15, 2006, Steven T. Guillen’s employment as the Company’s President
and Chief Executive Officer was terminated. Mr. Guillen remains a member
of the
board of directors. Pursuant to the employment agreement with Mr. Guillen
and in
connection with his termination, the Company accrued $261,000 at September
30,
2006 for severance obligations including continued coverage under the Company’s
health plan. The Company expects $76,000 of this amount to be paid during
the
remainder of 2006 and $185,000 is to be paid during 2007 contingent upon
Mr.
Guillen’s execution of a waiver and release of all claims against the Company.
In addition, the Company accrued back salary of approximately $75,000 at
September 30, 2006 owed to Mr. Guillen. On October 16, 2006, Mr. Guillen
filed a
lawsuit against the Company and up to 25 unnamed additional defendants. The
complaint alleges breaches of contract relating to Mr. Guillen’s employment
agreement and a promissory note that is in default, breach of implied covenant
of good faith and fair dealing, wrongful termination and violation of the
California Labor Code in relation to the non-payment of back pay. On March
10,
2006, we received $200,000 in exchange for an unsecured promissory note with
Mr.
Guillen. Interest and principal were due on September 10, 2006 and at September
30, 2006 were in default. On November 2, 2006, the Company repaid Mr. Guillen
the principal and accrued interest due on the promissory note in the amount
of
$209,000 and back pay with penalties and accrued interest of $96,000. We
are in
ongoing negotiations with Mr. Guillen’s counsel to settle the lawsuit. To the
date of this Report, the complaint has not been served upon OXIS or any other
defendant.
The
Company issued a $400,000 unsecured promissory note to Fagan Capital on March
31, 2006 and a modification and renewal note on July 26, 2006 as described
in
Note 3. In conjunction with the issuance of the renewal note, the Company
issued
to Fagan Capital a common stock purchase warrant. On October 25, 2006, the
Company prepaid the principal, accrued interest and legal fees due pursuant
to
the renewal note in the amount of $426,000.
Item
2. Management’s
Discussion and Analysis or Plan of Operation.
Statement
Regarding Forward-Looking Statements
The
statements contained in this Report on Form 10-QSB that are not purely
historical are forward-looking statements within the meaning of Section 27A
of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of
1934, or the Exchange Act, including, without limitation, statements regarding
our expectations, objectives, anticipations, plans, hopes, beliefs, intentions
or strategies regarding the future. Forward-looking statements include, without
limitation, statements regarding:
(1)
our plan to increase revenues to generate sufficient gross profit in excess
of
selling, general and administrative, and research and development expenses
in
order to achieve profitability; (2) our expectation that BioCheck will
continue
to be cash flow positive, and that its cash will be sufficient to sustain
its
operating activities; (3) our intention to seek equity financings to obtain
sufficient funds to sustain our operations and purchase the remaining 49%
of
BioCheck for approximately $3.0 million; (4) our plan to increase revenues
by
the introduction of new products; (5) our belief that the adoption of certain
accounting standards will have no impact on our financial condition or
results
of operations; (6) our expectation that $84,000 of employee severance package
expenses will be paid during the remainder of 2006 and $193,000 will be
paid
during 2007; (7) our plan to pursue the development of novel cardiac markers;
(8) our plan to develop the cardiac marker product through the combination
of
our MPO assay with other in-house assays; (9) our belief that our Ergothioneine
compound may be well suited for development as a nutraceutical supplement
that
can be sold over the counter and our testing of Ergothioneine; (10) our
intent
to pursue the development of Ergothioneine for use in over-the-counter
markets,
given the availability of sufficient capital resources; (11) our expectation
that a new myeloperoxidase research assay will be ready for commercial
launch in
the fourth quarter of 2006; (12) our expectation that the ID protein assays
and
reagents will be ready for commercial launch by late 2006;(134) our projections
for 2006, which are based upon our expectations that BioCheck will incur
similar
revenues and costs in 2006 as it incurred in 2005; (14) our expectation
that in
the fourth quarter 2006, product revenues will increase modestly from the
third
quarter as we introduce new products; (15) our intention to develop new
diagnostic test kits and evaluate our product offerings, pricing and
distribution network in order to increase sales volume; (16) our expectation
that fourth quarter 2006 product costs will increase proportionally with
any
increases in revenues; (17) our expectation that revenues and expenses
will
increase substantially from 2005 to 2006 with the consolidation of all
of
BioCheck’s results of operations during 2006; (18) our expectation that the
actual amount of research and development expenses will fluctuate with
the
availability of funding; (19) our expectation that fourth quarter 2006
selling,
general and administrative expenses will approximately the same as the
third
quarter; (20) our expectation that interest expense will increase signinficantly
from the third quarter of 2006 with additional debt financing during October
2006;
and
(21) our expectation that our cash position may not be sufficient to sustain
our
operations through the first
quarter of 2007 without
additional financing.
It
is
important to note that our actual results could differ materially from
those
included in such forward-looking statements due to a variety of factors
including (1) failure to complete our acquisition of BioCheck or to adequately
integrate the operations of the two companies; (2) failure to achieve any
benefits in connection with the recent changes in management or personnel;
(3)
disruption in operations due to the relocation plan and reduction in workforce;
(4) failure to comply with our obligations under the debenture transaction
agreements or to repay the debentures when such payments are due; (5) inability
to hire employees or management; (6) failure to make payments when required
under our Mutual Services Agreement with BioCheck to avoid termination;
(7)
failure to find alternative suppliers; (8) failure to develop or market
products successfully; (9) failure to obtain necessary financing;
(10) the cost of complying with regulatory requirements;
(11) uncertainties exist relating to issuance, validity
and
ability to enforce and protect patents, other intellectual property and
certain
proprietary information; (12) our products may not
meet product performance specifications; (13) new
products may be unable to compete successfully in either existing or new
markets; (14) availability and future costs of
materials and other operating expenses; (15) weakness
in the global economy and changing market conditions, together with general
economic conditions affecting our target industries, could cause our operating
results to fluctuate; (16) miscalculations in the assessment of our cash
position; and (17) our failure to accurately predict the impact of the
adoption
of certain accounting standards. These and other factors could cause actual
results to differ materially from the forward looking statements. For a
detailed
explanation of such risks, please see the section entitled “Factors that May
Affect Future Operating Results” beginning on page 36 of
this Report on Form 10-QSB. Such risks, as well as such other risks and
uncertainties as are detailed in our Securities and Exchange Commission,
or the
SEC, reports and filings for a discussion of the factors that could cause
actual
results to differ materially from the forward- looking statements. Given
these
uncertainties, readers are cautioned not to place undue reliance on the
forward-looking statements. All forward-looking
statements included in this Report on Form 10-QSB are based on
information available to us on the date hereof, and we assume no obligation
to
update any such forward-looking
statements.
The
following discussion of our financial condition and plan of operation should
be
read in conjunction with our consolidated financial statements and related
notes
included in this Report and our audited consolidated financial statements
and
related notes for the year ended December 31, 2005 included in our Annual
Report
on Form 10-KSB.
Overview
OXIS
International, Inc. develops technologies and products to research, diagnose,
treat and prevent diseases of oxidative stress associated with damage from
free
radical and reactive oxygen species. We derive our revenues primarily from
sales
of research diagnostic assays to research laboratories. Our diagnostic products
include approximately 30 research assays to measure markers of oxidative
stress. We
hold
the rights to three therapeutic classes of compounds in the area of oxidative
stress, and have focused our commercialization programs in clinical
cardiovascular markers, including MPO (myeloperoxidase) and GPx (glutathione
peroxidase), as well as a potent antioxidant, Ergothioneine, that may be
appropriate for sale over-the-counter as a dietary supplement. OXIS has acquired
a 51% interest in and has the option to purchase the remaining 49% of BioCheck,
Inc., or BioCheck.
Our
majority-held subsidiary, BioCheck, is
a
leading producer of clinical diagnostic assays, including high quality enzyme
immunoassay research services and immunoassay kits for cardiac and tumor
markers, infectious diseases, thyroid function, steroids, and fertility hormones
designed to improve the accuracy, efficiency, and cost-effectiveness of
in
vitro
(outside
the body) diagnostic testing in clinical laboratories. BioCheck
focuses primarily on the immunoassay segment of the clinical diagnostics
market.
BioCheck
offers over 40 clinical diagnostic assays
manufactured in its 15,000 square-foot, U.S. Food and Drug Administration,
or
FDA, certified Good Manufacturing Practices device-manufacturing facility
in
Foster City, California.
We
incurred net losses of $1.9 million in the nine months ended September 30,
2006 and $3.1 million in 2005. We began expensing stock options effective
January 1, 2006 in accordance with the Statement of Financial Accounting
Standards No. 123 (revised 2004), “Share-Based Payments,” or SFAS 123R. We
extended the terms of existing debt during the third quarter of 2006 and
obtained additional debt financings subsequent to September 30, 2006 that
included the issuance of warrants. Non-cash financing charges resulting from
such financing and the additional non-cash charges related to stock options
may
delay profitability. Our plan is to increase revenues to generate sufficient
gross profit in excess of selling, general and administrative, and research
and
development expenses in order to achieve profitability. However, we cannot
assure you that we will accomplish this task and there are many factors that
may
prevent us from reaching our goal of profitability.
On
a
consolidated basis, we had cash and cash equivalents of $677,000 at September
30, 2006 of which $656,000 was held by BioCheck. Since BioCheck has been
and is
expected to continue to be cash flow positive, management believes that its
cash
will be sufficient to sustain its operating activities.
The
OXIS
parent company had cash and cash equivalents of $21,000 at September 30,
2006.
OXIS cannot access the cash held by its majority-held subsidiary, BioCheck,
to
pay for the corporate purposes of the OXIS parent company. We have incurred
negative operating cash flows of $0.5 million during the first nine months
of
2006 and $2.1 million during 2005. The OXIS parent company incurred negative
operating cash flows of $0.9 million during the first nine months of 2006.
The
current rate of cash usage raises substantial doubt about the OXIS parent
company’s ability to continue as a going concern, absent any new sources of
significant cash flows. In an effort to mitigate this near-term concern,
we
obtained debt financing in which we received proceeds of $1,350,000 subsequent
to September 30, 2006 and are seeking equity financings to obtain sufficient
funds to sustain operations and purchase the remaining 49% of BioCheck for
approximately $3.0 million. From the aforementioned debt financing, $635,000
was
used to repay existing debt, accrued interest and related legal fees. We
plan to
increase revenues by the introduction of new products. However, we cannot
assure
you that we will successfully obtain equity financing, if any, sufficient
to
finance our goals or that we will increase product related revenues as such
events are subject to factors beyond our control. The financial statements
do
not include any adjustments relating to the recoverability and classification
of
recorded assets, or the amounts and classification of liabilities that might
be
necessary in the event OXIS cannot continue in existence.
Recent
Developments
Current
significant financial and operating events and strategies are summarized
as
follows:
Appointment
of New President and Chief Executive Officer.
On
September 15, 2006, our board of directors appointed Marvin S. Hausman, M.D.
as
President and Chief Executive Officer of OXIS. Dr. Hausman remains the Chairman
of the board of directors.
On
October 12, 2006, we mutually agreed with Marvin S. Hausman, M.D. to terminate
the consulting agreement with NW Medical Research Partners, of which Dr.
Hausman
is the sole member and manager, effective October 15, 2006. Under the consulting
agreement dated October 1, 2005, Dr. Hausman provided certain services
pertaining to licensing of intellectual property, development of potential
products, financing activities and other issues at the request of our Chief
Executive Officer. In conjunction with the termination of the consulting
agreement, the board of directors approved the issuance of 330,769 shares
of
restricted common stock to Dr. Hausman in lieu of cash payment of $67,000
in
fees and expenses due under the consulting agreement to the date of
termination.
On
November 6, 2006, we entered into an employment agreement with Dr. Hausman
that
commenced retroactively at October 15, 2006, or the Commencement Date. Dr.
Hausman will serve as the President and Chief Executive Officer of OXIS for
a
three year period from the Commencement Date, thereafter on a one year basis.
Dr. Hausman will receive annual compensation in the amount of $250,000, payable
quarterly in advance in cash, common stock based on a price equal to 85%
of
average of the five closing prices for the five trading days prior to the
date
that the issuance is authorized by the Board of Directors, or in ten year
warrants equal to that number of warrants equal to 1.5 times the number of
shares that would otherwise be received. For the initial quarterly payment,
Dr.
Hausman was issued 347,222 restricted shares of common stock. During the
three
year term of the agreement, Dr. Hausman will receive an annual bonus based
upon
the attainment of agreed upon goals and milestones as determined by the Board
of
Directors and its Compensation Committee. During the remainder of calendar
year
2006, Dr. Hausman’s bonus will be pro rated on an annual bonus rate in the range
of 25% to 50% of his base salary, and the bonus for subsequent years of the
term
of the agreement will be in a similar target range. The bonuses payable
hereunder will be paid in cash, although at Dr. Hausman’s sole option, they may
be paid in stock (or in the form of ten year warrants with cashless exercise
provisions, with 1.5 times the number of warrant shares to be issued in lieu
of
the number of shares of common stock), based upon the average of the closing
bid
and asked prices for the 5 trading days immediately prior to the awarding
to Dr.
Hausman of the bonus for a particular year. Once we have raised at least
$2.5
million in one or more financings (equity, debt or convertible debt, in addition
to the financing closed on October 25, 2006) or in a strategic transaction,
Dr.
Hausman may elect, at any time, in lieu of receiving a quarterly issuance
of
stock (or warrants in lieu thereof), to receive his base salary in cash,
payable
monthly on our regular pay cycle for professional employees. As part of the
compensation, we granted Dr. Hausman a ten year a non-qualified option to
purchase 495,000 shares of OXIS common stock at an exercise price of $0.20
per
share, vesting as follows: (i) 247,500 option shares vesting in four equal
quarterly installments commencing on January 15, 2007 and every three months
thereafter and (ii) and the remaining 247,500 option shares vesting in eight
quarterly installments over two years. Additionally, we granted Dr. Hausman,
as
a sign on bonus, 500,000 restricted shares of common stock and a ten year
common
stock purchase warrant to purchase 1,505,000 shares at an exercise price
of
$0.20 per share, with vesting in six equal installments, commencing on November
14, 2006, through the 180th
day
after the Commencement Date.
We
are
providing Dr. Hausman with an annual office expense allowance of $50,000,
for
the costs of maintaining an office in the Stevenson, Washington area, payable
quarterly in advance in the form of common stock, at a price equal to 85%
of the
market price. For the first installment, representing $12,500 of the office
expense allowance, Dr. Hausman was issued 69,444 restricted shares of common
stock. Once we have completed a qualifying financing, the office expense
allowance will be paid in cash in advance, commencing for the quarter next
following the quarter in which the Qualifying Financing occurred. Additionally,
Dr. Hausman will receive family health and dental insurance benefits and
short-term and long-term disability policies.
Agreements
with Ambient Advisors, LLC
On
May
12, 2006, we entered into an engagement letter with Ambient Advisors LLC,
or
Ambient Advisors. Gary M. Post, a member of the board of directors, is the
manager of Ambient Advisors. Ambient Advisors provided certain services
pertaining to strategic planning, investor communications and financing
strategies and other projects at the request of our chief executive officer
for
a one year period in return for monthly compensation of $5,000. We granted
Ambient Advisors a ten year warrant to purchase 108,000 shares of OXIS common
stock at an exercise price of $0.39 per share, with 9,000 shares becoming
exercisable each month over the term of the agreement. On October 12, 2006,
we
mutually agreed with Gary M. Post to terminate the engagement letter with
Ambient Advisors LLC, effective October 15, 2006, replace it with a new
consulting agreement and accelerate the vesting of the warrant to be fully
vested effective October 15, 2006.
On
November 6, 2006, we entered into an advisory agreement with Ambient Advisors
that commenced retroactively at October 15, 2006, or the Commencement Date.
Ambient Advisors will provide certain services pertaining to strategic planning,
financial planning and budgeting, investor relations, corporate finance and
such
additional roles and responsibilities as requested for a three year period
from
the Commencement Date, thereafter on a one year basis. Ambient Advisors will
receive annual compensation in the amount of $83,333, payable quarterly in
advance in cash, common stock based on a price equal to 85% of average of
the
five closing prices for the five trading days prior to the date that the
issuance is authorized by the Board of Directors, or in ten year warrants
equal
to that number of warrants equal to 1.5 times the number of shares that would
otherwise be received. For the initial quarterly payment, Ambient Advisors
received a ten year warrant to purchase 173,608 shares of common stock with
an
exercise price of $0.20 per share, vesting immediately. As part of the
compensation, we granted Ambient Advisors a ten year common stock purchase
warrant to purchase 550,000 shares of OXIS common stock at an exercise price
of
$0.20 per share, vesting as follows: (i) 275,000 warrant shares vesting in
four
equal quarterly installments commencing on January 15, 2007 and every three
months thereafter and (ii) and the remaining 275,000 warrant shares vesting
in
eight quarterly installments over two years. Additionally, OXIS granted Ambient
Advisors, as a sign on bonus, a non-qualified option to purchase 333,333
shares
at exercise price of $0.20 per share, with vesting in six equal installments,
commencing on November 14, 2006, through the 180th
day
after the Commencement Date. During the three year term of the agreement,
Ambient Advisors will receive an annual bonus based upon the attainment of
agreed upon goals and milestones as determined by the Board of Directors
and its
Compensation Committee. During the remainder of calendar year 2006, Ambient
Advisors’ bonus will be pro rated on an annual bonus rate in the range of 25% to
50% of the advisory fee, and the bonus for subsequent years of the term of
the
agreement will be in a similar target range. The bonuses payable hereunder
will
be paid in cash, although at Ambient Advisors’ sole option, they may be paid in
stock (or in the form of ten year warrants with cashless exercise provisions,
with 1.5 times the number of warrant shares to be issued in lieu of the number
of shares of common stock), based upon the average of the closing bid and
asked
prices for the 5 trading days immediately prior to the awarding to Ambient
Advisor of the bonus for a particular year.
Consulting
Agreement with John E. Repine, M.D.
On
November 6, 2006, OXIS entered into an consulting agreement with John E.
Repine,
M.D. that commenced retroactively at October 15, 2006, or the Commencement
Date
Dr.
Repine will advise us concerning matters of antioxidant and inflammation
research and potential acquisitions (including products/compounds/intellectual
property, companies), product research and development, and the development
and
establishment of reference labs for oxidative stress and inflammatory reactions
for a three year period from the Commencement Date, thereafter on a one year
basis. Dr. Repine will receive annual compensation in the amount of $36,000,
payable quarterly in advance in cash, common stock based on a price equal
to 85%
of average of the five closing prices for the five trading days prior to
the
date that the issuance is authorized by the Board of Directors, or in ten
year
warrants equal to that number of warrants equal to 1.5 times the number of
shares that would otherwise be received. For the initial quarterly payment,
Dr.
Repine received 50,000 restricted shares of common stock. As part of the
compensation under the consulting agreement, OXIS granted Dr. Repine a ten
year
stock option to purchase 200,000 shares of OXIS common stock at an exercise
price of $0.20 per share, vesting as follows: (i) 100,000 option shares vesting
in four equal quarterly installments commencing on January 15, 2007 and every
three months thereafter and (ii) and the remaining 100,000 option shares
vesting
in eight quarterly installments over two years. Additionally, we granted
Dr.
Repine, as a sign on bonus, a non-qualified option to purchase 200,000 shares
at
exercise price of $0.20 per share, with vesting in six equal installments,
commencing on November 14, 2006, through the 180th
day
after the Commencement Date. During the term of the consulting agreement,
Dr.
Repine is eligible to receive annual and special bonuses based upon the
attainment of agreed upon goals and milestones as determined by our Chief
Executive Officer. Each bonus payable will be paid in cash, although at Dr.
Repine’s sole option, such bonus may be paid in stock (or in the form of ten
year warrants with cashless exercise provisions, with 1.5 times the number
of
warrant shares to be issued in lieu of the number of shares of common stock),
based upon the average of the closing bid and asked prices for the 5 trading
days immediately prior to the awarding to Dr. Repine of the particular bonus.
Debt
Financing
On
October 25, 2006, we entered into a Securities Purchase Agreement, or Purchase
Agreement, with four accredited investors, or the Purchasers. In conjunction
with the signing of the Purchase Agreement, we issued Secured Convertible
Debentures, or Debentures, and Series A, B, C, D, and E Common Stock Warrants,
or Warrants, to the Purchasers, and the parties also entered into a registration
rights agreement and a Security Agreement, or collectively, the Transaction
Documents.
Pursuant
to the terms of the Purchase Agreement, we issued the Debentures in an aggregate
principal amount of $1,694,250 to the Purchasers. The Debentures are subject
to
an original issue discount of 20.318% resulting in proceeds to OXIS of
$1,350,000 from the transaction. The Debentures mature on October 25, 2008,
but
may be prepaid by us at any time provided that the common stock issuable
upon
conversion and exercise of the Warrants is covered by an effective registration
statement. The Debentures are convertible, at the option of the Purchasers,
at
any time, into shares of common stock at $0.35 per share, as adjusted pursuant
to a full ratchet anti-dilution provision, or the Conversion Price. Beginning
on
the first of the month following the earlier of the effective date of the
registration statement to be filed pursuant to the registration rights agreement
and February 1, 2007, we shall amortize the Debentures in equal installments
on
a monthly basis resulting in a complete repayment by the maturity date, or
the
Monthly Redemption Amounts. The Monthly Redemption Amounts can be paid in
cash
or in shares, subject to certain restrictions. If we choose to make any Monthly
Redemption Amount payment in shares of common stock, the price per share
is the
lesser of the Conversion Price then in effect and 85% of the weighted average
price for the 10 trading days prior to the due date of the Monthly Redemption
Amount.
Pursuant
to the Debentures, we covenant that we will not incur additional indebtedness
for borrowed money, other than our current Bridge Bank Promissory Note. We
also
covenant that we will not pledge, grant or convey any new liens on its assets.
The obligation to pay all unpaid principal will be accelerated upon an event
of
default, including upon failure to perform its obligations under the Debenture
covenants, failure to make required payments, default on any of the Transaction
Documents or any other material agreement, lease, document or instrument
to
which we are obligated, the bankruptcy of OXIS or related events. The Purchasers
have a right of first refusal to participate in up to 100% of any future
financing undertaken by us until the later of the date that the Debentures
are
no longer outstanding and the one year anniversary of the effective date
of the
registration statement. We are restricted from issuing shares of common stock
or
instruments convertible into common stock for 90 days after the effective
date
of the registration statement with certain exceptions. We are also prohibited
from effecting any subsequent financing involving a variable rate transaction
until such time as no Purchaser holds any of the Debentures. In addition,
until
such time as any Purchaser holds any of the securities issued in the Debenture
transaction, if we issue or sell any common stock or instruments convertible
into common stock which a Purchaser reasonably believes is on terms more
favorable to such investors than the terms pursuant to the Transaction
Documents, we are obligated to amend the terms of the Transaction Documents
to
such Purchaser the benefit of such better terms. We may prepay the entire
outstanding principal amount of the Debentures, plus accrued interest and
other
amounts payable, at our option at any time without penalty, provided that
a
registration statement is available for the resale of shares underlying the
Debentures and Warrants, as more fully described in the Debentures. The purpose
of this Debenture transaction is to provide us with intermediate term financing
as we seek longer term financing.
On
October 25, 2006 in conjunction with the signing of the Purchase Agreement,
we
issued to the Purchasers five year Series A Warrants to purchase an aggregate
of
2,420,357 shares of common stock at an initial exercise price of $0.35 per
share, one year Series B Warrants to purchase 2,420,357 shares of common
stock
at an initial exercise price of $0.385 per share, and two year Series C Warrants
to purchase an aggregate of 4,840,714 shares of common stock at an initial
exercise price of $0.35 per share. In addition, we issued to the Purchasers
Series D and E Warrants which become exercisable on a pro-rata basis only
upon
the exercise of the Series C warrants. The six year Series D Warrants to
purchase 2,420,357 shares of common stock have an initial exercise price
of
$0.35 per share. The six year Series E Warrants to purchase 2,420,357
shares of common stock have an initial exercise price of $0.385 per share.
The
initial exercise prices for each warrant are adjustable pursuant to a full
ratchet anti-dilution provision and upon the occurrence of a stock split
or a
related event.
Pursuant
to the registration rights agreement, we must file a registration statement
covering the public resale of the shares underlying the Series A, B, C, D
and E
Warrants and the Debentures within 45 days of the closing of the transaction
and
cause the registration to be declared effective within 120 days of the closing
date. Cash liquidated damages equal to 2% of the face value of the Debentures
per month are payable to the purchasers for any failure to timely file or
obtain
an effective registration statement.
Pursuant
to the Security Agreement, we agreed to grant the Purchasers, pari passu,
a
security interest in substantially all of our assets. We also agreed to pledge
our respective ownership interests in our wholly-owned subsidiaries, OXIS
Therapeutics, OXIS Isle of Man, and our partial subsidiary, BioCheck, Inc.
OXIS
Therapeutics and OXIS Isle of Man also provided a subsidiary guarantee to
the
Purchasers in connection with the transaction.
Termination
of our President and Chief Executive Officer, and related note and
lawsuit
On
March
10, 2006, we received $200,000 in exchange for an unsecured promissory note
with
Mr. Guillen. The related party note bears interest at 7.0%. Interest and
principal were due on September 10, 2006 and at September 30, 2006 were in
default. Mr. Guillens’s employment was terminated on September 15, 2006.
Mr. Guillen, who remains a member of our board of directors, filed a lawsuit
against OXIS and up to 25 unnamed additional defendants. The complaint alleges
breaches of contract relating to Mr. Guillen’s employment agreement and a
promissory note that is in default, breach of implied covenant of good faith
and
fair dealing, wrongful termination and violation of the California Labor
Code in
relation to the non-payment of back pay. On November 2, 2006, we repaid Mr.
Guillen the principal and accrued interest due on the promissory note in
the
amount of $209,000 and back pay with penalties and accrued interest of $96,000.
We are in ongoing negotiations with Mr. Guillen’s counsel to settle the lawsuit.
To the date of this Report, the complaint has not been served upon OXIS or
any
other defendant.
License
Agreement Extension
On
July
20, 2006, we entered into an amendment to the exclusive license and supply
agreement originally signed on September 28, 2004 with HaptoGuard, Inc.,
or
HaptoGuard, which has since been merged into Alteon Inc. We granted HaptoGuard
three-month extensions to fulfill its obligation to begin Phase II clinical
trials with a licensed product. HaptoGuard may obtain three such extensions
upon
payment of $50,000 for each extension. In addition, we agreed to change the
timeline for initiation of Phase IIb clinical trials with a licensed product
under the license agreement and agreed to allow the same extension arrangement
for that milestone. We received a $50,000 payment from HaptoGuard on July
24,
2006 for the first extension ending on September 30, 2006.
Acquisition
of BioCheck
On
September 19, 2005, we entered into a stock purchase agreement with BioCheck
and
its shareholders to purchase all of its common stock for $6.0 million in
cash. BioCheck is a leading producer of enzyme immunoassay diagnostic kits
for
clinical laboratories. On December 6, 2005, we purchased 51% of the
shares of BioCheck’s common stock from each of its shareholders on a pro rata
basis for $3,060,000 in cash. This acquisition was accounted for by the purchase
method of accounting according to Statement of Financial Accounting Standards
No. 141, “Business Combinations.” The consolidated statements of operations for
the three and nine months ended September 30, 2006 include the results of
operations of BioCheck and the consolidated balance sheets include the assets
and liabilities of BioCheck at December 31, 2005 and September
30, 2006. Pursuant to the stock purchase agreement, OXIS will use its
reasonable best efforts to consummate a follow-on financing transaction to
raise
additional capital with which to purchase the remaining outstanding shares
of
BioCheck in one or more additional closings.
Mutual
Services Agreement
On
June
23, 2006, we entered into a mutual services agreement with BioCheck. Both
OXIS
and BioCheck will provide certain services to the other corporation to be
charged monthly at an hourly rate with an overhead surcharge. The services
that
BioCheck will provide include manufacturing the bulk of OXIS’ research assay
test kits, assisting in packaging and shipping such research assay test kits
to
OXIS customers, and undertaking research and development of certain new OXIS
research assay test kits on a case-by-case basis to be agreed upon between
the
parties. OXIS will provide services to BioCheck, including marketing and
sales,
website management and materials requirement and control systems.
The
agreement terminates on December 6, 2009, or earlier upon mutual consent
of the
parties, upon 90 day prior written notice by either party, by either party
if a
monthly billing is unpaid after 60 days if a 15 day notice and opportunity
to
cure has been provided, or upon a material breach of the agreement after
30
days’ notice and opportunity to cure the breach. As of September 30, 2006, OXIS
owed BioCheck approximately $103,000 for services rendered under the agreement.
OXIS has not made that payment. If OXIS receives written notice of breach
of the
agreement due to this non-payment, it will have 15 days to cure that breach.
If
OXIS fails to cure the breach during the cure period, BioCheck would have
the
right to terminate the agreement.
Product
Development
During
the nine months ended September 30, 2006, we expanded our product portfolio
of
research assay kits for the research markets with the addition of eight new
assay products. Given the availability of sufficient capital resources, we
plan to pursue the development of cardiac markers. We are planning to
expand our cardiovascular and inflammatory products through the combination
of
our myeloperoxidase, or MPO, assay with other in-house assays and new assays
in
development. We also believe that our Ergothioneine compound may be well
suited for development as a nutraceutical supplement that can be sold over
the
counter. We are currently testing Ergothioneine produced in bulk to ensure
that its purity level is acceptable. Given the availability of sufficient
capital resources and the successful scale-up to a bulk manufacturing process
that ensures an acceptable level of purity, we intend to pursue the development
of Ergothioneine for use in the over the counter market, however, there can
be
no assurance as to when or if we will launch Ergotheioneine on a commercial
basis as a nutraceutical.
BioCheck
currently has several products under development for cancer,
cardiac/inflammatory and angiogenesis research applications. A research
assay and reagents for the detection of HMGA2, a marker for aggressive breast
cancer, are under development. Myeloperoxidase is an inflammatory
protein that has utility as a prognostic marker for cardiac events. A new
myeloperoxidase research assay has been developed that we expect will result
in
commercial sales in the fourth quarter of 2006.
Id
proteins play a central role in cell differentiation, and Id1 and Id3 play
a central and critical role in tumor related angiogenesis. BioCheck has
developed research assays and rabbit monoclonal antibodies for the detection
of
human and mouse Id proteins. We currently expect that the Id protein assays
and
reagents will be ready for commercial launch by late 2006.
Other
Loans and Warrant
The
$3,060,000 loan with KeyBank, N.A., or KeyBank, was repaid during February
2006
and a new one-year loan agreement for $3,060,000 was entered into with Bridge
Bank, National Association, or Bridge Bank. As part of the loan arrangement
with
Bridge Bank, we granted a security interest in a $3,060,000 certificate of
deposit transferred from KeyBank to Bridge Bank. The loan bears interest
at 3.0%
and the certificate of deposit bears interest at 1.0%.
On
March
31, 2006, we issued a $400,000 unsecured promissory note to Fagan Capital,
Inc.,
or Fagan Capital. Interest accrues at an annual rate of 8.0% and interest
and
principal were due on June 2, 2006. On July 26, 2006, Fagan Capital extended
the
maturity date of the promissory note to June 1, 2007 and we issued to Fagan
Capital a warrant to purchase 1,158,857 shares of common stock at an initial
exercise price of $0.35 per share. On October 25, 2006, the Company prepaid
the
principal, accrued interest and legal fees due pursuant to the Renewal Note
in
the amount of $426,000 and the Company undertook to finalize a registration
rights agreement covering the shares underlying the common stock purchase
warrant within 7 days of the prepayment of the Renewal Note. See Notes 3
and 7
to the unaudited consolidated financial statements included in this Report.
The
purpose of these loans was to provide us with short term financing as we
sought
longer term financing.
Relocation
of Operations
On
December 6, 2005, we initiated a relocation plan to cease our operations
in
Portland, Oregon and relocate to Foster City, California. We decided to relocate
after reviewing and evaluating all aspects of our operations to determine
the
profitability and viability of continuing in the Portland, Oregon location.
During February 2006, we signed a lease agreement for 4,136
square feet of space located immediately adjacent to those of BioCheck and
relocated our manufacturing operations to Foster City, California.
On
February 15, 2006, we ceased operations at the Portland, Oregon facility
and
most of the Portland, Oregon employees were terminated. In connection with
the
relocation, we accrued $119,000 during 2005 for employee severances offered
to
all regular full-time employees who were not relocated to Foster City,
California. Of this amount, $103,000 has been paid during the first nine
months
of 2006, resulting in $16,000 of accrued expenses at September 30, 2006.
We
expect $8,000 of this amount to be paid during the remainder of 2006 and
$8,000
is to be paid during 2007.
Results
of Operations
We
expect
revenues and expenses to increase substantially as described below from 2005
to
2006 with the consolidation of all of BioCheck’s results of operations for the
nine months ended September 30, 2006. BioCheck’s revenues and expenses are not
included in the results of operations for the nine months ended September
30,
2005 because they were incurred before the December 6, 2005 date of
acquisition. Our projections for 2006 are based upon our expectations that
BioCheck will incur similar revenues and costs in 2006 as it incurred in
2005.
We can give no assurances that we will be able to successfully merge
manufacturing operations without adversely affecting revenues and costs,
increase revenues, develop new products, finance our expansion plans and
purchase the remaining 49% of the BioCheck common stock we do not
own.
Revenues
The
following table presents the changes in revenues from 2005 to 2006:
|
|
Three
Months Ended September 30,
|
|
Nine
Months Ended September 30,
|
|
|
|
2006
|
|
2005
|
|
Increase
from 2005
|
|
2006
|
|
2005
|
|
Increase
from 2005
|
|
Revenues
|
|
$
|
1,512,000
|
|
$
|
532,000
|
|
$
|
980,000
|
|
|
184%
|
|
$
|
4,381,000
|
|
$
|
1,718,000
|
|
$
|
2,663,000
|
|
|
155%
|
|
For
the
three months ended September 30, the increase in revenues was primarily
attributable to the consolidation of $1,128,000 of revenues from BioCheck
and
$50,000 license fee payment from HaptoGuard that was partially offset by
a
$198,000 decrease in sales from the OXIS parent company. For the nine months
ended September 30, the increase in revenues was primarily attributable to
the
consolidation of $3,204,000 of revenues from BioCheck and $50,000 license
fee
payment from HaptoGuard that was partially offset by a $591,000 decrease
in
sales from the OXIS parent company. The decrease in OXIS parent company sales
is
attributable to lower sales volume that was caused, in part, by the interruption
arising from moving operations from Portland, Oregon to Foster City, California
and consolidating our product offerings. We expect fourth quarter 2006 product
revenues to increase modestly from the third quarter as we introduce new
products such as our improved MPO. We intend to develop new diagnostic test
kits
and evaluate our product offerings, pricing and distribution network with
the
plan of increasing sales volume.
Cost
of product revenues
The
following table presents the changes in cost of product revenues from 2005
to
2006:
|
|
Three
Months Ended September 30,
|
|
Nine
Months Ended September 30,
|
|
|
|
2006
|
|
2005
|
|
Increase
from 2005
|
|
2006
|
|
2005
|
|
Increase
from 2005
|
|
Cost
of product revenues
|
|
$
|
725,000
|
|
$
|
333,000
|
|
$
|
392,000
|
|
|
118%
|
|
$
|
2,374,000
|
|
$
|
906,000
|
|
$
|
1,468,000
|
|
|
162%
|
|
For
the
three months ended September 30, 2006, the increase in cost of product revenues
is attributable to the consolidation of $512,000 of costs from the operations
of
BioCheck that were partially offset by decreased labor and related costs
including contract labor of $86,000 and facility and related costs of $41,000.
For the nine months ended September 30, 2006, the increase in cost of product
revenues is attributable to the consolidation of $1,620,000 of costs from
the
operations of BioCheck that were partially offset by decreased labor and
related
costs of $115,000 and facility and related costs of $52,000. We expect fourth
quarter 2006 product costs to increase proportionally with any increases
in
revenues.
Gross
profit of $787,000 for the three months ended September 30, 2006 was higher
than
the gross profit of $199,000 in the comparable period of 2005 because of
the
additional profits from product sales from BioCheck. Gross profit as a
percentage of revenues was 52% in the three months ended September 30, 2006,
as
compared to 37% in the three months ended September 30, 2005. Gross profit
of
$2,007,000 for the nine months ended September 30, 2006 was higher than the
gross profit of $812,000 in the comparable period of 2005 because of the
additional profits from product sales from BioCheck. Gross profit as a
percentage of revenues was 46% in the nine months ended September 30, 2006,
as
compared to 47% in the nine months ended September 30, 2005.
Research
and development expenses
The
following table presents the changes in research and development expenses
from
2005 to 2006:
|
|
Three
Months Ended September 30,
|
|
Nine
Months Ended September 30,
|
|
|
|
2006
|
|
2005
|
|
Increase
from 2005
|
|
2006
|
|
2005
|
|
Increase
from 2005
|
|
Research
and development expenses
|
|
$
|
207,000
|
|
$
|
69,000
|
|
$
|
138,000
|
|
|
200%
|
|
$
|
598,000
|
|
$
|
191,000
|
|
$
|
407,000
|
|
|
213%
|
|
For
the
three months ended September 30, 2006, the increase in research and development
expenses is primarily attributable to the consolidation of $131,000 of costs
from the operations of BioCheck and increased patent amortization expense
of
$23,000. The increase was partially offset by decreased salary and benefits
costs of $8,000. For the nine months ended September 30, 2006, the increase
in
research and development expenses is primarily attributable to the consolidation
of $432,000 of costs from the operations of BioCheck and increased patent
amortization expense of $63,000. The increase was partially offset by decreased
salary and benefits costs of $50,000 and direct project expenses of $23,000.
We
expect fourth quarter 2006 research and development costs to be approximately
the same as the third quarter. However, the actual amount of research and
development expenses will fluctuate with the availability of funding.
Selling,
general and administrative expenses
The
following table presents the changes in selling, general and administrative
expenses from 2005 to 2006:
|
|
Three
Months Ended September 30,
|
|
Nine
Months Ended September 30,
|
|
|
|
2006
|
|
2005
|
|
Increase
from 2005
|
|
2006
|
|
2005
|
|
Increase
from 2005
|
|
Selling,
general and administrative expenses
|
|
$
|
953,000
|
|
$
|
470,000
|
|
$
|
483,000
|
|
|
103%
|
|
$
|
2,854,000
|
|
$
|
1,551,000
|
|
$
|
1,303,000
|
|
|
84%
|
|
For
the
three months ended September 30, 2006, the increase in selling, general and
administrative expenses is primarily attributed to the consolidation of costs
from the operations of BioCheck of $197,000, severance charges of $261,000
related to the termination of employment of our president and chief executive
officer, and increased costs for accounting, legal, shareholder communication
and investor relations activities of $20,000; and non-cash compensation of
$69,000 which, effective January 1, 2006, is required for employees to be
included in expenses by SFAS 123R. The increase was partially offset by
decreased costs for labor and related costs including contract labor and
associated transportation costs of $28,000. For the nine months ended September
30, 2006, the increase in selling, general and administrative expenses is
primarily attributed to the consolidation of costs from the operations of
BioCheck of $605,000, severance charges of $261,000 and increased costs for
accounting, legal, shareholder communication and investor relations activities
of $121,000; labor and related costs including contract labor and associated
transportation costs of $74,000; and non-cash compensation of $249,000. We
expect fourth quarter 2006 selling, general and administrative expenses to
be
approximately the same as the third quarter.
Interest
Income
The
decrease in interest income from $74,000 for the nine months ended September
30,
2005 to $45,000 in the same period in 2006 is primarily due to reduced cash
available for investment activities obtained in the $6,500,000 equity financing
received during December 2004 and January 2005.
Other
Income
Other
income is related to the sale of surplus equipment.
Interest
Expense
Interest
expense of $146,000 in the nine months ended September 30, 2006 was primarily
due to the loan with KeyBank that was transferred to Bridge Bank incurred
in
connection with the BioCheck acquisition, the addition of new debt of $600,000
in March 2006 and non-cash financing expense of $45,000 related to the renewal
of a note with Fagan Capital. We expect interest expense for the fourth quarter
to increase significantly from the third quarter of 2006 with additional
debt
financing obtained during October 2006. See Notes 3 and 7 to the unaudited
consolidated financial statements included in this Report.
Liquidity
and Capital Resources
On
a
consolidated basis, we had cash and cash equivalents of $677,000 at September
30, 2006 of which $656,000 was held by BioCheck. Since BioCheck has been
and is
expected to continue to be cash flow positive, management believes that its
cash
will be sufficient to sustain its operating activities.
The
cash
held by the OXIS parent company was $21,000 at September 30, 2006. OXIS cannot
access the cash held by its majority-held subsidiary, BioCheck, to pay for
the
corporate purposes of the OXIS parent company. We have incurred negative
operating cash flows of $0.5 million during the nine months ended September
30,
2006. The OXIS parent company incurred negative operating cash flows of $0.9
million during the first nine months of 2006. Our cash may not be sufficient
to
sustain our operations through the first quarter of 2007 without additional
financings. We obtained debt financing in which we received proceeds of
$1,350,000 subsequent to September 30, 2006 and are seeking equity financing
to
obtain sufficient funds to sustain operations and purchase the remaining
49% of
BioCheck for approximately $3.0 million. From the aforementioned debt financing,
$635,000 was used to repay existing debt, accrued interest and related legal
fees. We plan to increase revenues by introducing new products. However,
we
cannot assure you that we will successfully obtain equity financing, if any,
sufficient to finance our goals or that we will increase product related
revenues as such events are subject to factors beyond our control. If we
are
unable to raise additional capital in 2007, we will have to curtail or cease
operations.
Net
cash used in operating activities
The
following table presents cash flows from operating activities for 2006 and
2005:
|
|
Nine
Months Ended September 30,
|
|
|
|
2006
|
|
2005
|
|
Cash
paid to employees including benefits
|
|
$
|
(1,608,000
|
)
|
$
|
(675,000
|
)
|
Cash
paid to suppliers
|
|
|
(3,209,000
|
)
|
|
(2,630,000
|
)
|
Total
cash paid to employees and suppliers
|
|
|
(4,817,000
|
)
|
|
(3,305,000
|
)
|
Cash
received from customers
|
|
|
4,352,000
|
|
|
1,650,000
|
|
Interest
and other income received
|
|
|
47,000
|
|
|
74,000
|
|
Interest
paid
|
|
|
(88,000
|
)
|
|
(11,000
|
)
|
Net
cash used in operating activities
|
|
$
|
(506,000
|
)
|
$
|
(1,592,000
|
)
|
The
increase in cash paid to employees is primarily attributed to $1.0 million
of
cash paid by BioCheck for payroll and benefits. Cash paid to suppliers is
increased by approximately $1.6 million due to BioCheck that was offset by
2004
expenses recorded as liabilities at December 31, 2004 that were paid in the
first quarter of 2005 of approximately $0.5 million and an increase in accounts
payable and accrued expense in the first nine months of 2006 of approximately
$0.5 million. The increase in cash received from customers is attributed
to
increased revenues of $2.7 million. Interest paid increased primarily due
to
increased debt entered into during December 2005 of $3,060,000.
Cash
used in investing activities
During
the first quarter of 2006 we transferred our $3,060,000 restricted certificate
of deposit from KeyBank to Bridge Bank. Capital expenditures during the nine
months ended 2006 were primarily for equipment and leasehold improvements
at our
new Foster City, California location. We had no commitments for capital
expenditures at September 30, 2006. We paid $42,000 and $171,000 for
patent filings that were capitalized during the nine months ended 2006 and
2005,
respectively.
Net
cash provided by financing activities
On
October 25, 2006, we entered into a securities purchase agreement, or Purchase
Agreement, with four accredited investors, or the Purchasers. In conjunction
with the signing of the Purchase Agreement, we issued secured convertible
debentures, or Debentures, and Series A, B, C, D, and E common stock warrants,
or Warrants to the Purchasers, and the parties also entered into a registration
rights agreement and a Security Agreement. The Warrants issued to the Purchasers
are for the purchase of an aggregate of approximately 14.5 million shares
of
OXIS common stock, at initial exercise prices ranging from $0.35 to $0.385
per
share, subject to adjustment as provided therein, including full ratchet
anti-dilution. OXIS issued secured convertible debentures, or Debentures,
in an
aggregate principal amount of $1,694,250 to the Purchasers. The Series D
and E
Warrants are only exercisable pro rata subsequent to the exercise of the
Series
C Warrants. The Debentures are subject to an original issue discount of 20.318%
resulting in proceeds to OXIS of $1,350,000 from the transaction. The Debentures
are convertible, at the option of the Purchasers, at any time, into shares
of
common stock at $0.35 per share, as adjusted pursuant to a full ratchet
anti-dilution provision, or Conversion Price. Beginning on the first of the
month following the earlier of the effective date of the registration statement
to be filed pursuant to the registration rights agreement and February 1,
2007,
OXIS shall amortize the Debentures in equal installments on a monthly basis
resulting in a complete repayment by the maturity date or Monthly Redemption
Amounts. The Monthly Redemption Amounts can be paid in cash or in shares,
subject to certain restrictions. If OXIS chooses to make any Monthly Redemption
Amount payment in shares of common stock, the price per share is the lesser
of
the Conversion Price then in effect and 85% of the weighted average price
for
the 10 trading days prior to the due date of the Monthly Redemption
Amount.
On
March
31, 2006, we issued a $400,000 unsecured promissory note to Fagan Capital.
Interest accrues at an annual rate of 8.0% and interest and principal were
due
on June 2, 2006. On July 26, 2006, Fagan Capital extended the maturity date
of
the promissory note to June 1, 2007 and we issued to Fagan Capital a warrant
to
purchase 1,158,857 shares of common stock at an initial exercise price of
$0.35
per share. On October 25, 2006, we prepaid the principal, accrued interest
and
legal fees due in the amount of $426,000. See Note 7 to the unaudited
consolidated financial statements included in this Report. The purpose of
this
loan was to provide us with short term financing as we sought longer term
financing.
On
March
10, 2006, we received $200,000 in exchange for an unsecured promissory note
with
Steven T. Guillen, our president and chief executive officer at that time.
The
related party note bears interest at 7.0%. Interest and principal were due
on
September 10, 2006. Mr. Guillen’s employment was terminated on September 15,
2006. We were in default on this note at September 30, 2006. Subsequent to
September 30, 2006, Mr. Guillen sued the Company for payment of interest
and
principal due under the note. On November 2, 2006, we repaid the principal
and
accrued interest due on the promissory note with Mr. Guillen in the amount
of
$209,000.
On
December 2, 2005, we entered into a non-revolving one-year loan agreement
with KeyBank in the amount of $3,060,000, for the purpose of completing the
initial closing of the BioCheck acquisition. This loan was repaid during
February 2006 and a new one-year loan agreement for $3,060,000 was entered
into
with Bridge Bank.
The
OXIS
parent company had cash and cash equivalents of $21,000 at September 30,
2006.
OXIS cannot access the cash held by its majority-held subsidiary, BioCheck,
to
pay for the corporate purposes of the OXIS parent company. In an effort to
mitigate this near-term concern, we obtained debt financing in which we received
proceeds of $1,350,000 subsequent to September 30, 2006 and are seeking equity
financings to obtain sufficient funds to sustain operations and purchase
the
remaining 49% of BioCheck for approximately $3.0 million. From the
aforementioned debt financing, $635,000 was used to repay existing debt,
accrued
interest and related legal fees. However, we cannot assure you that we will
successfully obtain equity financing.
Critical
Accounting Policies
We
consider the following accounting policies to be critical given they involve
estimates and judgments made by management and are important for our investors’
understanding of our operating results and financial condition.
Basis
of Consolidation
The
consolidated financial statements contained in this Report include the accounts
of OXIS International, Inc. and its subsidiaries. All intercompany balances
and
transactions have been eliminated. On December 6, 2005, we purchased 51% of
the common stock of BioCheck. This acquisition was accounted for by the purchase
method of accounting according to Statement of Financial Accounting Standards
No. 141, “Business Combinations.” The consolidated statements of operations for
the three and nine months ended September 30, 2006 include the results of
operations of BioCheck and the consolidated balance sheets include the assets
and liabilities of BioCheck at September 30, 2006 and
December 31, 2005.
Revenue
Recognition
We
manufacture, or have manufactured on a contract basis, research and diagnostic
assays and fine chemicals, which are our primary products sold to customers.
Revenue from the sale of our products, including shipping fees, is recognized
when title to the products is transferred to the customer which usually occurs
upon shipment or delivery, depending upon the terms of the sales order and
when
collectibility is reasonably assured. Revenue from sales to distributors
of our
products is recognized, net of allowances, upon delivery of product to the
distributors. According to the terms of individual distributor contracts,
a
distributor may return product up to a maximum amount and under certain
conditions contained in its contract. Allowances are calculated based upon
historical data, current economic conditions and the underlying contractual
terms. Our mix of product sales are substantially at risk to market conditions
and demand, which may change at anytime.
We
recognize license fee revenue for licenses to our intellectual property when
earned under the terms of the agreements. Generally, revenue is recognized
upon
transfer of the license unless we have continuing obligations for which fair
value cannot be established, in which case the revenue is recognized over
the
period of the obligation. We consider all arrangements with payment terms
extending beyond twelve months not to be fixed or determinable. In certain
licensing arrangements there is provision for a variable fee as well as a
non-refundable minimum amount. In such arrangements, the amount of the
non-refundable minimum guarantee is recognized upon transfer of the license
and
collectibility is reasonably assured or over the period of the obligation,
as
applicable, and the amount of the variable fee is recognized as revenue when
it
is fixed and determinable. We recognize royalty revenue based on reported
sales
by third party licensees of products containing our materials, software and
intellectual property. Non-refundable royalties, for which there are no further
performance obligations, are recognized when due under the terms of the
agreements.
Inventories
Inventories
are stated at the lower of cost to purchase and/or manufacture the inventory
or
the current estimated market value of the inventory. We regularly review
our
inventory quantities on hand and record a provision for excess and obsolete
inventory based primarily on our estimated forecast of product demand and/or
our
ability to sell the products and production requirements. Demand for our
products can fluctuate significantly. Factors which could affect demand for
our
products include unanticipated changes in consumer preferences, general market
conditions or other factors, which may result in cancellations of advance
orders
or a reduction in the rate of reorders placed by customers and/or continued
weakening of economic conditions. Additionally, our estimates of future product
demand may be inaccurate, which could result in an understated or overstated
provision required for excess and obsolete inventory. Our estimates are based
upon our understanding of historical relationships which can change at
anytime.
Long-Lived
Assets
Our
long-lived assets include property, plant and equipment, capitalized costs
of
filing patent applications and goodwill and other assets. We evaluate our
long-lived assets for impairment in accordance with SFAS No. 144, “Accounting
for the Impairment or Disposal of Long-Lived Assets” whenever events or changes
in circumstances indicate that the carrying amount of such assets may not
be
recoverable. Estimates of future cash flows and timing of events for evaluating
long-lived assets for impairment are based upon management’s judgment. If any of
our intangible or long-lived assets are considered to be impaired, the amount
of
impairment to be recognized is the excess of the carrying amount of the assets
over its fair value.
Applicable
long-lived assets are amortized or depreciated over the shorter of their
estimated useful lives, the estimated period that the assets will generate
revenue, or the statutory or contractual term in the case of patents. Estimates
of useful lives and periods of expected revenue generation are reviewed
periodically for appropriateness and are based upon management’s judgment.
Goodwill and other assets are not amortized.
Share-Based
Compensation
In
December 2004, the Financial Accounting Standards Board, or FASB, issued
SFAS
123R. SFAS 123R replaces FASB Statement No. 123, “Accounting for Stock-Based
Compensation”, and supersedes APB Opinion No. 25, “Accounting for Stock Issued
to Employees,” or APB Opinion No. 25. SFAS 123R establishes standards for the
accounting for share-based payment transactions in which an entity exchanges
its
equity instruments for goods or services. It also addresses transactions
in
which an entity incurs liabilities in exchange for goods or services that
are
based on the fair value of the entity’s equity instruments or that may be
settled by the issuance of those equity instruments. SFAS 123R covers a wide
range of share-based compensation arrangements including share options,
restricted share plans, performance-based awards, share appreciation rights
and
employee share purchase plans. SFAS 123R requires a public entity to measure
the
cost of employee services received in exchange for an award of equity
instruments based on the fair value of the award on the grant date (with
limited
exceptions). That cost will be recognized in the entity’s financial statements
over the period during which the employee is required to provide services
in
exchange for the award. Management implemented SFAS 123R effective January
1,
2006. Methodologies used for calculations such as the Black-Scholes
option-pricing models and variables such as volatility and expected life
are
based upon management’s judgment. Such methodologies and variables are reviewed
and updated periodically for appropriateness and affect the amount of recorded
charges. See Note 1 to the unaudited consolidated financial statements included
in this Report for more information on the amounts, methodologies and variables
related to non-cash share-based compensation charges.
FACTORS
THAT MAY AFFECT FUTURE OPERATING RESULTS
We
operate in a rapidly changing environment that involves a number of risks,
some
of which are beyond our control. The following discussion highlights some
of
these risks and others are discussed elsewhere in this report or in our Annual
Report on Form 10-KSB for the period ended December 31, 2005 and our
Post-Effective Amendment No. 1 to Form SB-2 Registration Statement (SEC
File No. 333-123008).
Risks
Related to Our Business
We
will need to raise additional capital to fund our general and administrative
expenses, and if we are unable to raise such capital, we will have to curtail
or
cease operations.
The
OXIS
parent company had cash and cash equivalents of $21,000 at September 30,
2006.
OXIS cannot access the cash held by its majority-held subsidiary, BioCheck,
to
pay for the corporate purposes of the OXIS parent company. We obtained debt
financing in which we received proceeds of $1,350,000 subsequent to September
30, 2006 and are seeking equity financings to obtain sufficient funds to
sustain
operations, including our development and commercialization programs and
purchase the remaining 49% of BioCheck common stock we do not own. We have
incurred significant obligations in relation to the termination of our former
president and chief executive officer. We repaid debt including accrued interest
and legal fees in the amount of $426,000 to Fagan Capital and $209,000 to
our
former chief executive officer. If we are unable to raise additional capital
in
the first quarter of 2007, we may have to curtail or cease
operations.
If we
raise short term capital by incurring additional debt, we will have to obtain
equity financing sufficient to repay such debt and accrued interest. Further,
incurring additional debt may make it more difficult for us to successfully
consummate future equity financings.
Restrictive
provisions of the Securities Purchase Agreement signed with purchasers of
debentures and warrants in the recent debt financing may prohibit OXIS from
consummating an equity financing transaction.
Pursuant
to the Securities Purchase Agreement entered into with four accredited
purchasers on October 25, 2006, OXIS is prohibited from issuing shares of
common
stock or securities convertible into common stock except pursuant to options
issued under its stock option plan and other limited exceptions, until ninety
days after the effective date of the registration statement that OXIS is
required to file in relation to the Debenture transaction, unless the volume
weighted average price of our common stock for each of the twenty days
immediately prior to any such issuance of equity securities is in excess
of
$0.40 per share, subject to adjustment for stock splits. Given the recent
price
range of our common stock between $0.20 and $0.35, unless the price of our
common stock increases significantly within the next six to seven months,
we
will be unable to raise additional funds through an equity financing. Pursuant
to another provision of the Securities Purchase Agreement, the Purchasers
of the
Debentures have the right to participate in up to 100% of any future equity
financing involving issuance of common stock or securities issuable into
common
stock which OXIS undertakes within one year after the effective date of the
registration statement which OXIS is required to file regarding the Debenture
transaction. This provision may make potential investors reluctant to enter
into
term sheets with OXIS for future equity transactions.
Repayment
of recently issued Debentures in shares and the exercise of recently issued
warrants would cause substantial dilution to our stockholders and would likely
to depress our stock price, making it more difficult for OXIS to consummate
future equity financings.
In
the
debt financing transaction which OXIS entered into in October 2006 with four
accredited purchasers or the Purchasers, OXIS issued Secured Convertible
Debentures in an aggregate principal amount of $1,694,250 to the Purchasers.
OXIS also issued Series A, B, C, D, and E warrants to the Purchasers for
the
purchase of an aggregate of approximately 14.5 million shares of OXIS common
stock, at initial exercise prices ranging from $0.35 to $0.385 per share,
subject to adjustment as provided therein, including full ratchet
anti-dilution.. The Series D and E warrants are only exercisable pro rata
subsequent to the exercise of the Series C warrants. The Debentures are subject
to an original issue discount of 20.318% resulting in proceeds to OXIS of
$1,350,000 from the transaction. The Debentures are convertible, at the option
of the Purchasers, at any time, into shares of common stock at $0.35 per
share,
as adjusted pursuant to a full ratchet anti-dilution provision (the “Conversion
Price”). Beginning on the first of the month following the earlier of the
effective date of the registration statement to be filed pursuant to the
registration rights agreement and February 1, 2007, OXIS shall amortize the
Debentures in equal installments on a monthly basis resulting in a complete
repayment by the maturity date (the “Monthly Redemption Amounts”). The Monthly
Redemption Amounts can be paid in cash or in shares, subject to certain
restrictions. If OXIS chooses to make any Monthly Redemption Amount payment
in
shares of common stock, the price per share is the lesser of the Conversion
Price then in effect and 85% of the weighted average price for the 10 trading
days prior to the due date of the Monthly Redemption Amount.
Due
to
the floating conversion price of the Debentures applicable when OXIS chooses
to
repay the Debentures in shares, OXIS would need to issue approximately ten
million shares to the Purchasers, assuming that stock prices remain in their
recent price range. The number of shares which OXIS may have to issue to
the
Purchasers could increase significantly if the stock price declines from
the
current price range. In addition, OXIS would have to issue approximately
five
million shares if the Purchasers exercise the Series A and B warrants, an
additional approximately five million shares would be issued upon exercise
of
the Series C warrants and finally, an additional approximately five million
shares would be issued upon exercise of the Series D and E warrants pro rata
subsequent to the exercise of the Series C warrants. The future potential
dilution due to exercise of the above warrants could be increased if the
full
ratchet anti-dilution applicable to the exercise price of the warrants is
triggered. This future potential dilution would likely depress our stock
price,
making it difficult for us to consummate a future equity financing.
Restrictions
on OXIS’ ability to repay the Debentures in shares rather than in cash may
deplete OXIS’ cash resources and will require future financings to avoid
default.
Under
the
terms of the Debentures issued to purchasers in October 2006, OXIS right
to make
its monthly redemption payments to the Purchasers of the Debentures is
conditioned upon several factors. Beginning on the first of the month following
the earlier of the effective date of the registration statement to be filed
pursuant to the registration rights agreement and February 1, 2007, OXIS
is
obligated to amortize the Debentures in equal installments on a monthly basis
resulting in a complete repayment by the maturity date either in cash or
in
shares. The monthly redemptions, if made in cash to all Purchasers would
equal
approximately $85,000 per month. OXIS may not make the monthly redemption
in
shares if, among other conditions, the issuance of the shares to the Purchasers
would cause any such Purchaser to beneficially own in excess of either 9.99%
or
4.99% of the total outstanding shares of OXIS at that time (depending on
the
particular Purchaser either the 9.99% or the 4.99% applies). One of the
Purchasers currently beneficially owns approximately 9% of the total outstanding
shares. In addition, OXIS may not make monthly redemption payments to any
Purchasers in shares rather than cash if the daily trading volume for OXIS’
common stock does not exceed 50,000 shares per trading day for a period of
twenty trading days prior to any applicable date in question beginning after
April 25, 2007. If OXIS must make all or a substantial amount of its monthly
redemption payments to the Purchasers in cash rather than shares, its cash
reserves will be depleted and it will have to raise substantial additional
capital to avoid default of the Debentures.
As
we
have failed to make payments due to BioCheck under our Mutual Services
Agreement, BioCheck could exercise its rights under the default provisions
of
that agreement to terminate the agreement and cease production of many of
our
research test kit assays.
As
mentioned above, on June 23, 2006, we entered into a Mutual Services Agreement,
or Agreement, with our majority owned subsidiary, BioCheck. Pursuant to the
Agreement, OXIS agreed to pay BioCheck approximately $103,000 that it owed
to
BioCheck for services that BioCheck had provided to OXIS during the nine
months
ended September 30, 2006. OXIS has not made that payment. If OXIS receives
written notice of breach of the Agreement due to this non-payment, it will
have
15 days to cure that breach. If OXIS fails to cure the breach during the
cure
period, BioCheck would have the right to terminate the Agreement. Pursuant
to
the Agreement, BioCheck is manufacturing the bulk of OXIS’ research assay test
kits, assisting in packaging and shipping such research assay test kits to
OXIS
customers, and undertaking research and development of certain new OXIS research
assay test kits. If BioCheck ceases to perform services under the Agreement,
OXIS will have to turn to third party suppliers for the manufacturing of
its
research assay test kits, where that is possible, and will likely have to
cease
research and development of new OXIS research assay test kits. There can
be no
assurance that possible third party suppliers of research assay test kits
will
be willing or able to manufacture OXIS’ research assay test kits at competitive
prices or at all, or that OXIS would be able to pay for such services.
Disruption or cessation of manufacturing due to the termination of the Agreement
would have immediate and deleterious effects on OXIS future
revenues.
We
will need to raise additional capital in order to complete our acquisition
of
the outstanding shares of BioCheck.
On
September 19, 2005 we entered into a stock purchase agreement with BioCheck
and
the shareholders of BioCheck pursuant to which OXIS undertook to purchase
up to
all of the outstanding shares of common stock of BioCheck for an aggregate
purchase price of $6.0 million in cash. On December 6, 2005, pursuant to
the terms of the stock purchase agreement with BioCheck, at the initial closing,
we purchased an aggregate of fifty-one percent (51%) of the outstanding shares
of common stock of BioCheck from each of the shareholders of BioCheck on
a pro
rata basis, for an aggregate of $3,060,000 in cash. Pursuant to the stock
purchase agreement, OXIS will use its reasonable best efforts to consummate
a
follow-on financing transaction to raise additional capital with which to
purchase the remaining outstanding shares of BioCheck in one or more additional
closings. The purchase price for any BioCheck shares purchased after the
initial
closing will be increased by an additional 8% per annum from the date of
the
initial closing through the date of such purchase. If OXIS has not purchased
all
of the outstanding shares of BioCheck within twelve months of the initial
closing, the earnings before interest, taxes, depreciation and amortization
expenses, or EBITDA, if any, of BioCheck will be used to repurchase the
remaining outstanding BioCheck shares at one or more additional closings.
There
can be no assurance that there will be any EBITDA of BioCheck in the next
several years which could be utilized to purchase additional shares of BioCheck
pursuant to the stock purchase agreement. Even if there is some amount of
BioCheck EBITDA available to purchase additional shares of BioCheck, there
can
be no assurance that such EBITDA would be sufficient to complete our acquisition
of the remaining 49% of BioCheck outstanding shares.
To
avoid
an increase in the purchase price of the remaining shares of BioCheck at
the
rate of 8% per annum, we will need to consummate a financing transaction
to
complete the acquisition of the remaining 49% of the outstanding shares of
BioCheck. The successful completion of our acquisition of BioCheck is dependent
upon obtaining financing on acceptable terms. No assurances can be given
that we
will be able to complete such a financing sufficient to undertake our
acquisition of the outstanding shares of BioCheck on terms favorable to us,
or
at all. Any financing that we do undertake to finance the acquisition of
BioCheck will likely involve dilution of our common stock if it is an equity
financing or will involve the assumption of significant debt by
OXIS.
We
will need additional financing in order to complete our development and
commercialization programs.
As
of
September 30, 2006, we had an accumulated deficit of approximately $67,301,000.
We currently do not have sufficient capital resources to complete the
development and commercialization of our antioxidant therapeutic technologies
and oxidative stress assays, and no assurances can be given that we will
be able
to raise such capital in the future on terms favorable to us, or at all.
The
unavailability of additional capital could cause us to cease or curtail our
operations and/or delay or prevent the development and marketing of our
potential products. In addition, we may choose to abandon certain issued
United
States and international patents that we deem to be of lesser importance
to our
strategic direction, in an effort to preserve our financial resources.
Our
future capital requirements will depend on many factors including the following:
• continued
scientific progress in our research and development programs and the
commercialization of additional products;
• the
cost
of our research and development and commercialization activities and
arrangements, including sales and marketing;
• the
costs
associated with the scale-up of manufacturing;
• the
success of pre-clinical and clinical trials;
• the
establishment of and changes in collaborative relationships;
• the
time
and costs involved in filing, prosecuting, enforcing and defending patent
claims;
• the
time
and costs required for regulatory approvals;
• the
acquisition of additional technologies or businesses;
• technological
competition and market developments; and
• the
cost
of complying with the requirements of the Autorité des Marchés Financiers, or
AMF, the French regulatory agency overseeing the Nouveau Marché in
France.
We
will
need to raise additional capital to fund our development and commercialization
programs. Our current capital resources are not sufficient to sustain operations
and our development program with respect to our Ergothioneine as a nutraceutical
supplement. We have granted a licensee exclusive worldwide rights, in certain
defined areas of cardiovascular indications, to develop, manufacture and
market
BXT-51072 and related compounds from our library of such antioxidant compounds.
The licensee is responsible for worldwide product development programs with
respect to the licensed compounds. Due to the lack of financial resources,
we
ceased further testing of BXT-51072 but continue to review the possibility
of
further developing applications for BXT-51072 and related compounds outside
of
the areas defined in the license. However, further development and
commercialization of antioxidant therapeutic technologies, oxidative stress
assays or currently unidentified opportunities, or the acquisition of additional
technologies or businesses, may require additional capital. The fact that
further development and commercialization of a product or technology would
require us to raise additional capital, would be an important factor in our
decision to engage in such further development or commercialization. No
assurances can be given that we will be able to raise such funds in the future
on terms favorable to us, or at all.
If
we
complete our acquisition of BioCheck, our business could be materially and
adversely affected if we fail to adequately integrate the operations of the
two
companies.
If
we
complete the acquisition of BioCheck, or the Acquisition, as planned, and
we do
not successfully integrate the operations of the two companies, or if the
benefits of the transaction do not meet the expectations of financial or
industry analysts, the market price of our common stock may decline. The
Acquisition could result in the use of significant amounts of cash, dilutive
issuances of equity securities, or the incurrence of debt or expenses related
to
goodwill and other intangible assets, any of which could materially adversely
affect our business, operating results and financial condition.
We
may
not be able to successfully integrate the BioCheck business into our existing
business in a timely and non-disruptive manner, or at all. In addition, the
Acquisition may result
in, among other things, substantial
charges
associated with acquired in-process research and development, future write-offs
of goodwill that is deemed to be impaired, restructuring charges related
to
consolidation of operations, charges associated with unknown or unforeseen
liabilities of acquired businesses and increased general and administrative
expenses. Furthermore, the Acquisition may not produce revenues, earnings
or
business synergies that we anticipate. There
can
be no assurance that BioCheck will continue to manufacture our research assay
test kits if that agreement is terminated.
In
addition, acquisitions in general involve numerous risks, including:
• difficulties
in assimilating the operations, technologies, products and personnel of an
acquired company;
• risks
of
entering markets in which we have either no or limited prior
experiences;
• the
diversion of management’s attention from other business concerns; and
• the
potential loss of key employees of an acquired company.
The
time,
capital management and other resources spent on the Acquisition, if it fails
to
meet our expectations, could cause our business and financial condition to
be
materially and adversely affected.
Our
relocation plan could adversely affect our operations.
As
part
of our decision to acquire BioCheck, we implemented a relocation and integration
plan, including a strategy to reduce our cost structure. In doing so, we
significantly reduced our employee workforce from 15 full time employees
to six
at November 10, 2006, outsourced certain company functions and have taken
other
steps intended to reduce costs and improve efficiencies. Our
business may continue to be disrupted and adversely affected by this reduction
in work force until we employ new personnel to replace certain open positions.
Our business may also be disrupted due to our move to new
facilities.
The
payment of severance benefits resulting from employee terminations will cause
us
to utilize cash. There can be no assurances that we will be able to improve
efficiencies and function properly following such reductions.
We
may experience disruption or may fail to achieve any benefits in connection
with
the recent changes in executive management and in Board membership.
During
the second quarter of 2004, our former Chief Executive Officer retired, and
during the third quarter of 2004 our Chief Operating and Financial Officer
left
the employment of our company. As a result, others who had limited experience
with OXIS were appointed to serve as acting Chief Executive Officer, acting
Chief Operating Officer and acting Chief Financial Officer.
On February 28, 2005, the Board appointed Mr. Steven T. Guillen to the
positions of President and Chief Executive Officer of OXIS, and as a member
of
our board. On January 6, 2006, we hired Michael D. Centron as our Vice President
and Chief Financial Officer. On
September 15, 2006, Mr. Guillen’s employment as President and Chief Executive
Officer was terminated, and Marvin S. Hausman, M.D. was appointed our new
President and Chief Executive Officer. In
addition, during 2004 and early 2005, following the acquisition of a
then-majority interest in OXIS by Axonyx, eight directors resigned from the
board resulting in a four person board. During 2005 we added independent
director John E. Repine, M.D., and Gary M. Post joined our Board of Directors
on
March 15, 2006, resulting in a six-person board. Timothy C. Rodell, M.D.,
declined to stand for re-election at the Annual Meeting of Stockholders held
on
August 1, 2006. All five directors currently serving on the board commenced
their service on the board during the period of 2004 through the date
hereof.
One
impact of such changes has been to delay our sales promotions in the research
assay market and in the development of Ergothioneine market opportunities.
Further, we narrowed our strategic focus to concentrate resources, including
discontinuing our Animal Health Profiling program. In addition, the decreased
OXIS parent company sales during the third quarter of 2006 are attributable
to
lower sales volume that was caused, in part, by the interruption arising
from
moving operations from Portland, Oregon to Foster City, California and
consolidating our product offerings. There can be no assurances that these
changes will not cause further disruptions in, or otherwise adversely affect,
our business and results of operations.
If
we
fail to attract and retain key personnel, our business could suffer.
Our
future depends, in part, on our ability to attract and retain key personnel.
We
may not be able to hire and retain such personnel at compensation levels
consistent with our existing compensation and salary structure. We deferred
the
hiring of senior management personnel in order to allow our newly-engaged
full
time Chief Executive Officer to select such key personnel. While we succeeded
in
engaging Mr. Steven T. Guillen as our President and Chief Executive Officer
in
February 2005 and Michael D. Centron as our Chief Financial Officer in January
2006, we cannot predict whether we will be successful in finding suitable
new
candidates for key management positions within OXIS. On September 15, 2006, Mr.
Guillen’s employment as President and Chief Executive Officer was terminated,
and Marvin S. Hausman, M.D. was appointed our new President and Chief Executive
Officer. While we have entered into a letter agreement of employment with
Mr.
Centron and an employment agreement with Dr. Hausman, they are free to terminate
their employment “at will.” Further, we cannot predict whether Dr.
Hausman or Mr. Centron will
be
successful in their roles as our President and Chief Executive Officer, and
Chief Financial Officer, or whether senior management personnel hires will
be
effective. The loss of services of executive officers or key personnel, any
transitional difficulties with our new Chief Financial Officer or the inability
to attract qualified personnel could have a material adverse effect on our
financial condition and business. As we currently have limited cash resources,
if any of our key personnel leaves, replacing them will be difficult.
We
do not
have any key employee life insurance policies with respect to any of our
executive officers.
The
success of our business depends upon our ability to successfully develop
and
commercialize products.
We
cannot
assure you that our efforts to develop and commercialize a cardiac predictor
product, an Ergothioneine
nutraceutical product or any other products will be successful. The cost
of such
development and commercialization efforts can be significant and the likelihood
of success of any such programs is difficult to predict. The failure to develop
or commercialize such new products could be materially harmful to us and
our
financial condition.
Our
future profitability is uncertain.
We
cannot
predict our ability to reduce our costs or achieve profitability. We may
be
required to increase our research and development expenses in order to develop
potential new products. As evidenced by the substantial net losses during
and
the first six months of 2006 and in fiscal year 2005, losses and expenses
may
increase and fluctuate from quarter to quarter. There can be no assurance
that
we will ever achieve profitable operations.
We
have no biopharmaceutical or clinical diagnostic products available for sale
and
we may never be successful in developing products suitable for
commercialization.
All
of
our biopharmaceutical and clinical diagnostic candidates are at an early
stage
of development and all of such therapeutic and clinical diagnostic candidates
will require expensive and lengthy testing and regulatory clearances. None
of
our therapeutic or clinical diagnostic candidates have been approved by
regulatory authorities. We have no therapeutic or clinical diagnostic products
available for sale and we may not have any products commercially available
for
several years, if at all. There are many reasons we may fail in our efforts
to
develop our therapeutic and clinical diagnostic candidates,
including:
• our
therapeutic and clinical diagnostic candidates may be ineffective, toxic
or may
not receive regulatory clearances,
• our
therapeutic and clinical diagnostic candidates may be too expensive to
manufacture or market or may not achieve broad market acceptance,
• third
parties may hold proprietary rights that may preclude us from developing
or
marketing our therapeutic and clinical diagnostic candidates, or
• third
parties may market equivalent or superior products.
Clinical
development is inherently uncertain and expense levels may fluctuate
unexpectedly because we cannot accurately predict the timing and level of
such
expenses.
Our
future success may depend in part upon the results of clinical trials undertaken
by us or our licensees designed to assess the safety and efficacy of our
potential products. We do not have substantial experience in developing and
running clinical trials. The completion of clinical trials often depends
significantly upon the rate of patient enrollment, and our expense levels
will
vary depending upon the rate of enrollment. In addition, the length of time
necessary to complete clinical trials and submit an application for marketing
and manufacturing approvals varies significantly and is difficult to predict.
The expenses associated with each phase of development depend upon the design
of
the trial. The design of each phase of trials depends in part upon results
of
prior phases, and additional trials may be needed at each phase. As a result,
the expense associated with future phases cannot be predicted in advance.
Further, if we undertake clinical trials, we may decide to terminate or suspend
ongoing trials. Failure to comply with extensive FDA regulations may result
in
unanticipated delay, suspension or cancellation of a trial or the FDA's refusal
to accept test results. The FDA may also suspend our clinical trials at any
time
if it concludes that the participants are being exposed to unacceptable risks.
As a result of these factors, we cannot predict the actual expenses that
we will
incur with respect to clinical trials for any of our potential products,
and we
expect that our expense levels will fluctuate unexpectedly in the future.
Competition
in most of our primary current and potential market areas is intense and
expected to increase.
The
diagnostic, pharmaceutical and nutraceutical industries are highly competitive.
The main commercial competition at present in our research assay business
is
represented by, but not limited to, the following companies: Cayman Chemical
Company, Assay Designs and Randox Laboratories Ltd. In addition, our competitors
and potential competitors include large pharmaceutical/nutraceutical companies,
universities and research institutions. Relative to OXIS, these competitors
may
have substantially greater capital resources, research and development staffs,
facilities, as well as greater expertise manufacturing and making products.
In
addition, these companies, as well as others, may have or may develop new
technologies or use existing technologies that are, or may in the future
be, the
basis for competitive products. There can be no assurance that we can compete
successfully.
In
addition, current and potential competitors may make strategic acquisitions
or
establish cooperative relationships among themselves or with third parties,
thereby increasing the ability of their products to address the needs of
our
current and prospective customers. Accordingly, it is possible that new
competitors or alliances among current and new competitors may emerge and
rapidly gain significant market share. Such competition could materially
adversely affect our ability to commercialize existing technologies or new
technologies on terms favorable to us. Further, competitive pressures could
require us to reduce the price of our products and technologies, which could
materially adversely affect our business, operating results and financial
condition. We may not be able to compete successfully against current and
future
competitors and any failure to do so would have a material adverse effect
upon
our business, operating results and financial condition.
TorreyPines
Therapeutics, Inc. holds the voting power to influence matters affecting
us.
TorreyPines
Therapeutics, Inc. or TorreyPines, which merged with Axonyx Inc. in October
2006, currently owns approximately 32% of our issued and outstanding stock.
In
addition, Dr. Marvin Hausman is a member of the board of directors of
TorreyPines and is our President and Chief Executive Officer and the chairman
of
our board of directors. Given these circumstances, TorreyPines may influence
our
business direction and policies, and, thus, may have the ability to control
certain material decisions affecting us. In addition, such concentration
of
voting power could have the effect of delaying, deterring or preventing a
change
of control or other business combination that might otherwise be beneficial
to
our shareholders. Section 203 of the Delaware General Corporation Law prohibits
a Delaware corporation from engaging in any business combination with any
interested shareholder for a period of three years unless the transaction
meets
certain conditions. Section 203 also limits the extent to which an
interested shareholder can receive benefits from our assets. These provisions
could complicate or prohibit certain transactions (including a financing
transaction between OXIS and TorreyPines), or limit the price that other
investors might be willing to pay in the future for shares of our common
stock.
If
we
are unable to develop and maintain alliances with collaborative partners,
we may
have difficulty developing and selling our products and services.
Our
ability to realize significant revenues from new products and technologies
is
dependent upon, among other things, our success in developing business alliances
and licensing arrangements with nutraceutical/biopharmaceutical and/or health
related companies to develop and market these products. To date, we have
had
limited success in establishing foundations for such business alliances and
licensing arrangements and there can be no assurance that our efforts to
develop
such business relationships will progress to mature relationships or that
any
such relationships will be successful. Further, relying on these or other
alliances is risky to our future success because:
• our
partners may develop products or technologies competitive with our products
and
technologies;
• our
partners may not devote sufficient resources to the development and sale
of our
products and technologies;
• our
collaborations may be unsuccessful; or
• we
may
not be able to negotiate future alliances on acceptable terms.
Our
revenues and quarterly results have fluctuated historically and may continue
to
fluctuate, which could cause our stock price to decrease.
Our
revenues and operating results may fluctuate due in part to factors that
are
beyond our control and which we cannot predict. Material shortfalls in revenues
will materially adversely affect our results and may cause us to experience
losses. In particular, our revenue growth and profitability depend on sales
of
our research assays and fine chemicals. Factors that could cause sales for
these
products and other products to fluctuate include:
• an
inability to produce products in sufficient quantities and with appropriate
quality;
• an
inability to obtain sufficient raw materials;
• the
loss
of or reduction in orders from key customers;
• variable
or decreased demand from our customers;
• the
receipt of relatively large orders with short lead times;
• our
customers' expectations as to how long it takes us to fill future orders;
• customers'
budgetary constraints and internal acceptance review procedures;
• there
may
be only a limited number of customers that are willing to purchase our research
assays and fine chemicals;
• a
long
sales cycle that involves substantial human and capital resources;
and
• potential
downturns in general or in industry specific economic conditions.
Each
of
these factors has impacted, and may in the future impact, the demand for
and
availability of our products and our quarterly operating results. For example,
due to the unavailability of beef liver as a source for bSOD we were unable
to
sell any bSOD during 2005 and 2004, as compared to sales of $562,000 in 2003.
We
do not
anticipate this source becoming available again within the foreseeable future
and do not anticipate any revenues from sales of this product in the foreseeable
future. In addition, a decrease in the demand for our Ergothioneine product
resulted in a reduction of sales of Ergothioneine to $18,000 in 2005 and
$87,000
in 2004, compared to $333,000 in 2003. We cannot predict with any certainty
our
future sales of Ergothioneine.
If
the
sales or development cycles for research assays and fine chemicals lengthen
unexpectedly, our revenues may decline or not grow as anticipated and our
results from operations may be harmed.
Changes
in accounting standards regarding stock option plans could increase our reported
losses, cause our stock price to decline and limit the desirability of granting
stock options.
In
December 2004, the FASB issued SFAS 123R. SFAS 123R replaces SFAS No. 123
and
supersedes APB Opinion No. 25. SFAS 123R establishes standards for the
accounting for share-based payment transactions in which an entity exchanges
its
equity instruments for goods or services. It also addresses transactions
in
which an entity incurs liabilities in exchange for goods or services that
are
based on the fair value of the entity’s equity instruments or that may be
settled by the issuance of those equity instruments. SFAS 123R covers a wide
range of share-based compensation arrangements including share options,
restricted share plans, performance-based awards, share appreciation rights
and
employee share purchase plans. SFAS 123R requires a public entity to measure
the
cost of employee services received in exchange for an award of equity
instruments based on the fair value of the award on the grant date (with
limited
exceptions). That cost will be recognized in the entity’s financial statements
over the period during which the employee is required to provide services
in
exchange for the award. Management implemented SFAS 123R effective January
1,
2006. Expensing such stock options will add to our losses or reduce our profits,
if any. In addition, stock options are an important employee recruitment
and
retention tool, and we may not be able to attract and retain key personnel
if we
reduce the scope of our employee stock option program.
Our
income may suffer if we receive relatively large orders with short lead times,
or our manufacturing capacity does not otherwise match our demand.
Because
we cannot immediately adapt our production capacity and related cost structures
to rapidly changing market conditions, when demand does not meet our
expectations, our manufacturing capacity will likely exceed our production
requirements. Fixed costs associated with excess manufacturing capacity could
adversely affect our income. Similarly, if we receive relatively large orders
with short lead times, we may not be able to increase our manufacturing capacity
to meet product demand, and, accordingly, we will not be able to fulfill
orders
in a timely manner. During a market upturn, we may not be able to purchase
sufficient supplies to meet increasing product demand. In addition, suppliers
may extend lead times, limit supplies or increase prices due to capacity
constraints or other factors. These factors could materially and adversely
affect our results.
Our
success will require that we establish a strong intellectual property position
and that we can defend ourselves against intellectual property claims from
others.
Maintaining
a strong patent position is important to our competitive advantage. We currently
have 81 patents either granted or applied for in 16 countries with expiration
dates ranging from 2009 to 2025. Litigation on patent-related matters has
been
prevalent in our industry and we expect that this will continue. Patent law
relating to the scope of claims in the technology fields in which we operate
is
still evolving and the extent of future protection is highly uncertain, so
there
can be no assurance that the patent rights we have or may obtain will be
valuable. Others may have filed, or may in the future file, patent applications
that are similar or identical to ours. To determine the priority of inventions,
we may have to participate in interference proceedings declared by the United
States Patent and Trademark Office that could result in substantial costs
in
legal fees and could substantially affect the scope of our patent protection.
We
cannot assure investors that any such patent applications will not have priority
over our patent applications. Further, we may choose to abandon certain issued
United States and international patents that we deem to be of lesser importance
to our strategic direction, in an effort to preserve our financial resources.
Abandonment of patents could substantially affect the scope of our patent
protection. In addition, we may in future periods incur substantial costs
in
litigation to defend against patent suits brought by third parties or if
we
initiate such suits.
In
addition to patent protection, we also rely upon trade secret protection
for our
confidential and proprietary information. There can be no assurance, however,
that such measures will provide adequate protection for our trade secrets
or
other proprietary information. In addition, there can be no assurance that
trade
secrets and other proprietary information will not be disclosed, that others
will not independently develop substantially equivalent proprietary information
and techniques or otherwise gain access to or disclose our trade secrets
and
other proprietary information. If we cannot obtain, maintain or enforce
intellectual property rights, competitors can design and commercialize competing
technologies.
We
may
face challenges from third parties regarding the validity of our patents
and
proprietary rights, or from third parties asserting that we are infringing
their
patents or proprietary rights, which could result in litigation that would
be
costly to defend and could deprive us of valuable rights.
Extensive
litigation regarding patents and other intellectual property rights has been
common in the biotechnology and pharmaceutical industries. The defense and
prosecution of intellectual property suits, United States Patent and Trademark
Office interference proceedings, and related legal and administrative
proceedings in the United States and internationally involve complex legal
and
factual questions. As a result, such proceedings are costly and time-consuming
to pursue and their outcome is uncertain. Litigation may be necessary to:
• enforce
patents that we own or license;
• protect
trade secrets or know-how that we own or license; or
• determine
the enforceability, scope and validity of the proprietary rights of others.
Our
involvement in any litigation, interference or other administrative proceedings
could cause us to incur substantial expense and could significantly divert
the
efforts of our technical and management personnel. An adverse determination
may
subject us to loss of our proprietary position or to significant liabilities,
or
require us to seek licenses that may not be available from third parties.
An
adverse determination in a judicial or administrative proceeding, or a failure
to obtain necessary licenses, may restrict or prevent us from manufacturing
and
selling our products. Costs associated with these arrangements may be
substantial and may include ongoing royalties. Furthermore, we may not be
able
to obtain the necessary licenses on satisfactory terms, if at all. These
outcomes could materially harm our business, financial condition and results
of
operations.
We
may be exposed to liability due to product defects.
The
risk
of product liability claims is inherent in the testing, manufacturing, marketing
and sale of our products. We may seek to acquire additional insurance for
liability risks. We may not be able to obtain such insurance or general product
liability insurance on acceptable terms or in sufficient amounts. A product
liability claim or recall could have a serious adverse effect on our business,
financial condition and results of operations.
Disclosure
controls are no assurance that the objectives of the control system are
met.
Although
we have an extensive operating history, resources are limited for the
development and maintenance of our control environment. We have a very limited
number of personnel and therefore segregation of duties can be somewhat limited
as to their scope and effectiveness. We believe, however, that we are in
reasonable compliance with the best practices given the environment in which
we
operate. Although existing controls in place are deemed appropriate for the
prevention, detection and minimization of fraud, theft and errors, they may
result in only limited assurances, at best, that the total objectives of
the
control system are met. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues and instances of fraud, if any, can be detected and/or prevented
and as such this is a risk area for investors to consider.
Risks
Related to Our Common Stock
Our
common stock is traded on the OTCBB, our stock price is highly volatile,
and you
may not be able to sell your shares of our common stock at a price greater
than
or equal to the price you paid for such shares.
Our
shares of common stock are currently traded on the Over the Counter Bulletin
Board, or OTCBB. Stocks traded on the OTCBB generally have limited trading
volume and exhibit a wide spread between the bid/ask quotation. The market
price
of our common stock is extremely volatile. To demonstrate the volatility
of our
stock price, during the nine-month period ending on September 30, 2006, the
volume of our common stock traded on any given day ranged from 0 to 2,786,900
shares. Moreover, during that period, our common stock traded as low as
$0.21 per
share
and as high as $0.46 per share, a 119% difference. This may impact an investor’s
decision to buy or sell our common stock. As of September 30, 2006 there
were
approximately 5,200 holders of our common stock. Factors affecting our stock
price include:
• our
financial results;
• fluctuations
in our operating results;
• announcements
of technological innovations or new commercial health care products or
therapeutic products by us or our competitors;
• government
regulation;
• developments
in patents or other intellectual property rights;
• developments
in our relationships with customers and potential customers; and
• general
market conditions.
Furthermore,
volatility in the stock price of other companies has often led to securities
class action litigation against those companies. Any such securities litigation
against us could result in substantial costs and divert management's attention
and resources, which could seriously harm our business and financial
condition.
Our
common stock may be subject to “penny stock” rules which may be detrimental to
investors.
Our
common stock may be, or may become, subject to the regulations promulgated
by
the SEC for “penny stock”. SEC regulation relating to penny stock is presently
evolving, and the OTCBB may react to such evolving regulation in a way that
adversely affects the market liquidity of our common stock. Penny stock
currently includes any non-NASDAQ equity security that has a market price
of
less than $5.00 per share, subject to certain exceptions. The regulations
require that prior to any non-exempt buy/sell transaction in a penny stock,
a
disclosure schedule set forth by the SEC relating to the penny stock market
must
be delivered to the purchaser of such penny stock. This disclosure must include
the amount of commissions payable to both the broker-dealer and the registered
representative and current price quotations for the common stock. The
regulations also require that monthly statements be sent to holders of penny
stock that disclose recent price information for the penny stock and information
of the limited market for penny stocks. These requirements may adversely
affect
the market liquidity of our common stock.
Sales
of our common stock may require broker-dealers to make special suitability
determinations regarding prospective purchasers.
Our
common stock may be, or may become, subject to Rule 15g-1 through 15g-9 under
the Exchange Act, which imposes certain sales practice requirements on
broker-dealers which sell our common stock to persons other than established
customers and “accredited investors” (generally, individuals with a net worth in
excess of $1,000,000 or an annual income exceeding $200,000 (or $300,000
together with their spouses)). For transactions covered by this rule, a
broker-dealer must make a special suitability determination for the purchaser
and have received the purchaser’s written consent to the transaction prior to
the sale. Applicability of this rule would adversely affect the ability of
broker-dealers to sell our common stock and purchasers of our common stock
to
sell their shares of such common stock. Accordingly, the market for our common
stock may be limited and the value negatively impacted.
We
will incur expenses in connection with registration of our shares which may
be
significant.
We
are
required to pay fees and expenses incident to the registration with the SEC
of
the shares issued in the private placement of equity which closed on January
6,
2005 and maintain adequate disclosure in connection with such registration,
including updating prospectuses and under certain circumstances, filing amended
registration statements. These expenses were $302,000 in 2005, and we may
incur
significant additional expenses in the future related to maintaining effective
registration statements for prior financings and any additional registrations
related to future financings. We have also agreed to indemnify such selling
shareholders against losses, claims, damages and liabilities arising out
of
relating to any misstatements or omissions in our registration statement
and
related prospectuses, including liabilities under the Securities Act. In
the
event such a claim is made in the future, such losses, claims, damages and
liabilities arising therefrom could be significant in relation to our
revenues.
Item
3. Controls
and Procedures.
Under
the
supervision and with the participation of our management, including our
principal executive officer and principal financial officer, we have evaluated
the effectiveness of the design and operation of our disclosure controls
and
procedures as of September 30, 2006, and, based on their evaluation, our
principal executive officer and principal financial officer have concluded
that
these controls and procedures are effective. On
January 6, 2006, we hired Michael D. Centron as our Vice President and Chief
Financial Officer. We
relocated our headquarters on February 15, 2006 from Portland, Oregon to
Foster
City, California, and on that date we terminated the employment of our financial
controller. Temporary accounting facilities were established during this
transition period. Our accounting procedures and disclosure controls and
procedures have changed during this period, and management believes that
disclosure controls and procedures have been adequately maintained during
this
period and that reporting controls and procedures have been improved. There
has
been no change in our internal control over financial reporting that occurred
during our most recent fiscal quarter that has materially affected or is
reasonably likely to materially affect our internal control over financial
reporting.
Disclosure
controls and procedures are our controls and other procedures that are designed
to ensure that information required to be disclosed by us in the reports
that we
file or submit under the Exchange Act is recorded, processed, summarized
and
reported, within the time periods specified in the SEC’s rules and forms.
Disclosure controls and procedures include, without limitation, controls
and
procedures designed to ensure that information required to be disclosed by
us in
the reports that we file under the Exchange Act is accumulated and communicated
to our management, including our principal executive officer and principal
financial officer, as appropriate to allow timely decisions regarding required
disclosures.
PART
II. OTHER INFORMATION
Item
1. Legal Proceedings.
A
member
of the OXIS board of directors, Steven T. Guillen, who was terminated as
the
President and Chief Executive Officer of OXIS on September 15, 2006, filed
a
lawsuit against OXIS and up to 25 unnamed additional defendants. To the date
of
this Report, the complaint has not been served upon OXIS or any other defendant.
The complaint alleges breaches of contract relating to Mr. Guillen’s employment
agreement and a promissory note that is in default, breach of implied covenant
of good faith and fair dealing, wrongful termination and violation of the
California Labor Code in relation to the non-payment of back pay. On March
10,
2006, we received $200,000 in exchange for an unsecured promissory note with
Mr.
Guillen. Interest and principal were due on September 10, 2006 and at September
30, 2006 were in default. On November 2, 2006, we repaid Mr. Guillen the
principal and accrued interest due on the promissory note in the amount of
$209,000 and back pay with penalties and accrued interest of $96,000. We
are in
ongoing negotiations with Mr. Guillen’s counsel to settle the lawsuit.
Item
2. Unregistered Sales of Equity Securities and Use of
Proceeds.
None.
Item
3. Defaults Upon Senior Securities.
None.
Item
4. Submission of Matters to a Vote of Security Holders.
We
held
our Annual Meeting of Stockholders on August 1, 2006. Set forth below is a
summary of each matter voted upon at the meeting and the number of votes
cast
for, against, withheld or abstained.
Proposal
#1:
The
election of Marvin S. Hausman, M.D., Steven T. Guillen, S. Colin Neill, John
E.
Repine, M.D. and Gary M. Post to serve on the Company’s Board of
Directors:
Nominee
|
|
Total
Votes For All Nominees
|
|
Total
Votes Withheld From All Nominees
|
Marvin
S. Hausman, M.D.
|
|
27,831,835
|
|
147,671
|
Steven
T. Guillen
|
|
27,864,835
|
|
114,671
|
S.
Colin Neill
|
|
27,823,366
|
|
156,140
|
John
E. Repine, M.D.
|
|
27,868,705
|
|
110,801
|
Gary
M. Post
|
|
27,832,255
|
|
147,251
|
Proposal
#2:
Amendment of the Certificate of Incorporation to increase the number of common
shares authorized from 95,000,000 to 150,000,000:
Total
Votes For
|
|
Total
Votes Against
|
|
Abstained
|
27,494,463
|
|
372,270
|
|
112,773
|
Proposal
#3:
Amendment of the 2003 Stock Incentive Plan to increase the number of shares
authorized from 3,600,000 to 5,600,000:
Total
Votes For
|
|
Total
Votes Against
|
|
Abstained
|
19,216,113
|
|
743,311
|
|
31,148
|
Item
5. Other Information.
None.
Item
6. Exhibits
See
Index
to Exhibits on page 53.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
|
|
OXIS
International, Inc. |
|
|
|
Date:
November 14, 2006 |
By: |
/s/ Michael
D. Centron |
|
Michael
D. Centron |
|
Vice
President and Chief Financial
Officer |
Exhibit
Index
|
|
|
Incorporated
by Reference
|
Exhibit
Number
|
|
Exhibit
Description
|
|
Form
|
|
Date
|
|
Number
|
|
Filed
Herewith
|
10.1
|
|
Engagement
Letter with Ambient Advisors LLC.
|
|
8-K
|
|
5/12/06
|
|
10.1
|
|
|
10.2
|
|
Mutual
Services Agreement between OXIS International, Inc. and BioCheck,
Inc.
dated June 23, 2006.
|
|
8-K
|
|
6/23/06
|
|
10.1
|
|
|
10.3
|
|
Renewal
and Modification Promissory Note dated June 2, 2006.
|
|
8-K
|
|
7/20/06
|
|
10.1
|
|
|
10.4
|
|
Common
Stock Purchase Warrant dated June 2, 2006.
|
|
8-K
|
|
7/20/06
|
|
10.2
|
|
|
10.5
|
|
Amendment
#2 to Exclusive License and Supply Agreement dated July 19,
2006.
|
|
8-K
|
|
7/20/06
|
|
10.3
|
|
|
10.6
|
|
Form
of Securities Purchase Agreement dated October 25, 2006.
|
|
8-K
|
|
10/26/06
|
|
10.1
|
|
|
10.7
|
|
Form
of Secured Convertible Debenture dated October 25, 2006.
|
|
8-K
|
|
10/26/06
|
|
10.2
|
|
|
10.8
|
|
Form
of Series A, B, C, D, E Common Stock Purchase Warrant dated October
25,
2006.
|
|
8-K
|
|
10/26/06
|
|
10.3
|
|
|
10.9
|
|
Form
of Registration Rights Agreement dated October 25, 2006.
|
|
8-K
|
|
10/26/06
|
|
10.4
|
|
|
10.10
|
|
Form
of Security Agreement dated October 25, 2006.
|
|
8-K
|
|
10/26/06
|
|
10.5
|
|
|
10.11
|
|
Employment
Agreement between OXIS International, Inc. and Marvin S. Hausman,
M.D.
dated November 6, 2006.
|
|
8-K
|
|
11/13/06
|
|
10.1
|
|
|
10.12
|
|
Advisory
Agreement between OXIS International, Inc. and Ambient Advisors,
LLC dated
November 6, 2006.
|
|
8-K
|
|
11/13/06
|
|
10.2
|
|
|
10.13
|
|
Consulting
Agreement between OXIS International, Inc. and John E. Repine,
M.D. dated
November 6, 2006.
|
|
8-K
|
|
11/13/06
|
|
10.3
|
|
|
|
|
|
Incorporated
by Reference
|
Exhibit
Number
|
|
Exhibit
Description
|
|
Form
|
|
Date
|
|
Number
|
|
Filed
Herewith
|
31.1
|
|
Certification
of the Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a),
as adopted pursuant to Section 302 of the Sarbanes-Oxley Act
of
2002.
|
|
|
|
|
|
|
|
X
|
31.2
|
|
Certification
of the Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a),
as adopted pursuant to Section 302 of the Sarbanes-Oxley Act
of
2002.
|
|
|
|
|
|
|
|
X
|
32.1
|
|
Certification
of the Principal Executive Officer pursuant to 18 U.S.C. Section
1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
|
|
|
|
|
|
|
X
|
32.2
|
|
Certification
of the Principal Financial Officer pursuant to 18 U.S.C. Section
1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
|
|
|
|
|
|
|
X
|